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Abstract 
Chronic wet cough (i.e. lasting > 4 weeks) is common in children and is associated with 
significant burden on children, families and the healthcare system. Although some 
clinicians view chronic cough in children as trivial, for parents, chronic cough is associated 
with significant quality of life impairment, which improves when the cough resolves. 
Further, chronic cough in children may signify the presence of underlying lung disease, 
such as bronchiectasis.      
Prior to this thesis, my supervisors were the first to define the clinical entity of protracted 
bacterial bronchitis (PBB) in children. PBB is characterised by chronic wet cough, 
response to antibiotics (suggestive of bacterial infection of the airways) and absence of 
pointers indicating an alternative cause for cough. This early research demonstrated the 
existence of a recognisable pattern of lower airway inflammation and bacterial infection in 
children with chronic wet cough. However, many questions relating to chronic wet cough 
and PBB remained.  
This thesis explored the clinical, demographic, immunological and microbiological 
characteristics of children with chronic wet cough and PBB, with specific focus on viruses 
and viral-bacterial interactions. A longitudinal 2-year cohort study was also undertaken to 
describe the natural history of PBB. The medium-term risk of bronchiectasis (BE), in 
children with PBB, was evaluated; with the over-arching aim of identifying a link between 
these two conditions and identifying specific risk factors for a diagnosis of bronchiectasis.  
The objectives of the thesis were, to: 
1. Examine and contrast the lower airway findings of children with different types of 
cough (wet and dry) compared to no cough, with respect to infection and 
inflammation. 
2. Evaluate the sensitivity, specificity and predictive values of nasopharyngeal aspirate 
(NPA) for detecting viruses in bronchoalveolar lavage (BAL); and determine the 
relationship between infection and lower airway neutrophilic inflammation in children 
with non-acute respiratory illness. 
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3. Evaluate the major human adenovirus genotypes/species, and relationships to 
bacterial co-infection, in children with PBB and BE.  
4. Delineate the clinical and laboratory characteristics of children with PBB with a 
specific focus on viruses. 
5. Determine the 2-year outcomes and risk factors for BE and recurrent PBB, in 
children with PBB.  
6. Undertake a systematic review on the efficacy of short-course antibiotic therapy for 
bronchiectasis in children and review specific treatment options for cough in 
children in general practice. 
Five of these objectives have been published (as 6 papers) and presented as chapters. 
The remaining chapter (objective 5) has been submitted to a peer-reviewed journal. An 
overview of the major findings, with respect to each chapter is detailed below: 
Objective-1 is a study on 232 children undergoing bronchoscopy for evaluation of 
respiratory symptoms. Children were grouped using a cough nature symptom-based 
approach into “wet cough,” “dry cough” and “no cough”. Children with wet cough were 
more likely to have lower airway infection (bacterial, viral and viral-bacterial). Viral-bacterial 
co-infection was associated with maximal lower airway neutrophilic inflammation.    
Objective-2 included extended viral panel analyses on paired NPA and BAL specimens 
from 75 children with chronic respiratory symptoms. We found that the agreement between 
NPA and BAL, with respect to virus detection using PCR, was dependant on viral species. 
A good agreement was seen for adenoviruses and poor agreement for rhinoviruses. 
Adenovirus, but not rhinovirus, positivity in the airway was associated with lower airway 
neutrophilic inflammation. 
Objective-3 examined BAL samples from 245 children with PBB and BE and found a 
strong association between human adenovirus (HAdV) positivity on PCR and bacterial 
lower airway infection. Genotyping, performed on a subset of HAdV positive samples, 
showed that HAdV species C is the major detectable species in the BAL of children with 
PBB and BE. 
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Objective-4, which included 104 children with PBB, showed that PBB typically affects very 
young boys and is characterised by prolonged wet cough and parent-reported wheeze. 
Compared to controls (n=49), children with PBB had higher rates of childcare attendance, 
elevated NK-cell levels in blood and increased virus detection rates (particularly 
adenovirus) in BAL. 
Objective-5 showed that in 161 children with PBB, 106 of whom were followed for 2 years, 
bronchiectasis was diagnosed in 13 (8.1%). On multi-variate analysis, risk factors for BE 
diagnosis at 2-years were: recurrent episodes of PBB (p=0.003) and H. influenzae lower 
airway infection in the BAL (p=0.013).  
Objective-6 consists of two publications. The first is a review of drug treatments of 
childhood cough. The second is a systematic review of the efficacy of short-course (i.e. ≤4 
weeks) antibiotics for treatment of bronchiectasis in adults and children. In this review, we 
concluded that there is insufficient evidence, in the current literature, to support the use of 
short course antibiotics in bronchiectasis and further RCTs are needed.  
The limitations of the studies have been outlined in their respective chapters. The studies 
arising from this thesis provide new knowledge in relation to: 
• The significance of wet cough, as a symptoms and sign, in relation to lower airway 
infection and inflammation. 
• The agreement between NPA and BAL with respect to virus detection on PCR; and, 
the association between pathogen type (viral and/or bacterial) and neutrophilic 
lower airway inflammation. 
• Further description of PBB, including systematic evaluation of clinical, demographic, 
infective and inflammatory characteristics.  
• Identification of the potential role of adenovirus C in chronic suppurative lung 
diseases in children.  
• The medium-term risk of BE diagnosis in children with PBB; and, risk factors for BE. 
• Evaluation of current evidence supporting the use of short course antibiotics in 
adults and children with BE. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW  
1.1 CHRONIC COUGH 
Chronic cough is a common reason for referral to paediatric respiratory physicians and is 
associated with significant impairment in quality of life for children and families [1]. Several 
inter-related factors influence the presence, nature and duration of cough in an individual 
child. The median age of children included in paediatric cough studies is 2-3 years, hence, 
young age is likely to be an important risk factor for chronic cough in the paediatric 
population [2-4]. Cough quality i.e. whether it is wet or dry, is known to be the most 
important single predictor of a specific cause for cough in children [5] and is a valuable tool 
in clinical medicine and research. 
 
1.1.1 DEFINITION OF CHRONIC COUGH 
The definitions of chronic cough in children vary. In Australian [6] and the US [7] cough 
guidelines, chronic cough in children is defined as cough lasting >4 weeks. Acute and 
protracted acute cough are defined as cough lasting <2 and 2-4 weeks, respectively [8]. In 
contrast, British guidelines define chronic cough in children as cough lasting >8 weeks [9]. 
The rationale for the Australian and US approach is several-fold. Prospective studies on 
young children with acute cough suggest that in approximately 90%, cough has resolved 
by 3 weeks [10, 11] and morbidity is reduced if intervention for chronic cough occurs within 
30 days e.g. in the case the foreign body aspiration [12]. 
 
In addition to chronicity as a means of classifying cough, cough can be divided according 
its quality i.e. ‘wet’ versus ‘dry’. 
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1.1.2 ‘WET’ VERSUS ‘DRY’ COUGH 
The sound produced during cough is caused by turbulent flow of expired air causing 
vibration of large airways and laryngeal structures [13] with shearing of secretions from 
within the airways. In contrast, laminar flow through smaller airways (ie. <2mm in diameter) 
is inaudible to the ear. The rheological properties and the cilial transportability of mucous 
also influence the sound of cough. [14]. The exact amount of secretions per airway calibre 
needed to produce wet cough in children is unknown. Animal studies on cats have shown 
that as little as 0.5ml of mucus instilled into the trachea is sufficient to alter cough sound 
[15]. Similar studies in humans have not been performed.  
 
In young children, ‘wet’ (or ‘moist’) cough is the preferred terminology used to describe 
cough associated with a presumed increase in lower airway secretions. The equivalent 
term used in adults is ‘productive cough.’ The terms evolved differently as, unlike adults, 
young children rarely expectorate sputum. ‘Dry cough’ implies no, or minimal, lower airway 
secretions.  
 
In the evaluation of children with chronic cough, presence of ‘wet’ vs ‘dry’ cough is a key 
clinical sign and symptom used by respiratory specialists. It has utility in predicting a 
specific cause of cough and the likelihood of response to treatment [16, 17]. The validity of 
wet cough has also been shown in research studies [18-20]. When cough is wet, this 
implies the presence of increased airway mucous, which is usually infected with bacteria 
[18]. There is good agreement between parents’ versus clinicians’ assessment of wet 
cough  (K=0.75, 95% CI, 0.58-0.93) with good sensitivity and specificity with lower airway 
findings of increased secretions on bronchoscopy (0.75 and 0.79 respectively) [19].  
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In contrast to the validity of wet cough as a symptom and sign, parent-reported wheeze 
poorly reflects true wheeze and asthma [21, 22] and has a low level of agreement with 
doctor assessment of wheeze [23]. A possible link between wheeze and bacterial infection 
of the lower airways in children has been shown [24]. Further exploration of the symptom 
of wheeze and its co-existence with wet cough is needed and hence addressed in this 
thesis. 
 
The mechanisms responsible for the development of wet cough are further discussed in 
Section 1.3.  
 
1.1.3 THE BURDEN AND COST OF CHRONIC COUGH IN 
CHILDREN 
The burden of chronic cough in children is significant. An Australian study examining the 
prevalence of persistent cough (defined in this study as >3 weeks) showed that 5-10% of 
school-aged children between 6-12 years reported its presence [25]. It is likely that 
prevalence is even higher in pre-school aged children. This assumption is based on the 
indirect observation that the majority of children with chronic cough seen in respiratory 
specialist clinics are young (median age 2-3 years) [2, 3].  
 
The frequency of doctor consultations for cough is substantial and cough constitutes the 
most common reason for new medical visits [26]. Previous research has shown that 
children have multiple doctor visits for cough before referral is made to a respiratory 
specialist [1]. An Australian study by Marchant et al found that over a half (53%) of children 
had >10 medical consultations (for cough) and >80% had 5 visits in the 12 months 
preceding specialist evaluation [1].  
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Chronic cough has been shown to be associated with significant morbidity [25, 27], 
financial burden and reduction in quality of life for parents and children [28] [1]. Parents 
worry about the impact of their child’s cough. An Australian study by Marchant et al [1] 
involving 190 families, showed that parents were most concerned about the cause of their 
child’s cough and whether it indicated a serious illness. Other major concerns included: 
their child not sleeping well and cough causing damage to their child’s chest. Such 
parental worries largely resolved after resolution of the cough with treatment [1]. Other 
studies have had concordant findings with parental concerns largely relating to sleep 
disturbance [29], discomfort and fear that the cough may cause permanent damage to 
their child’s chest or that their child may choke or die [28].  
 
Studies on adults with chronic report increased rates of anxiety and depression in those 
with cough when compared to healthy controls [30, 31]. This is not the case for parents of 
children with chronic cough however, whose worries and concerns resolve after the 
successful treatment of their child’s cough [1].  
 
In addition to the impact on quality of life for families, cough confers significant financial 
burden and substantial resource utilisation. The cost of medications (prescribed and over 
the counter), doctor visits, medical investigations and work absenteeism, although difficult 
to quantify, is likely to be in the order of several millions of dollars per year in Australia.  
 
1.2 ANATOMY AND PATHOPHYSIOLOGY OF COUGH 
In order to understand the pathophysiology of cough in the context of the paediatric 
patient, we will briefly summarise the basic principles of cough and respiratory physiology.  
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1.2.1 WHAT IS COUGH? 
Cough is a forced expulsive manoeuvre against a closed glottis that produces a 
characteristic sound [32]. Simplistically, cough is a protective reflex that aims to clear the 
host respiratory tract from secretions or potential irritants e.g. aspirated upper airway 
secretions or gastric contents, inhaled particulate matter or infectious organisms [33, 34]. 
For example, when cough is suppressed e.g. during general anaesthesia, secretions 
accumulate and atelectasis and pneumonia can result. However, cough may also play a 
detrimental role. Forceful or persistent coughing can result in rib fracture, vomiting, 
syncope and reduction in quality of life [1]. Further, airway mucosal trauma may cause, or 
result from, repetitive coughing and lead to development of chronic cough [33]. Further, 
cough pathway sensitisation can perpetuate cough when its original cause has resolved. 
Cough also facilitates respiratory droplet spread and transmission of organisms, such as 
influenza or Bordetella pertussis, between individuals [1, 33]. Hence, effective treatment of 
cough requires consideration of the multitude of factors involved in its aetio-pathogenesis. 
 
The cough reflex is a complex pathway involving cough receptors, afferent and efferent 
sensory limbs, cough centre and effector muscles. Cough has three distinct phases: 1) an 
initial deep inspiration, 2) a brief, strong expiration against a closed glottis and 3) glottic 
opening, with nasopharynx closure, and forceful expulsion of air through the mouth 
producing a characteristic sound [35].  
 
Cough receptors are located throughout the respiratory tract and are particularly abundant 
in the larynx, carina and at proximal bronchial bifurcations. When cough receptors are 
activated, the vagus nerve provides afferent sensory pathways that lead to cough centres 
in the brainstem, whilst efferent pathways supply the respiratory tract muscles responsible 
for effecting cough [36]. A functional MRI study on adults, using capsaicin inhalation to 
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stimulate cough, demonstrated activation of several areas of the cerebral cortex during 
cough [37]. This suggests that the cerebral cortex may also influence cough production. 
While cough receptors are also present outside the respiratory tract in some, further 
discussion of cough receptors is beyond the scope of my thesis. A recent review of the 
physiology of cough is available [34]. 
 
1.2.2 IN-UTERO AND EX-UTERO LUNG AND CHEST WALL 
DEVELOPMENT  
In utero lung development is complex and begins just prior to day 28 of gestation [38]. 
Although most of the lung structure is present at birth, development continues until the 
postnatal period. In utero, four processes occur in lung development to enable the lung to 
perform its function of gas exchange. The first involves branching of the airways to form 
conducting and respiratory airways. Septation then divides the airpaces to enable 
alveolisation and lung vascularisation. This latter process accompanies the development 
of bronchi [39]. Alveolar multiplication begins at around 27 weeks gestation, increasing 
rapidly until 2-3 years of age then continuing at a slower rate until 8-10 years, before 
reaching adult levels [38].  
 
Other post-natal changes include an increase in the diameter of the large airways and a 
relative increase in peripheral airways size, compared to central airways, as well as an 
increase in lung volumes with age. Additionally, the rib cage changes to a more vertical 
orientation. This change in rib orientation is influenced by the transition to an upright 
posture. The ribs are pulled in a caudal direction, elongating the thoracic cavity [39]. 
During this time, rib ossification also occurs with both factors acting to improve overall lung 
biomechanics resulting in an increase in thoracic volume and functional residual capacity 
(FRC) [38]. Prior to 2 years of age, chest wall compliance relative to lung compliance is 
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high as rib cage ossification is incomplete and respiratory muscles are underdeveloped. 
By age 2, chest wall and lung compliance are similar, as seen in adults [39]. 
 
An additional factor impacting on respiratory muscle efficiency in young children is the 
angle of insertion of the diaphragm [40]. The horizontal (as opposed to oblique in adults) 
angle of insertion of the diaphragm into the chest wall results in the chest wall being drawn 
inward rather than downwards, making drawing air into the chest cavity less efficient in 
young children than in older children and adults [39]. Together with the high compliance of 
the infant rib cage this significantly influences susceptibility to respiratory muscle fatigue 
[41]. This is particularly relevant during REM sleep when the splinting effect of the 
intercostal muscles on the chest wall is inhibited and paradoxical inward movement of the 
rib cage occurs during inspiration [42]. REM sleep comprises over 50% of total sleep time 
in term infants, and a larger percentage in preterm infants [43]. A recent study on 22 
infants showed that these paradoxical movements resolved by 3.3 years of age [44].  
 
The characteristic biomechanics and smaller airways caliber of young children represent a 
respiratory disadvantage. In addition to their impact on breathing efficiency, these factors 
are likely to interfere with the adequacy of secretion clearance, particularly from smaller 
airways. This latter factor may be relevant to the pathogenesis of cough and indeed to the 
development of chronic suppurative lung diseases in young children, though this remains 
speculative. 
 
1.2.3 PHYSIOLOGY OF COUGH 
Cough is generally considered a respiratory reflex whose aim is to protect the lungs. Its 
presence usually signifies an underlying condition or irritant exposure [45]. The 
pathophysiology of cough is complex. A detailed description of the anatomy and 
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neurophysiology of cough is beyond the scope of this thesis and is covered 
comprehensively in a recent review [34]. In this chapter, I will provide a brief summary of 
the aspects of cough physiology relevant to the thesis topic. 
 
Age influences several key physiological domains relevant to cough in children. A 
schematic overview of these age-dependent physiological domains is presented and 
explained in detail in a paper by Chang et al [46]. To summarise, these domains include 
physiology relating to 1) cough 2) the respiratory system as a whole 3) other body systems 
eg. the immune system and 4) general physiology [46]. Although presented as separate 
entitites, Chang explains that these domains are in fact overlapping and inter-related. 
These domains influence cough aetiology, interpretation of investigation results and 
response to treatment [47].   
 
Individual factors governing the timing, nature, frequency and effectiveness of cough are 
protean. These include, but are not limited to, anatomic, neurologic, metabolic, 
immunologic and hormonal contributors. As mentioned, many of these influences are age-
dependant, but gender is also important. For example, gender does not influence cough 
sensitivity in childhood [48], however, post-pubertal females have greater cough sensitivity 
than males [49], suggesting a gender or hormonal influence. 
 
With regards to neurological influences, the cough reflex is immature and pharyngeal 
coordination under-developed at birth. It is weak in infants, and more so in premature 
infants, particularly those who have required intubation and mechanical ventilation for a 
prolonged period who may have abnormal development of suck and swallow rhythms [50]. 
Children with co-existent neurological impairment are at further risk of swallowing 
dysfunction. 
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As young children are more prone to aspiration events as compared to older children, 
close attention is given to the consistencies of food provided to them to ensure that these 
are appropriate for the child’s stage of development. For example, parents are advised 
that children should not consume whole nuts until the age of 5 years, because of risk of 
aspiration.  
 
For many reasons, young children are generally unable to expectorate sputum, even when 
secretions are abundant [19]. Hence, the term ‘wet’ or ‘moist’ cough is used in children, as 
opposed to ‘productive’ cough that is used in adults. 
 
From an anatomical perspective, children differ from adults in a number of ways. 
Understanding these differences helps to explain disease pathogenesis. Factors such as 
small airway calibre, lack of collateral ventilation [51], tracheal cartilage plasticity [52] and 
rib orientation disadvantage airway physiology in infants and young children. Overall, 
these factors may lead to an increased propensity to small airways obstruction/closure and 
atelectasis, and, secondarily, to mucociliary clearance impairment. This is of particular 
relevance to conditions associated with airway mucous hyper-secretion e.g. chronic 
suppurative lung diseases such as PBB and bronchiectasis and aspiration lung diseases 
that cause additional, intra-luminal airway obstruction [47]. 
 
The anatomical and physiological differences between adults and children may contribute 
to certain acute paediatric conditions, such as a bronchiolitis and croup, entities that do not 
usually occur in adults. Similarly, adult conditions such as chronic obstructive pulmonary 
disease are not recognised entities in children. Protracted bacterial bronchitis is a 
paediatric diagnosis not described in adult literature on cough. This thesis further explores 
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this common paediatric condition and provides further insight into aetiological factors that 
contribute to its origin.  
 
The literature review will now focus on chronic wet cough and the clinical entity of 
protracted bacterial bronchitis. 
 
1.3 CHRONIC WET COUGH 
As mentioned in section 1.1.2, chronic wet cough in children implies cough that is 
associated with increased lower airways secretions and present for >4 weeks. In this 
section, I will briefly review the mechanisms by which mucous over production occurs and 
its role in airway clearance. 
   
Three histopathological mechanisms can potentially cause mucous overproduction leading 
to wet cough. These include: 1) overexpression of mucin genes leading to increased 
secretion; 2) hyperplasia, hypertrophy or metaplasia of secretory cells (i.e. goblet cells, 
submucosal glands and possibly Clara cells); 3) oversecretion of stored mucin from 
secretory cells [45].   
 
From a functional perspective, cough, together with mucociliary clearance, encourages the 
flow of mucous in the airways in order to facilitate its removal. Based upon a physical 
model by Scherer and Burtz, involving turbulent airflow through a straight tube with a 
mucous-like fluid, cough improved mucociliary clearance of mucus down to the level of the 
12th airway generation [53].  
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In general, voluntary cough manoeuvres are considered ineffective in the absence of 
mucous hypersecretion [45]. Indeed, Yeates et al showed no effect of voluntary coughing 
on mucous flow in healthy adults [54]. This is believed to be due to the fact that the 
mucous layer is substantially thinner in health (<20µm) compared to in bronchitis 
(>200µm) [55, 56]. Hence, cough, and more importantly wet cough, usually signifies 
presence of disease [5] and is the most sensitive pointer indicating a specific cause of 
cough [LR 26.2 (95% CI, 3.8-181.5)] [20]. Further, a study by Goyal et al showed that 
children whose chronic wet cough is non-responsive to 4 weeks’ appropriate antibiotic 
therapy are more likely, than those whose cough responds to antibiotics, to have 
bronchiectasis on CT chest [57]. However, to date, no aetiological studies have specifically 
used chronic wet cough as an inclusion criteria, to determine the relative frequency of 
individual diagnoses.  
 
We will briefly describe the range of conditions known to be associated with mucous 
hypersecretion and hence presenting with chronic wet cough. We will then discuss current 
knowledge on the clinical condition of protracted bacterial bronchitis. 
 
1.3.1 CAUSES OF CHRONIC WET COUGH 
The major causes of chronic cough in children differ to those in adults, hence, paediatric 
specific cough algorithms should be utilised. In a study involving children with chronic 
cough (both wet and dry), Marchant et al evaluated the utility of an adult-based algorithm 
for the diagnosis [2]. This study found that the 3 major causes of chronic cough in adults 
(asthma, gastro-oesophageal reflux disease and upper airways cough syndrome) differed 
from those in children (Protracted bacterial bronchitis and natural resolution accounted for 
62% of cases)[2]. Hence, empirical therapies for cough, based upon adult algorithms, are 
inappropriate for use in children. 
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Chronic wet cough in children has a number of possible causes, ranging from aspiration 
lung disease and bronchiectasis to atypical infections e.g. tuberculosis. Clinical conditions 
predisposing to the development of chronic wet cough include: immune-deficiencies 
(acquired or congenital), cilial motility disorders and CFTR gene mutations. Large airway 
obstruction e.g. resulting from foreign body inhalation may present with acute onset dry 
cough followed several days later by wet cough. Clinical management 
pathways/algorithms, for the assessment and management of chronic cough in children, 
have recently been developed. These are well validated and have been shown to improve 
clinical outcomes [16].  
 
1.3.2 POPULATIONS AT RISK  
The median age of referral of children to respiratory specialists for the evaluation of 
chronic cough ranges from 2.8 - 4.5 years in Australian studies with male children being 
over-represented in these cohorts [5, 16]. The longer-term significance of chronic wet 
cough with regards to the risk of bronchiectasis has not been investigated in a 
prospectively designed study. 
 
Racial and ethnic factors may be important to chronic cough. Although prevalence data is 
limited, rates of chronic wet cough are higher in Indigenous compared to non-Indigenous 
populations; for example, in a cross-sectional survey of middle-school children, chronic 
productive cough was reported in 26% of Alaskan native children compared to only 7% of 
Seattle children [58].  
 
Bronchiectasis is an important cause of chronic wet cough and diagnoses are increasing 
both within Australia and the US [59, 60]. Indigenous populations living within resource-
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rich countries appear to be at increased risk, compared to non-Indigenous populations. 
Examples of populations with high rates of bronchiectasis include: Aboriginal and Torres 
Strait Islander children in Australia, Maori and Pacific Islanders in New Zealand and 
Alaskan children in the United States [61-63].   
 
The prevalence of non-CF bronchiectasis is estimated at 14.7 per 1,000 Aboriginal 
children aged <15 years [64], based on data collected from children in Central Australia 
[65]. This is equivalent to approximately 1 in 68 children, which is 40 times higher than that 
of cystic fibrosis among non-Indigenous Australian children according to data published in 
2000 [66]. It is likely that this is an under-estimate of the true rate of non-CF bronchiectasis 
for two reasons. First, cough is often under-reported by those from remote Indigenous 
communities, hence bronchiectasis would be missed in a proportion [67]. Second, recent 
data on the point prevalence of CF births has shown a 17% reduction in the live-birth 
prevalence of CF since 1989, coinciding with the introduction of newborn screening in 
Australia [68]. Hence, the disparity in prevalence of non-CF and CF bronchiectasis is likely 
higher than estimated but is also projected to continue to rise. Research into risk factors 
for non-CF bronchiectasis in Indigenous populations suggests that recurrent episodes of 
lower respiratory tract infection [61], together with environmental irritants e.g. smoke 
exposure [69], are likely contributors. 
 
Air pollution (both indoor and outdoor) has been shown to be associated with cough [70]. 
Environmental irritants, similar to tobacco smoke exposure, are believed to have additive 
effects in terms of contribution to respiratory disease, rather than being the sole aetiology 
[35]. This is supported by research studies that have shown that cough resolution is 
achievable in those with high exposure rates [71].  However, it is beyond the scope of my 
PhD work to examine the effects of airway pollution other than accounting for tobacco 
 14 
smoke exposure in the cohorts of children examined. Where relevant, age and ethnicity 
were also taken into account in my PhD studies.  
 
1.3.3 BRONCHOSCOPY, BRONCHOALVEOLAR LAVAGE AND WET 
COUGH  
Examining the lower airways is a key element in furthering our understanding of chronic 
wet cough in children. There is limited data on the lower airways of children with chronic 
cough. As many of these studies have included children with PBB, these are described 
together in section 1.4. My PhD work (Chapter 2) involves examining the BAL of children 
with chronic wet cough.  
 
In 2006, Marchant et al conducted a cohort study involving 108 children with cough >3 
weeks to examine the most common aetiologies [2]. The authors described similar, 
characteristic lower airway findings in 40% of children presenting with chronic cough (of 
which 89% had chronic wet cough). These findings included: lower airway bacterial 
infection (with H. influenzae, M. catarrhalis and/or S. pneumoniae) and intense neutrophilic 
inflammation. Cough in these children responded to 2-weeks of appropriate antibiotic 
therapy, resulting in resolution of their cough [2]. This clinical entity was named protracted 
bacterial bronchitis or PBB and resembled the previous, poorly-defined condition known as 
chronic bronchitis of childhood [72]. The following section 1.4 provides an up-to-date 
review of current knowledge on PBB. 
 
1.4 PROTRACTED BACTERIAL BRONCHITIS (PBB)  
Protracted Bacterial Bronchitis (PBB), first defined by our research group in 2006 [2], is 
now a well-recognised clinical entity [6, 9, 38, 73, 74]. It is characterised by chronic wet 
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cough (lasting >4 weeks), response to 2 weeks’ of appropriate antibiotics and absence of 
indicators to suggest an alternative cause of cough [6]. PBB is the commonest cause of 
chronic wet cough in Australian children as published in single and multicentre studies on 
108 [2] and 346 children with chronic cough, respectively [16, 27]. In the latter study, the 3 
most common causes of primary of cough were: PBB (41.0%), asthma/reactive airways 
disease (15.9%), and bronchiectasis (9.0%).  
 
PBB is also a major cause of chronic wet cough in the UK and US and has been the 
subject of research by several groups [75-77]. However, these studies were limited by 
retrospective design, absence of a control group or small number of study participants. For 
example, a retrospective study by Zgherea et al showed that 46% of children with chronic 
wet cough had positive bacterial cultures on bronchoalveolar lavage, however, no 
comparator/control group was included [77]. This raised the need for further research on 
this topic. Further, the potential role of viruses in PBB is unknown. These research gaps 
were addressed in this thesis. 
 
Although bronchoscopic assessment provides definitive evidence for lower airway 
bacterial infection and facilitates a diagnosis of PBB, bronchoscopy is not always feasible 
in the clinical context, particularly in primary care settings. Hence, clinical criteria for PBB 
diagnosis in children were devised to obviate the need for bronchoscopy [6]. Bacterial 
infection of the lower airways is inferred by the observation of a clinical response to 
appropriate antibiotics. ‘Appropriate antibiotics’ refers to antimicrobials sufficiently broad-
spectrum to cover common respiratory pathogens, including beta-lactamase producing H. 
influenzae strains, M. catarrhalis (inherently beta-lactamase positive) and S. pneumoniae. 
Amoxycillin combined with clavulanic acid is the usual first choice in PBB.  
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The definition of PBB, and its iterations over time, is detailed in Chapter 1.4.2.1. 
 
1.4.1 LOWER AIRWAY FINDINGS IN PBB 
Bacterial Infection  
Early studies on wet cough and chronic bronchitis in adults showed that bacterial infection 
was a common finding. In a study in adults published in the Lancet in 1957, 25 of 61 (41%) 
sputum samples from adults with chronic bronchitis showed infection with respiratory 
bacteria. The most common bacterial species isolated were H. influenzae and S. 
pneumoniae, with the same organisms predominating in the sputum of adults with 
bronchiectasis [78].  
 
An earlier study by Boyd, published in 1931, described 56 children with bronchiectasis and 
reported recurrent or chronic bronchitis to be the second most common cause of 
bronchiectasis in children, after bronchopneumonia [79]. Boyd showed that S. pneumoniae 
and H. influenzae were amongst the commonest organisms identified on lung aspiration or 
suction. The study concluded that the 2 most important factors in the development of 
bronchial dilatation were: 1) obstruction of a bronchus, especially if partial; and 2) infection 
[79].  
 
Studies on the lower airways of children are limited as children are generally unable to 
expectorate sputum, and hence we rely on lower airway sampling techniques. Recent 
research into the lower airways of children with chronic cough has been limited to 
retrospective studies and small cohorts. Fitch et al published a prospective study on 23 
children with chronic unexplained cough and found that those with chronic cough had 
significantly higher neutrophils in their BAL compared to controls and postulated that this 
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was due to underlying persistent airways infection [80]. Subsequent research further 
supported this finding. In 2007, in a retrospective chart review of 81 patients with PBB, in 
which bronchoscopy was performed in 19 patients, Donnelly et al observed that 
neutrophils were the major cell line in the BAL samples and that H. influenzae and S 
pneumoniae were again the most common organisms seen. The airways of children with 
PBB appeared oedematous and had presence of secretions [75]. These findings were 
consistent with Marchant et al’s observations in the original studies in which PBB was first 
defined [2].  
 
In 2012, Zgherea et al published a retrospective chart review of 197 children with chronic 
wet cough undergoing evaluation. The majority (55%) were 0-3 years of age and most 
(56%) had purulent bronchitis (as opposed to non-purulent bronchitis) on bronchoscopy. 
Positive bacterial cultures were also a major feature, being present in almost half (46%). 
Lower airway neutrophilia was seen, with the severity of the neutrophilia being more 
pronounced in those with purulent bronchitis, compared to non-purulent bronchitis [77]. 
 
Kompare et al’s retrospective study of 70 children, published in the same year had 
concordant findings. The link between bacterial infection and neutrophilia of the lower 
airways was once again observed, with an additional finding of high rates of airway 
malacias (74% had tracheo- and/or bronchomalacia) on bronchoscopy [76].  
 
Hence, the triad of chronic wet cough (that responds to antibiotics), bacterial infection and 
neutrophilic inflammation of the lower airways had been supported by studies both within 
Australia and internationally. There is also notable similarity in these key features of PBB 
and those of non-CF bronchiectasis. Lower airway bacterial infection is widely accepted as 
detrimental to the lung and, together with neutrophilic airway inflammation and impairment 
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of mucociliary clearance, constitute major components of Cole’s “vicious cycle” hypothesis 
on the pathogenesis of bronchiectasis [81].  
 
Growth of one or more bacterial species, at a density consistent with infection (e.g. ≥104 
cfu/ml), is present in the lower airway secretions of most children with PBB. However, this 
is not an absolute criteria for a diagnosis of PBB. The reasons for this are explained later 
in this section. The 3 bacterial species most commonly identified in the BAL of children 
with PBB include: Haemophilus influenzae, Streptococcus pneumoniae and Moraxella 
catarrhalis [2]. Research into S. pneumoniae serotypes isolated from the airways of 
children with PBB has shown that both vaccine and non-vaccine serotypes are present, 
suggesting that serotype replacement is unlikely to be the sole explanation for the specific 
strains identified [82]. The majority of H. influenzae isolates from the nasopharynx and 
lower airways of children with non-CF bronchiectasis are NTHi [83]. It is assumed that this 
is also true for children with PBB, although prior to this thesis, this had not been studied.  
 
The effectiveness of antibiotic therapy in the treatment of chronic wet cough has been 
shown in retrospective studies [2, 75]. Further, a Cochrane review published in 2005 [84] 
evaluated the utility of antibiotics in the treatment of chronic cough (>75% had moist 
cough). In the 2 included studies with a total of 140 participants, antibiotics reduced the 
proportion of children not cured at follow-up, with number needed to treat (NNT) of 3 (95% 
CI 2 to 4). More recently, a double-blinded randomised controlled trial by Marchant et al 
[85] showed that chronic wet cough in children responded to amoxycillin-clavulanate 
antibiotics, with a NNT of 3 (95%CI 2 to 4). This study also showed that requirement for 
further antibiotics was significantly lower in those receiving antibiotics, with NNT of 4 (95% 
CI 3-5) [85]. Hence, the effectiveness of antibiotics in the treatment of wet cough has been 
demonstrated. 
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It is nevertheless important to note that a proportion of children with PBB have negative 
bacterial cultures of their BAL [2]. There are a number of factors that may account for this. 
First, antibiotic exposure at the time of sampling may suppress colony counts to below the 
threshold to be classified as ‘infection’; second, inadequate bronchoalveolar lavage 
technique with poor return or very localised sampling may miss the infected portion of the 
lung [86]; and third, sub-optimal sample handling e.g. a delay in processing, inadequate 
storage, plating etc may result in failure to culture an organism that may be present. This 
may be of particular relevance in the case of fastidious organisms e.g. nontypeable H. 
influenzae  (NTHi) [87].  
 
In earlier studies on PBB [2], children with respiratory viruses in BAL were excluded and 
hence, prior to this thesis, the role of viruses in PBB had not been explored. Chapter 2.2 
explores the role of viral co-infections in the BAL of children with chronic wet cough.  
 
Viral Infection  
Prior to this thesis, most studies on PBB have focused on bacterial infection of the airways 
[2, 4, 75-77]. Respiratory viruses, such as respiratory syncytial virus (RSV), influenza 
viruses and rhinoviruses are commonly associated with acute cough and self-limiting 
respiratory illnesses in children. They are also associated with acute exacerbations of non-
CF bronchiectasis in children [88], Adenovirus can persist in the airway and has been 
linked to chronic respiratory diseases such as bronchiectasis and bronchiolitis obliterans 
[89]. The role of respiratory viruses in the pathogenesis of PBB, and indeed chronic cough, 
are a focus of this PhD thesis. I also focus on and review the potential role of adenoviruses 
in this context. 
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Adenovirus is a common cause of upper and lower respiratory tract infections in children. 
Although most infections are mild or asymptomatic [90], studies reporting on lower 
respiratory tract infections in hospitalised infants and young children have found 
adenovirus to be responsible for 7-15% of cases with high rates of viral-viral co-infection 
(60-80%) [91-94].  
 
The role of adenoviruses in the pathogenesis of chronic respiratory diseases, such as 
bronchiectasis and bronchiolitis obliterans, is well-described [89, 95-98]. A meta-analysis 
published by Edmond et al, examined the long-term sequelae from childhood pneumonia, 
and showed that adenovirus pneumonia was associated with the highest risk of sequelae 
(54.8% [95%CI 39.2%-70.5%]). These sequelae included: restrictive lung disease, 
obstructive lung disease, bronchiectasis, chronic bronchitis, asthma or a combination of 
conditions [99]. 
 
Adenovirus can cause chronic or persistent infection in the airways. Longitudinal studies 
where children were followed over a 1-year period, have shown that 81% of children with 
repeated isolation of adenovirus in their upper airway carry the same strain, suggesting 
chronic rather than repeated infection [100]. Macek and colleagues demonstrated 
persistence of HAdV in the lower airways of 9 of 11 children with persistent asthma who 
underwent repeated lower airway sampling [101]. HAdVs can cause latent infection within 
lymphocytes [102], tonsillar tissue [103] and the lung [104]. These findings support the 
hypothesis that adenovirus may play a role in the pathogenesis of certain chronic 
respiratory disorders [102] and this is explored further, in my PhD, in relation in PBB.  
 
I will briefly discuss viral-bacterial co-infection in relation to respiratory tract disease. 
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Viral bacterial co-infection  
Viral bacterial co-infection of the lung is associated with increased severity of lower 
respiratory tract symptoms [105, 106]. Further, numerous studies in animals [107-110] and 
several studies in humans support the concept of viral potentiation of bacterial infection 
[111-113]. There are several mechanisms by which viral infections increase the likelihood 
of secondary bacterial infection. 
 
In the upper respiratory tract, viral infection predisposes to secondary bacterial infection 
via impairment of the epiglottal-cough reflex, interruption of the muco-ciliary function and 
disruption of ciliary ultrastructure with loss of cilia and ciliated cells [114]. Changes to cilial 
beat frequency also occur impairing the ability to remove fluid, particles and bacteria from 
the middle ear, sinuses and lower respiratory tract [108-110]. In addition to structural and 
consequently functional impairment, certain viruses e.g. adenoviruses and herpes viruses, 
modulate the host immune response to enable persistence of virus within the airways 
[115]. Prolonged faecal excretion of adenovirus 1 and 2 (for up to 515 days) has been 
shown in children suggesting persistence within human enteral tissues as well as the 
respiratory tract [116]. 
 
Enhanced adherence of bacterial pathogens is seen in virus infected or damaged cells. 
Viral proteins on the cell surface can act as bacterial receptors. Also, loss of airway 
epithelial cells exposes the basement membrane, thereby enabling more sites for bacterial 
binding [117-119]. Clinical studies correlating viral bacterial co-infection and bronchitis in 
children are lacking. Potential synergy between viruses and bacteria has been 
documented in other acute respiratory diseases such as pneumonia [120] and RSV 
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bronchiolitis [121]. We postulate that viral-bacterial co-infection and microbial synergy is 
also a key feature of PBB. 
 
To date, the most convincing evidence for microbial synergy between common respiratory 
pathogens has arisen from animal models of otitis media. Dramatic increases in bacteria 
positive otitis media were found with co-infection between adenovirus and S. pneumonia 
(67%), as compared to each pathogen alone (4% and 21% respectively) [107]. Similar 
synergy has been shown in animal studies of otitis media between adenovirus and non-
typeable H. influenzae [108]. This study also showed that timing of infection was important. 
Adenovirus prior to H. influenzae infection resulted in the greatest mucosal inflammation 
and tympanic membrane dysfunction [108]. The relevance of these findings with regards to 
the respiratory tract of humans warrants further study. 
 
Neutrophilic Inflammation 
Neutrophilic lower airway inflammation is an important feature of a number of chronic 
respiratory diseases. Lower airway neutrophilic inflammation is a common and almost 
universal finding in children with PBB. This has been shown in numerous studies of the 
lower airway secretions of children with PBB [2, 75-77]. With regards to cellularity of the 
lower airway, no significant findings in relation to lymphocytes or eosinophils have been 
seen in children with PBB [2]. A study by Zimmerman et al, examining eosinophil counts in 
induced sputum of children with and without asthma with post-infectious cough, showed 
eosinophil levels in sputum to be significantly higher in those with untreated allergic 
asthma [122]. Similar findings have not been seen in children with PBB. The influence of 
infection on lower airway cellularity and presence of neutrophilic airway inflammation 
requires further study and was explored in Chapter 2.  
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Less commonly studied markers of lower airway inflammation, including: toll-like receptor 
(TLR 2 and 4) mRNA and inflammatory cytokines (interleukin-8 and matrix 
metalloprotease-9) have been shown to be increased in BAL fluid of children with PBB [4], 
suggesting innate immune system activation in children with this condition, however, these 
studies were preliminary. A further study on the innate immune system and PBB is 
included in appendix 2. 
 
1.4.2 NOMENCLATURE 
 ‘Original’ versus ‘revised’ definition of PBB 
The original definition of PBB was first published in 2006 [2] as described in chapter 1.3.3. 
This study included 108 young children referred to respiratory specialists for assessment 
of chronic cough. The aims of the study were to identify the major causes of chronic cough 
in children and to evaluate the utility of an adult-based cough algorithm in the diagnosis of 
cough in children. This study was first to identify the clinical triad of PBB. The definition of 
PBB has evolved over time [2]. 
 
The original definition of PBB included the following criteria: 1) prolonged wet cough 
lasting >3 weeks 2) presence of bacterial infection of the lower airways as seen on BAL 
and 3) with resolution of cough with 2 weeks of appropriate antibiotic therapy [2]. In 2010, 
the definition was adapted for increased feasibility, to include: 1) presence of isolated 
chronic wet cough lasting >4 weeks 2) resolution of cough with appropriate antibiotic 
treatment and 3) absence of pointers suggestive of an alternative specific cause of cough 
[6]. For increased feasibility and applicability to both primary and tertiary care settings, the 
BAL component was omitted in the revised definition of PBB [123]. This was further 
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supported by a randomised controlled trial on children with chronic cough (n=50) that 
showed significantly higher cough-resolution rates in children receiving 2-weeks of 
amoxycillin clavulanate antibiotics (48%), compared to placebo (16%) [85].  
 
Recurrent versus non-recurrent PBB 
The importance of differentiating recurrent versus non-recurrent PBB in an individual child 
is based upon the theory that those with more frequent episodes of protracted wet cough 
are at greater risk of bronchiectasis. This is substantiated by studies on adults, newly 
diagnosed with bronchiectasis, that show that most (60-80%) have a history of chronic wet 
cough since childhood [124, 125]. Chronic bacterial infection and concomitant neutrophilic 
inflammation of the lower airways, key features of PBB, are also the major features 
described in Cole’s vicious circle hypothesis on the pathogenesis of bronchiectasis. 
Damage to airway epithelium (e.g. secondary to acute or chronic respiratory infection) 
impairs mucociliary clearance and predisposes to chronic bacterial infection thus initiating 
an inflammatory response that further inhibits mucociliary clearance, resulting in a vicious 
circle phenomenon [81]. 
 
Young children presenting with PBB frequently experience repeated episodes.  A recent 
retrospective review of 44 children (median age 2.7 years) of which 33 had PBB, 25 (76%) 
had further relapse/s over an unspecified median follow-up period [126]. An earlier review 
of 81 children with clinical PBB found that 41 (51%) were symptom free after 2 courses of 
antibiotics, however 11 (13%) needed 6 or more courses of antibiotics [75]. No studies 
have examined the relationship between recurrent episodes of PBB and later diagnosis of 
bronchiectasis. Hence, this important question comprised a major aim of my PhD thesis. 
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In this PhD, we have defined recurrent PBB as >3 episodes of PBB per year. This cut-off 
was chosen, based upon the observation in clinical practice that children with more 
frequent episodes of PBB are less likely to “grow-out” of their wet cough episodes. It is 
unknown, however, whether these clinical observations were indeed important and hence, 
the postulated link between recurrent PBB and bronchiectasis is examined in chapter 5.  
 
1.5 THE IMMUNE SYSTEM AND PBB 
Studies on children undergoing evaluation for chronic cough have included basic immune 
function testing and children with major immune-deficits were excluded from earlier studies 
on PBB. The rationale for this approach was that children with major immune-deficiencies 
are closely monitored for bronchiectasis, a well-known complication of these conditions. 
The focus of PBB research is therefore on immune-competent, otherwise healthy children, 
in whom the index of suspicion for chronic suppurative lung diseases is low.  
 
It is postulated that a defect in the innate immune system, or possibly immaturity of the 
adaptive immune system, predisposes to the development of PBB in children [4]. Prior to 
this thesis, studies examining the immune system in PBB focused on aspects of innate 
immunity, such as toll-like receptors and cytokines [4]. Another study explored the 
relationship between bacterial infection, neuropeptides and innate immune mediators in 
BAL fluid [127]. Both studies concluded that further studies in this area were warranted. 
 
1.5.1 INNATE IMMUNITY 
The innate immune system comprises a complex network of molecules, receptors and 
inflammatory mediators. In health, the innate immune system fulfills two major functions: 1) 
to provide rapid recognition and primary defense against invading pathogens and 2) to 
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communicate with (and shape) the subsequent adaptive immune system response  [128]. 
The innate immune system differentiates between ‘self’ and ‘non-self’ to protect the host 
from invading organisms. In disease, any of the aforementioned processes may be 
altered. The innate immune system is pre-programmed and, unlike, the adaptive immune 
system has no specific memory. Major cell lines involved in the innate immune response 
include neutrophils, natural killer cells, mast cells, basophils and the complement system 
[128]. 
 
The important and complex role of the innate immune system, in lung health and disease, 
is recognised [129]. Few studies, however, have examined the innate immune system of 
children with PBB. In a small study, Marchant et al [4] found increased median cytokine 
levels (IL-8 and active MMP-9) and TLR-2 and TLR-4 mRNA expression in the BAL of 
children with PBB when compared to controls who were cough-free or had natural 
resolution of cough. TLR-2 and TLR-4 are known for their role in responding to bacterial 
infection. This finding was in association with the presence of positive bacterial cultures 
from lower airway secretions and increased total cell count and percentage neutrophils. IL-
8 and MMP-9 were also increased in BAL and correlated with neutrophil levels. IL-8 is 
known to potentiate MMP-9. Hence, this study’s findings, of significant innate immune 
system up-regulation in children with PBB, suggested enhanced, rather than deficient, 
innate immune response in these children. Further, a positive feedback loop, initiated by 
the presence of bacterial infection, may exist between the 2 cytokines studied as well as 
recruited airway neutrophils, leading to a state of chronic inflammation in the airway [4].  
 
In another study, Grissell et al [127], examined the relationship between bacterial infection 
of the lower airways in children with gene expression for TLRs 2, 3, 4; chemokine 
receptors (CCR3, CCR5, CXCR1); neurotrophins and neurokinin genes (TAC1, TAC3, 
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CGRP, NGF). This study found that, in children with bacterial colonization of their lower 
airways, there was an airway inflammatory response, with increased BAL neutrophils, IL-8 
protein, and CXCR1 expression. Further, Substance P (TAC1) and TLR4 RNA expression 
were reduced in the presence of bacterial infection. Overall, these findings suggested 
possible co-regulation of neuropeptides with the innate immune system, a relationship that 
may suggest impaired clearance of bacteria from the airways of children with PBB [127].  
 
The above provides clues to the role of the host immune response in diseases such as 
PBB. While this importance is acknowledged, it is beyond the scope of my PhD to further 
examine these aspects.  
 
1.5.2 ADAPTIVE IMMUNITY 
In defending against invading pathogens, the role of the adaptive immune system is to 
respond to signals from the innate immune system to initiate antibody (B cell) and cellular 
(helper and cytotoxic T cell) mechanisms of immune defense [128]. Complex processes 
occur: including antigen presentation and T or B cell recognition; followed by cell priming; 
activation and differentiation resulting in release of antibodies into the blood or tissues 
(from activated B cells) or activated T cells leaving lymphoid tissue and localisation at the 
disease site [128]. Unlike the innate immune system, the adaptive immune system 
displays immunological memory, hence, if previous exposure to a pathogen type has 
occurred, subsequent detection and removal is enhanced. Similar to the innate immune 
system, aberrations in the function of the adaptive immune system can lead to impaired 
immunity, with resultant disease [128].  
 
Forerunner studies on adaptive immunity in PBB have included measurement of major 
antibody types and subtypes (IgG and IgG subtypes, IgA, IgM and IgE) [5] [2]. The 
 28 
majority of children had intact immune function, and any child with major immune 
deficiency was excluded from further studies. However, these previous cohorts were small 
(n ranging from 38-45) and incomplete immune assessments were described [4]. Given 
this research gap, my PhD work addressed describing basic immune function and atopy in 
a much larger cohort of children with PBB (Chapter 5). Availability of such data will help 
clinicians to better understand the complex interplay between the developing immune 
system and PBB.  
1.6 POTENTIAL SIGNIFICANCE OF PBB 
PBB and bronchiectasis share many similarities. Indeed, their clinical presentations are 
alike i.e. recurrent and/or protracted episodes of wet cough responsive to antibiotics, 
coupled with lower airway findings of neutrophilia and bacterial infection. This observation 
led to a hypothesis by Chang that the 2 conditions were linked and represented a clinical 
spectrum (see Figure 1 below) [51].  
 
Figure 1.1: Figure reproduced with permission from A Chang. 
No studies to date however, have prospectively examined the temporal relationship between PBB 
and BE to provide definitive support for the proposed link. Hence, this question represented the 
overarching aim of my thesis. 
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1.7. CURRENT TREATMENT APPROACH TO CHRONIC 
WET COUGH AND PBB 
Chronic cough pathways, for the assessment and management of chronic cough in 
children, assist in the accurate diagnosis of chronic cough, resulting in earlier resolution of 
cough [16, 27]. 
 
If a child presents with chronic wet cough lasting >4 weeks, a thorough history and 
examination is undertaken. Specific cough pointers, suggestive of an underlying diagnosis, 
are sought. These include a history of developmental delay, feeding difficulties, recurrent 
lower respiratory tract infection, wheeze, previous treatment response etc. Examination 
includes assessment for chest wall deformity, clubbing, abnormality on chest auscultation 
and growth parameters. Chest X-ray (in all) and lung function tests (if school-aged or 
above) are performed. In the absence of indicators to suggest an alternative specific cause 
for cough (e.g. asthma, viral bronchitis) a 2-week trial of antibiotic therapy with an 
appropriate antibiotic (e.g. amoxycillin-clavulanate) is indicated. A randomised controlled 
trial published by Marchant et al in 2012 supports this approach. This showed that 
antibiotics (amoxycillin-clavulanate) were associated with higher cough resolution rates 
compared to placebo. In 50 children with wet cough lasting >3 weeks, antibiotics were 
associated with a cough resolution rate of 48% versus 16% in those receiving placebo 
(p=0.016) [85].  
 
Follow-up is then undertaken at 2-3 weeks to ensure cough resolution and confirm a 
diagnosis of PBB. If a child has a partial response to antibiotics, a further 2-4 weeks’ 
course is usually given and further aspects of the history are elicited e.g. adherence to 
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treatment and appropriateness of dose, with reassessment of the original diagnosis. 
Subsequent investigations and follow-up are based upon individual clinician practice. 
 
1.8 WHY THIS THESIS IS ABOUT PBB AND CHRONIC 
WET COUGH 
Chronic wet cough commonly affects children and places substantial burden on families 
and the healthcare system. Hence, accurate identification of the aetiology of cough is 
important to ensure that the most effective treatment is instituted. Using clear-cut 
diagnostic criteria, my supervisors were first to define the clinical entity of PBB providing 
the platform for further research on this important topic.  
 
This thesis aims to further expand on current knowledge in relation to wet cough and PBB 
with a focus on the role of viral and bacterial infection. The medium-term significance of 
PBB with respect to development of bronchiectasis is also evaluated. We further describe 
the clinical profile of PBB and explore potential aetiological factors from the perspective of 
the environment, infection and the immune system. The overarching aim of this research 
was to delineate the natural history of PBB in children to evaluate the postulated link to 
bronchiectasis. 
 
1.9 ADDRESSING CLINICAL RESEARCH GAPS  
Several research groups have explored PBB in children however many questions 
remained. Chronic wet cough is the principle clinical feature of PBB. Further exploration of 
this “grass roots” symptom of PBB, and its relationship to lower airway neutrophilic 
inflammation and infection, warranted further exploration. Second, bacterial infection is a 
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key feature of PBB however the role of viral infection (and viral-bacterial co-infection) had 
not been investigated. Third, to date, descriptions of the clinical profile of children with PBB 
were based on small cohorts and further, in-depth characterisation was needed. Lastly, 
and arguably the most significant question, was whether PBB represent a risk for future 
bronchiectasis. This question warranted evaluation in a large prospective cohort study. 
Addressing these research gaps formed the basis of this PhD manuscript.  
 
1.10 HYPOTHESIS AND AIMS 
The over-arching aim of my thesis was to determine whether PBB is antecedent to a 
diagnosis of bronchiectasis, and if so, whether identifiable risk factors exist for a diagnosis 
of bronchiectasis. The principle hypothesis of this thesis was that PBB and bronchiectasis 
represent a clinical spectrum.  
 
In order to address the aforementioned research gaps, the specific aims of the studies 
were to: 
1. Examine and contrast the lower airway findings of children with different types of cough 
(wet and dry) compared to no cough, with respect to infection and inflammation. 
2. Evaluate the sensitivity, specificity and predictive values of NPA for detecting viruses in 
bronchoalveolar lavage (BAL); and determine the relationship between infection and lower 
airway neutrophilic inflammation in children with non-acute respiratory illness. 
3. Evaluate the major human adenovirus genotypes/species, and relationships to bacterial 
co-infection, in children with PBB and BE.  
4. Delineate the clinical and laboratory characteristics of children with PBB with a specific 
focus on viral detection. 
 32 
5. Determine the 2-year outcomes and risk factors for BE and recurrent PBB, in children with 
PBB.  
6. Undertake a systematic review on the efficacy of short-course antibiotic therapy for 
bronchiectasis in children and review specific treatment options for cough in children in 
general practice. 
 
1.11 THESIS DESIGN 
The studies included within this PhD thesis were designed to address key research gaps, 
as already outlined. Chapter 2 explores the principle clinical feature of PBB i.e. wet cough. 
It evaluates the significance of wet cough, compared to dry and no cough, in relation to 
presence of lower airway infection (bacterial and/or viral) and neutrophilic airway 
inflammation. This study explores the significance of viral-bacterial co-infection and 
provides the foundation for further studies. 
 
Viral infections are an important cause and contributor to respiratory disease 
pathogenesis. The relationship between viruses in the upper, versus the lower, airways, is 
poorly studied. Chapter 3 evaluates the relative yield and agreement between viruses 
detected on NPA compared to BAL. It relates these findings to presence of neutrophilic 
inflammation of the lower airways. 
 
The link between adenovirus and bronchiectasis is established. Chapter 4 investigates the 
adenovirus genotypes present in the lower airways of children with PBB and 
bronchiectasis. It also examines the potential link between adenovirus and bacterial 
infection of the lower airways. 
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Previous studies on PBB have been small and/or retrospective. Chapter 5 further 
describes the clinical profile of children with PBB to assist clinicians in the more accurate 
diagnosis of this condition. The natural history of PBB, with respect to the development of 
bronchiectasis, is unknown. Chapter 6 explores the medium-term outcome of children with 
PBB and investigates potential risk factors for a diagnosis of bronchiectasis at 2-years.  
 
Chapter 7 discusses the current literature relating to cough treatments. Chapter 7.1 is a 
Cochrane review that examines the efficacy of short-course antibiotics in the treatment of 
bronchiectasis in children and adults. Chapter 7.2 is a review of available cough remedies 
in children, with relevance to general practice.   
 
The final chapter (Chapter 8) summarises the thesis’ major research findings in the context 
of current literature. Potential areas for further research are also explored.  
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CHAPTER 2 
2.1 INTRODUCTION TO CHAPTER 2 
In Chapter 1.3.1 we have outlined the major diagnostic entities causing chronic wet cough 
in children. In clinical medicine, accurate diagnosis of these conditions can be challenging. 
Pre-school aged children, who comprise the majority of the cohort presenting with chronic 
cough, are usually unable to perform lung function testing, expectorate sputum for analysis 
or provide a detailed and accurate history. Hence, diagnosis is frequently based upon 
indirect findings. Further, data specifically examining the relationship between cough 
nature i.e. wet versus dry cough, and lower airway infection and inflammation is lacking.  
This study included a large cohort of young children presenting to a tertiary respiratory 
specialist clinic for investigation of chronic respiratory symptoms, the majority of whom had 
chronic cough. The remaining children were undergoing evaluation for indications such as 
persistent wheeze, stridor or noisy breathing. Children were divided according to a cough-
nature, symptom-based approach into 3 groups (‘wet cough,’ ‘dry cough’ and ‘no cough.’) 
We compared rates of lower airway infection (with bacteria, viruses and viral-bacterial co-
infection) in the 3 groups and explored the relationship with lower airway neutrophilic 
inflammation.  
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2.2 Wet cough in Children: Infective and Inflammatory 
Characteristics in Bronchoalveolar Lavage Fluid  
 
Pediatric Pulmonology
Wet Cough in Children: Infective and Inflammatory
Characteristics in Broncho-Alveolar Lavage Fluid
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Summary. Wet cough is a common feature of many disease processes affecting children. Our
aim was to examine the relationships between cough nature, lower airway infection (bacterial,
viral, and viral–bacterial) and severity of neutrophilic airway inflammation. We hypothesized
that viral–bacterial co-infection of the lower airway would be associated with wet cough and
heightened neutrophilic airway inflammation. We prospectively recruited 232 children undergo-
ing elective flexible bronchoscopy. Participants were grouped using a cough nature symptom-
based approach, into wet, dry or no cough groups. Broncho-alveolar lavage (BAL) and clinical
data, including presence, nature, and duration of cough and key demographic factors, were
collected. Children with wet cough (n ¼ 143) were more likely to have lower airway bacterial
infection (OR 2.6, P ¼ 0.001), viral infection (OR 2.04, P ¼ 0.045) and viral–bacterial co-infec-
tion (OR 2.65, P ¼ 0.042) compared to those without wet cough. Wet cough was associated
with heightened airway neutrophilia (median 19%) as compared to dry or no cough. Viral–bac-
terial co-infection was associated with the highest median %neutrophils (33.5%) compared to
bacteria only, virus/es only and no infection (20%, 18%, and 6%, respectively, P < 0.0001).
Children with wet cough had higher rates of lower airway infection with bacteria and viruses.
Maximal neutrophilic airway inflammation was seen in those with viral–bacterial co-infection.
Cough nature may be a useful indicator of infection and inflammation of the lower airways in
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INTRODUCTION
Chronic wet cough is the presenting feature of sever-
al different disease processes in children, ranging from
viral respiratory tract infections to bronchiectasis.1 Wet
cough is an important discriminating sign in children
presenting for evaluation of respiratory symptoms.2 Un-
like the symptom of wheeze,3 wet cough is reliably
reported by parents when compared to clinician’s as-
sessment and bronchoscopic findings.4
The association between chronic wet cough, bacterial
infection and extent of lower airway suppuration
has been described in prospective2,5 and retrospective
studies.6–8 However, these studies have been limited by
lack of a comparative group or small cohorts. Further-
more, there are no studies to date that report on com-
mon respiratory viral pathogens associated with chronic
wet cough, nor on the rates of lower airway infection
in children without cough. Beyond the field of cystic
fibrosis (CF), research into the role of viral–bacterial
co-infection and cough in children is scarce.
Neutrophilic inflammation of the lower airways is
common in children with chronic wet cough.9 It is also
a key factor in Cole’s ‘‘vicious circle’’ hypothesis on
the pathogenesis of bronchiectasis whereby infection,
inflammation, and impairment of mucociliary clearance
mechanisms are responsible for airway destruction.10
The effectiveness of antimicrobials in the treatment of
chronic wet cough in children has been shown in cohort
studies7,8,11 and further supported by a recent double-
blinded randomized controlled trial.12
In this study, 232 children were assigned to symp-
tom-based cough groups and associations between
cough presence and nature (i.e., wet or dry), lower air-
way infection (viral and/or bacterial), and inflammation
were evaluated. We hypothesized that neutrophilic in-
flammation of the lower airways is greater in children
with wet cough, as compared to those with dry cough
or no cough, and is most intense in the presence of
viral–bacterial co-infection.
MATERIALS AND METHODS
Study Design
Any child referred by a pediatric respiratory physi-
cian for elective flexible bronchoscopy (between
March 2008 and November 2011) was eligible for in-
clusion. The single exclusion criterion was CF, as deter-
mined by sweat chloride level and/or CF gene mutation
analysis. Two hundred fifty-four children were enrolled
and BAL data was available for 232 children. Cough
category, that is, ‘‘wet,’’ ‘‘dry,’’ or ‘‘no cough’’ was de-
termined by parental assessment (on the day of bron-
choscopy) as previously done2,11 and validated.4
The majority of children enrolled in the study had
recurrent or chronic (>4 weeks) cough (71.1%). Other
common indications for bronchoscopy included: stridor
or recurrent croup (7.8%), wheeze or noisy breathing
(3.4%) and chronic X-ray changes or recurrent pneumo-
nias (3.1%). Thirty-six (15.5%) participants had radio-
logically proven bronchiectasis. All children underwent
pre-anesthetic assessment by an anesthetist who did not
allow performance of bronchoscopy in children with an
acute respiratory illness. The Queensland Children’s
Health Services Ethics Committee approved the study
and all parents provided written informed consent.
A standardized clinical questionnaire was undertaken
on the day of the bronchoscopy. This included current
respiratory symptoms (with detailed questions regarding
cough presence or absence and cough nature), past
medical history and relevant demographic factors in-
cluding household cigarette smoking.
Flexible bronchoscopy (Olympus; Tokyo, Japan) was
performed under general anesthesia. BAL was obtained
as per European Respiratory Society guidelines.13 Ster-
ile normal saline solution, in three aliquots of 1 ml/kg
(maximum 20 ml), was instilled into the most affected
area or into the right middle lobe in patients with gen-
eralized disease. Gentle suction was applied and the
sample was collected in a mucus trap. To reduce upper
airway contamination, suction through the broncho-
scope was avoided until the tip was wedged in the ap-
propriate segment.
The first aliquot was used for microbiological assess-
ment; the second and third were pooled for cellularity
studies. Microbiological assessment included quantita-
tive aerobic bacterial cultures, specific testing for myco-
bacterial species using inoculation of Lowenstein–
Jensen media, and PCR techniques for mycoplasma.
Positive bacterial culture was defined as growth of
!105 colony-forming units (cfu)/ml.9 Bacteria consid-
ered as significant respiratory pathogens included:
Streptococcus pneumoniae, Moraxella catarrhalis, Hae-
mophilus influenzae, Pseudomonas aeruginosa, Staphy-
lococcus aureus, Enterobacteriaceae, Mycobacteria,
Aspergillus species, and Mycoplasma pneumonia.14
ABBREVIATIONS:
BAL Broncho-alveolar lavage
BALF Broncho-alveolar lavage fluid
BLP Beta-lactamase positive
BLN Beta-lactamase negative
CF Cystic fibrosis
RSV Respiratory syncytial virus
hMPV Human metapneumovirus
PCR Polymerase chain reaction
PBB Protracted bacterial bronchitis
TCC Total cell count
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Detection of respiratory viruses was undertaken using
polymerase chain reaction (PCR), as previously de-
scribed,15 to detect respiratory syncytial virus (RSV),
adenovirus, parainfluenza virus (Types 1–3), influenza
and human metapneumovirus (hMPV). A total cell
count (TCC) was performed and cell differential profile
(minimum 400 cells counted—modified Wright’s stain,
Diff Quik, Lab Aids, Narrabeen, NSW, Australia) as
described in prior studies.9
Statistical Analyses
Statistical analysis was carried out using IBM SPSS
Statistics (Version 20.0, IBM Corp., Armonk, NY).
Medians and inter-quartile ranges were reported as data
were non-normally distributed. Mann–Whitney’s U-test
was used for two group comparisons and Kruskal–Wallis
test for >2 groups comparisons of continuous variables.
Pearson’s chi-square test was used for categorical varia-
bles, with continuity correction used for 2 ! 2 analyses.
Children were divided into three groups for the purposes
of analysis: ‘‘wet cough,’’ ‘‘dry cough,’’ and ‘‘no
cough.’’ For calculation of odds ratios and confidence
intervals, ‘‘dry cough’’ and ‘‘no cough’’ groups were
combined as a single group and compared to the ‘‘wet
cough’’ group. For all analyses, we used two-sided tests,
with P-values < 0.05 denoting statistical significance.
RESULTS
Participants
The median age of the 232 children (151 male, 81
female) recruited to the study was 26.5 months (IQR
15, 62). Children with dry cough were significantly
older than those with wet or no cough and were more
likely to be receiving corticosteroid medication. The
median duration of cough overall was 28 weeks (8, 58);
that in the wet cough group was 28 weeks (11.5, 56.3)
and dry cough was 52 weeks (6, 108). There were no
other significant differences in baseline characteristics
between groups (Table 1).
Of the 232 BAL results, 115 (49.6%) had positive
bacterial cultures ("105 cfu/ml) and/or one or more vi-
rus detected. Of the total group, 94 (40.5%) cultured
one or more bacterial species, 50 (21.6%) were PCR
positive for one or more virus and 29 (12.5%) had co-
infection with both bacteria and virus/es (Fig. 1).
Bacteria
The proportion of children that had positive culture
("105 cfu/ml) of one or more bacterial species varied
significantly between groups; 70/143 (49%) in the wet
cough group, 5/18 (27.8%) in the dry cough group, and
19/71 (26.8%) in the no cough group (P ¼ 0.004).
H. influenzae was the predominant pathogen in both the
wet and dry cough groups, being present in 49 of 143
(34.2%) of the wet cough group and 4 of 18 (22%) of
the dry cough group and 7 of 71 (9.9%) of the no cough
group (P ¼ 0.001). A large proportion of H. influenzae
strains isolated were B-lactamase positive, with 17/49
(34.7%) in the wet cough group, only 1/7 (14.3%) in
the no cough group, and none in the dry cough group
(P ¼ 0.012).
M. catarrhalis was the second most common organism
in the wet cough group, present in 26/143 (18.2%), fol-
lowed by S. pneumoniae in 22/143 (15.4%) and S. aureus
in 8/143 (5.6%). In the dry cough group, S. pneumoniae
was present in 1 of 18 (5.6%). In the no cough group,
M. catarrhalis was isolated in 7 of 71 (9.9%), S. aureus
in 3 of 71 (4.2%), S. pneumoniae 4 of 71 (5.6%) and
Escherichia coli 1 of 71 (1.4%). Of the 209 children
where data for M. pneumoniae PCR were available, 4
were positive (3 with wet cough, 1 with no cough). None
in the ‘‘dry cough’’ group had M. pneumoniae.
Antibiotic use in the 24 hr prior to the bronchoscopy
appeared to be associated with lower rates of bacterial
infection, however, this was not statistically significant
(P ¼ 0.062). Only nine of 36 (25%) children who re-
ceived antibiotics were positive for bacteria compared
to 84/194 (43.3%) who did not receive antibiotics being
positive (two missing data-points for antibiotic usage).
TABLE 1—Background Characteristics of Study Participants According to Cough Group
Characteristic Wet cough, n ¼ 143, n (%) Dry cough, n ¼ 18, n (%) No cough, n ¼ 71, n (%) P-valuea
Sex, M:F (% male) 94:49 (66) 11:7 (61) 46:25 (65) 0.926
Median age, mo (IQR) 26 (15, 60) 66 (31, 159) 25 (11, 59) 0.001
Household tobacco smoke exposure 55 (39) 2 (12) 22 (32) 0.069
Siblings—1þ 115 (80) 16 (89) 55 (78) 0.551
Indigenous statusb 9 (6) 1 (6) 7 (10) 0.837
Bronchiectasis (radiologically proven) 24 (17) 2 (11) 10 (14) 0.759
Antibiotics prior 24 hr 28 (20) 2 (12) 6 (9) 0.092
Corticosteroid use (oral or inhaled) n ¼ 118, 22 (19) n ¼ 11, 5 (46) n ¼ 64, 8 (13) 0.031
aP-value tests whether all three groups have the same percentage, median, or frequency. P-values < 0.05 considered significant and denoted in bold.
bThree in wet cough group and one in no cough group had unknown indigenous status.
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Viruses
One or more viruses were detected in 37/143
(25.9%) of the wet cough group, 1/18 (5.6%) of the dry
cough group, and 12/71 (16.9%) of the no cough group
(P ¼ 0.074). Adenovirus was the most common virus
isolated in the BAL samples across cough categories. In
those with wet cough, 21 of 143 (14.7%) were positive
for adenovirus, with 1/18 (5.6%) and 5/71 (7%) positive
in the dry and no cough groups (P ¼ 0.183). Parain-
fluenza was the second most common virus, present in
9/143 (6.3%), none and 3/71 (4.2%) in the wet, dry, and
no cough groups, respectively (P ¼ 0.478). RSV was
present in 6 (4.2%), 0 and 2 (2.8%) participants in each
of the wet cough, dry cough and no cough groups re-
spectively (P ¼ 0.616). Influenza was present uncom-
monly, with 2 (1.4%) in the wet cough and 2 (4.2%) in
the no cough groups (P ¼ 0.636). hMPV was isolated
in a single participant in the wet cough group (0.7%).
To account for seasonal influences on viral carriage,
the season in which the bronchoscopy was performed
was compared to each individual virus. Parainfluenza
was the only virus whose presence was associated with
a particular season, being detected significantly more
frequently in winter (P ¼ 0.038).
Viral–Bacterial Co-Infection
Viral–bacterial co-infection was identified in 23/143
(16.1%) of children with wet cough, 1/18 (5.6%) with
dry cough, and 5/71 (7%) with no cough (P ¼ 0.110).
The most common viral–bacterial combination was ade-
novirus and H. influenzae, with 13 of 29 (44.8%) hav-
ing this combination, of which the majority, 10 of 13
(76.9%) had wet cough (Table 2). Due to small partici-
pant numbers in the no cough group, dry and no cough
categories were combined into a single category in
Table 3.
Airway Cellularity
Cellularity data were available for 212 participants.
Median TCC differed significantly across cough groups
with wet cough having the highest median TCC, fol-
lowed by the dry cough and no cough groups (Table 4).
Wet cough also had the highest median %neutrophils,
and the lowest median %macrophages. Only 30
(14.2%) participants had any eosinophils identified
(range: 1–16%). Of these children, 14 (6.6%) had clini-
cally significant eosinophilia defined as %eosinophils
on BAL >2.5%.16 Nine had wet cough, of which three
were receiving inhaled corticosteroids and/or beta-ago-
nists. There was no significant difference in eosinophil
count across cough groups (P ¼ 0.759).
When grouped in accordance with infection category
(Fig. 2), median %neutrophils were highest in the viral–
bacterial co-infection group followed by the bacterial,
viral and no infection groups (P < 0.0001). Conversely,
median %macrophages were highest in the no infection
group and lowest in the viral–bacterial co-infection
group (P ¼ 0.002). There was no significant difference
in median %lymphocytes across groups (P ¼ 0.349).
No significant differences in %eosinophils were seen
across infection groups (P ¼ 0.111), there were insuffi-
cient numbers to generate a boxplot.
Children with no cough and bacterial infection had
similar airway %neutrophils and TCC to those with no
cough without bacterial infection. Airway %neutrophils
(median 4% ‘‘no bacteria’’ vs. 4.5% ‘‘bacteria present,’’
P ¼ 0.976) and TCCs (median 137 " 106/L vs.
155 " 106/L, P ¼ 0.37) showed no significant difference.
Corticosteroid use was identified in 35 patients at the
time of BAL but did not influence airway cellularity
(results not shown).
Fig. 1. Venn diagram illustrating relative number of partici-
pants demonstrating lower airway infection (bacterial, viral,
and viral–bacterial) in BALF.
TABLE 2—Patterns of Viral–Bacterial Co-Infection and
Number With Wet Cough
Co-infection (viral–bacterial) No. of children No. with wet cough
Adenovirus and H. influenzaea 13 10
RSV and H. influenzab 4 4
Parainfluenza and H. influenzaec 3 2
Adenovirus and S. pneumoniae 2 2
Parainfluenza and M. catarrhalisd 2 2
Adenovirus and M. catarrhalise 1 0
Parainfluenza and S. pneumoniae 1 0
Parainfluenza and M. pneumonia 1 1
Influenza and M. catarrhalis 1 1
Influenza and S. aureus 1 1
Total 29 23
aFour also had M. catarrhalis, 3 had S. pneumonia, 1 S. aureus.
bTwo also had S. pneumoniae, 2 had M. catarrhalis.
cOne also had S. aureus and S. pneumonia.
dOne also had adenovirus.
eOne also had E. coli.
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DISCUSSION
Findings from this large prospective cohort study in-
dicate that rates of lower airway infection with bacteria
and/or viruses are significantly higher in children with
wet cough compared to those with dry or no cough. In
addition, airway neutrophilia is higher in children with
wet cough and most heightened in the presence of vi-
ral–bacterial co-infection. The use of a symptom-based
approach increases the relevance and utility of our find-
ings to clinical practice.
Our prior studies reporting BAL findings in children
with wet cough have largely focused on protracted bac-
terial bronchitis (PBB), one of the most common causes
of chronic wet cough in children,11 findings which have
subsequently been supported by retrospective stud-
ies.7,8,17 This study’s cohort of children was recruited
after our previously studied cohorts and included those
with a range of clinical indications. One of the strengths
of this study is the use of cough groupings, that is, ‘‘wet
cough,’’ ‘‘dry cough,’’ and ‘‘no cough,’’ in place of diag-
nostic categories. It is well known that significant symp-
tom overlap exists between common pediatric respiratory
conditions causing cough.7,11 Our rationale was that
symptom-based categories are likely to be more objective
and repeatable than diagnostic categories. Children with
CF were excluded due to their exaggerated airway in-
flammatory responses and unique microbiota.18,19 We in-
cluded children with non-CF bronchiectasis, the majority
of whom had idiopathic bronchiectasis, as their airway
cellularity and microbiota are similar to children with
PBB.20 Our justification for including these children was
to reflect the diverse spectrum of disease presentation
with wet cough and increase the value and general appli-
cability of our findings.
Persistent lower airway neutrophilic inflammation is
known to be important in the pathogenesis of many
TABLE 4—Differential BAL Cell Count According to Cough Category
Wet cough, n ¼ 132 Dry cough, n ¼ 15 No cough, n ¼ 65 P-valuea
Total cell count ("106/L) 200 (108, 381) 185 (101, 414) 140 (82, 268) 0.016
Neutrophil %b 19 (6, 53) 11 (8, 36) 4 (2,11) <0.0001
Macrophage % 63 (39, 83) 74 (44, 88) 83 (69, 92) <0.0001
Lymphocyte % 9 (5, 17) 8 (3, 15) 7 (5, 15) 0.612
Eosinophil %c 0 (0, 0) 0 (0, 0) 0 (0, 0)
All values within cough categories given as median (IQR).
Median cell counts/% rounded to nearest whole number.
Due to a lack of standardization of BAL sampling and processing methods, there is currently no international consensus on normal BAL cell
counts in children.13 We have quoted cutoffs used in our center.
aP-values calculated using Kruskal–Wallis test to compare medians across three groups. P-values < 0.05 denoted in bold.
bNeutrophilia defined as >6.5% neutrophils in BAL fluid.11
cEosinophilia defined as >2.5% eosinophils in BAL fluid.16
TABLE 3—Cough Categories Versus Lower Airway Infection (‘‘Dry Cough’’ and ‘‘No Cough’’ Groups Combined)
Wet cough
Odds ratio (95% CI) P-valueaYes, n ¼ 143, n (%) No, n ¼ 89, n (%)
No infection 59 (41.3) 58 (65.2) 0.38 (0.22, 0.65) <0.0001
Any bacterial species 70 (49) 24 (27) 2.60 (1.47, 4.60) 0.001
H. influenzae 49 (34.3) 11 (12.4) 3.65 (1.78, 7.50) <0.0001
H. influenzae (BLP) 17 (11.9) 1 (1.1) 11.87 (1.55, 90.86) 0.017
H. influenzae (BLN) 32 (22.4) 10 (11.2) 2.28 (1.06, 4.90) 0.035
M. catarrhalis 26 (18.2) 7 (7.9) 2.60 (1.08, 6.28) 0.033
S. pneumoniae 22 (15.4) 5 (5.6) 3.06 (1.11, 8.39) 0.030
S. aureus 8 (5.6) 3 (3.4) 1.70 (0.44, 6.58) 0.443
Any viral species 37 (25.9) 13 (14.6) 2.04 (1.02, 4.10) 0.045
Adenovirus 21 (14.7) 6 (6.7) 2.38 (0.92, 6.15) 0.073
Parainfluenza 9 (6.3) 3 (3.4) 1.93 (0.51,7.31) 0.336
RSV 2 (1.4) 6 (6.7) 0.53 (0.10, 2.66) 0.436
Influenza 2 (1.4) 2 (2.2) 0.62 (0.09,4.46) 0.632
Viral–bacterial co-infection 23 (16.1) 6 (6.7) 2.65 (1.04, 6.80) 0.042
Adenovirus and H. influenza 10 (7) 3 (3.4) 2.16 (0.58, 8.06) 0.383
BLP, beta-lactamase positive; BLN, beta-lactamase negative.
aP-values < 0.05 denoted in bold.
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respiratory diseases.21,22 Neutrophilic inflammation is a
common pathological feature of diseases such as
COPD, bronchiectasis, and severe asthma.22 Its effect
on the growing lung may be particularly relevant. It is
postulated that recurrent or prolonged episodes of wet
cough are antecedent to bronchiectasis,20,23 with neutro-
philic inflammation being the presumed mechanism.
Therefore, our findings of neutrophilic inflammation in
symptom-based ‘‘wet cough’’ groupings may be clini-
cally relevant and important.
Research on viral–bacterial co-infection in the lower
airway epithelium suggests a role for increased patho-
gen adherence and delayed clearance,24 with im-
pairment of mucociliary clearance being an important
contributor.25 Clinically, viral–bacterial co-infection is
thought to play an important role in the pathogenesis of
respiratory diseases such as severe RSV bronchiolitis,26
pneumonia,27 otitis media,28,29 and sinusitis.30,31 We
have shown that viral–bacterial co-infection is more
common in children with (compared to those without)
wet cough, and that it causes a heightened neutrophilic
airway response. It is possible that viral–bacterial co-
infection may also play a role in the pathogenesis of
bacterial bronchitis and further research is needed.
Interestingly, in this study, the same organisms were
identified in children with and without wet cough
(Table 3) albeit with varying frequencies. We observed
higher rates of beta-lactamase positive H. influenzae in
the wet cough compared to the no wet cough group.
This finding may be explained by antibiotic selection
pressure (these children may have had greater
cumulative antibiotic exposure), however, we did not
specifically examine for this. Lower airway infection
rates in the cough-free group were also interesting.
Over a quarter (27%) of cough-free children had bacte-
ria detected with no significant increase in their median
%neutrophils in BAL (median neutrophils: 4% in those
without bacteria vs. 4.5% in those with bacteria). This
indicates that bacteria were present without signs of ac-
tive infection, that is, cough or neutrophilia. Upper air-
way contamination of the bronchoscope may explain
this finding, however, the higher threshold of !105 cfu/
ml for diagnosis of bacterial infection used in this study
should minimize such interference. Viruses were
detected in 16.9% of the cough-free children despite
having no acute viral lower respiratory tract infection
symptoms. Together, these findings support recent liter-
ature suggesting that the lung has a characteristic
microbiota, both in health and disease,32,33 and is un-
likely to be sterile, as previously believed.
The high prevalence of virus in the BAL has to be
interpreted with caution in the context that viruses
detected by PCR can be found in up to 33% of asymp-
tomatic children.34 Nevertheless, the role of viruses in
the pathogenesis of chronic cough in children is the fo-
cus of further research by our group at present. Prelimi-
nary results show that viral infection probably plays an
important role in the initiation of conditions such as
PBB (results not yet published), the most common
cause of chronic wet cough in children.11,17
There were a number of relevant negative findings
from our study. Firstly, we did not find a statistically
Fig. 2. A and B: Boxplots illustrating median (A) %neutrophils and (B) %macrophages accord-
ing to infection presence and type on BAL; no infection, virus, bacteria and both virus and
bacteria. Of the outliers (represented by asterisks/open circles in (A), most had wet cough (11
of 16). Five had elevated (>2.5%) eosinophils on BAL. Cough improved or resolved in 9 who
received antibiotics. It is likely that some of these children had undetected bacterial infection
(i.e., <105 cfu/ml), asthma or other conditions such as aspiration, to explain these elevated
neutrophil counts.
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significant inverse relationship between antibiotic use
(in the 24 hr prior to bronchoscopy) and significant
bacterial growth (!105 cfu/ml on BAL). However,
our study was not powered to detect this difference,
and we would expect a significant association with
larger participant numbers. Secondly, there was no
difference in airway lymphocyte nor eosinophil
counts across infection groups, even in the presence
of viral infection, nor was there any association be-
tween corticosteroid use and cellularity. However, 9
of the 14 children with airway eosinophilia on BAL
had wet cough; 3 of these were receiving inhaled cor-
ticosteroids and/or beta-agonist at time of bronchos-
copy. Although not specifically examined in this
paper, bacterial infection has recently been found to
be associated with wheeze (and possibly later devel-
opment of asthma).35–37 We believe that asthma and
PBB co-exist in some children, and the two condi-
tions are not mutually exclusive.
There are some important limitations of this study.
Firstly, due to the ethical issues in obtaining control
BAL data in children, we used a comparator rather than
a control group. This comparator group was children
without cough having bronchoscopy for investigation of
other respiratory symptomatology, for example, stridor.
It is difficult to predict the effect of these ‘‘other respi-
ratory symptomatology’’ on the infective and inflamma-
tory properties of the lower airway but we would
expect a reduction in the strength of the observed asso-
ciations. This factor may explain the large number of
cough-free children having bacteria and viruses
detected. Secondly, we did not undertake PCR for hu-
man rhinovirus (HRV), a very common upper airway
virus. The importance of HRV in the lower airways of
children remains unknown. Thirdly, as bronchoscopies
were performed for clinical indications only, the major-
ity of participants had only a single BAL performed.
Without multiple lower airway specimens over time, we
were unable to attribute causality. Lastly, we did not
look specifically at biomarkers of neutrophilic inflam-
mation, such as IL-8.
In conclusion, our study has several important and
novel findings. Foremost, wet cough is associated with
higher rates of lower airway infection, with bacteria
and viruses, compared to dry or no cough, with similar
organisms present across cough groups. Bacteria and/or
viruses are commonly present in the lower airway of
children without symptoms of viral respiratory tract in-
fection and who are cough-free. Viral–bacterial co-in-
fection of the lower airways is associated with a
significantly heightened neutrophilic airway response.
Lastly, a direct correlation exists between cough nature
and neutrophilic airway inflammation; children with
wet cough have greater neutrophilic inflammation com-
pared to children with dry cough.
Our symptom-based approach shows that cough na-
ture in children correlates with severity of underlying
airway inflammation and neutrophilic response as found
in BAL, highlighting the importance of accurate charac-
terization of cough during pediatric respiratory consul-
tations. The finding of high rates of lower airway
infection associated with wet cough may assist clini-
cians in making management decisions and inform fu-
ture research in this area.
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CHAPTER 3 
3.1 INTRODUCTION TO CHAPTER 3 
In Chapter 2 we demonstrated that children with wet cough have higher rates of lower 
airway infection with bacteria, viruses and viral-bacterial co-infection. We have also shown 
that children with viral-bacterial co-infection have the greatest neutrophilic lower airway 
inflammation, raising the possibility of microbial synergy. To date, research into chronic 
wet cough in children has focused on bacterial pathogens. The role of viral infections 
therefore needed further evaluation.  
Nasopharyngeal aspirate (NPA) is a common sampling method for detection of respiratory 
tract viruses in children. Unlike bronchoalveolar lavage (BAL), a positive NPA does not 
necessarily reflect presence of virus in the lower respiratory tract. However, BAL is 
significantly more invasive than NPA. The level of agreement between NPA and BAL for 
the detection of respiratory viruses in children with non-acute respiratory illness had been 
poorly studied. Further, the relationship between virus presence in the airways (as 
detected by PCR) and lower airway neutrophilic inflammation needed further elucidation.  
Specific viruses may exert greater influence on airway inflammation and may have 
relevance to the pathogenesis of certain chronic respiratory disorders in children. In this 
study, we tested for an extended panel of viruses in paired upper (NPA) and lower (BAL) 
respiratory tract samples from children undergoing bronchoscopy and BAL for assessment 
of chronic respiratory symptoms. The final diagnosis in the majority of the children in the 
study (64%) was PBB or bronchiectasis whilst those remaining (36%) had either no 
specific diagnosis or an airway abnormality. Of those with no final diagnosis, most (55%) 
were being investigated for chronic cough (73% had wet cough, 27% had dry cough) whilst 
the remainder had complaints of stridor, persistent wheeze, noisy breathing, haemoptysis 
or persistent auscultatory findings. 
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3.2 Respiratory Virus Detection in Nasopharyngeal 
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Virus Type in Children with Chronic Respiratory 
Symptoms 
Journal of Clinical Virology 58 (2013) 683– 688
Contents lists available at ScienceDirect
Journal  of  Clinical  Virology
j ourna l h om epage: www.elsev ier .com/ locate / j cv
Respiratory  virus  detection  in  nasopharyngeal  aspirate  versus
bronchoalveolar  lavage  is  dependent  on  virus  type  in  children  with
chronic  respiratory  symptoms
Danielle  F.  Wurzela,b,∗, Julie  M.  Marchanta,b, Julia  E.  Clarke,  Ian  M.  Mackayf,
Claire Y.T.  Wangf, Theo  P.  Sloots f, John  W.  Uphamc, Stephanie  T.  Yerkovichc,g,
I. Brent  Mastersa,b, Peter  J.  Bakerd, Sophie  Anderson-Jamesa,b, Anne  B.  Changa,b,h
a Queensland Children’s Medical Research Institute, The University of Queensland, Brisbane, Australia
b Queensland Children’s Respiratory Centre, Royal Children’s Hospital, Brisbane, Australia
c School of Medicine, The University of Queensland, Herston, Australia
d School of Population Health, The University of Queensland, Herston, Australia
e Department of Infectious Diseases, Royal Children’s Hospital, Brisbane, Australia
f Queensland Paediatric Infectious Diseases Laboratory, Queensland Children’s Medical Research Institute, Sir Albert Sakzewski Virus Research Centre,
Children’s Health Queensland Hospital and Health Service, The University of Queensland, Herston, Australia
g Queensland Lung Transplant Service, Prince Charles Hospital, Brisbane, Australia
h Child Health Division, Menzies School of Health Research, Darwin
a  r  t i  c  l  e  i  n  f  o
Article history:
Received 2 July 2013
Received in revised form
12 September 2013
Accepted 13 September 2013
Keywords:
Bacteria
Human adenovirus
Human rhinovirus
Neutrophilic airway inflammation
Polymerase chain reaction
Co-infection
a  b  s  t  r  a  c  t
Background:  The  comparative  yield  of respiratory  virus  detection  from nasopharyngeal  aspirate  (NPA)
versus  bronchoalveolar  lavage  (BAL)  is  uncertain.  Furthermore,  the  significance  of virus detection and  its
relationship  to lower  airway  neutrophilic  inflammation  is poorly  studied.
Objectives:  To evaluate  the  sensitivity,  specificity  and  predictive  values  of  NPA  for  detecting  respiratory
viruses  in BAL;  and  to  determine  the relationship  between  viruses  and  lower  airway neutrophilia  in
children  with  non-acute  respiratory  illness.
Study design:  150 paired  NPA  and  BAL  samples  were  obtained  from  75 children  aged  <18  years  undergoing
flexible  bronchoscopy  for investigation  of chronic  respiratory  symptoms.  Viral  studies  were performed
using  polymerase  chain  reaction  (PCR).  Cellularity  studies  were  performed  on BALs.  Diagnostic  param-
eters  of NPA  compared  to BAL  and  associations  between  viruses  and lower  airway  %neutrophils  were
evaluated.
Results:  NPA  had  a higher  yield  than  BAL  for  detection  of  any  respiratory  virus  (52  versus  38,  respectively).
NPA  had  a high  sensitivity  (92%)  and low specificity  (57%)  for  detecting  HRV  in  BAL  with  poor  kappa
agreement  value  of 0.398  (95%  CI 0.218–0.578,  p  < 0.001).  NPA  had  a  fair  sensitivity  (69%)  and good
specificity  (90.3%)  for detecting  HAdV  on BAL, kappa  agreement  was 0.561  (95%  CI 0.321–0.801,  p <  0.001).
HAdV  positivity  on  NPA,  compared  to negativity,  was  independently  associated  with  heightened  airway
neutrophilia  [mean  difference  (95%  CI): 18  (1,35);  p =  0.042].
Conclusions:  NPA has  a higher  yield  for  respiratory  virus  detection  than  BAL,  however  its  diagnostic
accuracy  is dependent  on  viral species.  Adenovirus  positivity  is associated  with  significantly  heightened
lower  airway  neutrophilia  in  children  with  chronic  respiratory  symptoms.
Crown Copyright ©  2013 Published by Elsevier B.V. All rights reserved.
Abbreviations: NPA, nasopharyngeal aspirate; BAL, bronchoalveolar lavage; PCR,
polymerase chain reaction; RVI, respiratory virus infection; HRV, human rhinovirus;
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omavirus.
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1. Background
Accurate identification of respiratory pathogens is important
in clinical medicine and research. In bacteriology, upper airway
sampling can misrepresent the lower airway microbiota [1,2].
In contrast, there is little such comparative data for virology.
Nasopharyngeal aspirates (NPA) or nasal washes are regarded as
the specimen of choice for detection of upper respiratory tract
viruses by polymerase chain reaction (PCR) [3,4]. Upper airway
sampling is relatively simple, can be performed at the bedside
and is minimally invasive. In contrast, lower airway sampling
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in young children is invasive, requiring a bronchoalveolar lavage
(BAL).
Traditionally, BAL has been considered the ‘gold-standard’ for
the microbiological diagnosis (viral and bacterial) of lower respira-
tory tract infection in children. However, as BAL requires specialist
input and is often performed under anesthesia, it is reserved for
patients with complex or severe disease, e.g., in the setting of
intensive care; immune-compromise or in children with chronic
or recurrent respiratory tract symptoms. The disparities in ease of
collection of NPA versus BAL, raise two important questions. Firstly,
what is the comparative yield of NPA compared to BAL for respira-
tory virus detection in children? Secondly, what is the significance
of a positive NPA with respect to lower airway inflammation? Given
the lack of studies addressing these important questions [5,6], we
evaluated paired NPA and BAL specimens in 75 children.
2. Objectives
To compare the yield and diagnostic parameters of respiratory
virus detection on NPA versus BAL using molecular methods, and
to evaluate whether virus positivity on NPA correlates with lower
airway neutrophilic inflammation and by inference, active viral
pulmonary disease.
3. Study design
The Queensland Children’s Health Services Ethics Committee
approved the study and written informed consent was obtained
from each parent or guardian. Children undergoing flexible bron-
choscopy, for any clinical indication, as arranged by their treating
physician, were eligible. Samples evaluated in this article were
obtained from children recruited to a larger cohort study on chronic
cough in children [7]. Caregivers completed a standardized clin-
ical questionnaire on the day of bronchoscopy including current
respiratory symptoms and relevant demographics. Children with
symptoms of significant acute lower respiratory tract infection,
e.g., high fever, tachypnea/shortness of breath, wheeze or rattly
chest were deemed, by an anesthetist, to be unfit for anesthesia
and excluded from the study.
Contemporaneous NPA and BAL sampling was performed under
general anesthesia. NPA was collected first, using a disposable
catheter connected to a mucous trap. Dry nasopharyngeal suc-
tion, via both nares, was performed, followed by suction of 2–3 ml
of sterile normal saline directly into the suction catheter to rinse
through remaining contents.
Bronchoscopic BAL was then performed using standardized
methods as per European Respiratory Society guidelines [8]. Ster-
ile normal saline, in three aliquots of 1 ml/kg (maximum 20 ml),
was instilled into the most affected area, or right middle lobe in
patients with generalized disease. To minimize upper airway con-
tamination, suction through the bronchoscope was  avoided until
the tip had entered the distal airways. The first aliquot was  used
for microbiological testing, the second and third were pooled for
cellularity studies.
Viral studies were undertaken using real-time PCR techniques,
as described previously [9–13], to detect 16 respiratory virus
types and subtypes. These included human rhinoviruses (HRV),
human adenoviruses (HAdV), respiratory syncytial virus (RSV),
human influenza A virus (IFAV), human influenza B virus (IFBV),
human para-influenza virus 1–3 (HPIV1–3), human metapneu-
movirus (hMPV), human bocavirus (HBoV), human coronaviruses
(HCoV – NL63, OC43, 229E, HKU1), WU polyomavirus (WUPyV) and
KI polyomavirus (KIPyV). BAL specimens were refrigerated imme-
diately and processed within 24 h. NPA specimens were stored at
−70 ◦C prior to processing.
We  defined positive bacterial culture as growth of ≥105 colony-
forming units (cfu)/ml [10] of any of the following pathogens on
BAL: Streptococcus pneumoniae, Moraxella catarrhalis,  Haemophilus
influenzae,  Pseudomonas aeruginosa,  Staphylococcus aureus or
Enterobacteriaceae. Total cell count and differential profile (min-
imum 400 cells counted) were performed on BAL as described
previously [14].
3.1. Statistical analyses
Statistical analyses were carried out using IBM SPSS (v20, San
Francisco, USA). Medians and inter-quartile ranges were reported
as data were non-normally distributed. Kappa analyses were used
to assess levels of agreement between sampling techniques. Com-
parisons of categorical variables were performed using Pearson’s
!2 test or Fisher exact test if any category had an expected value of
<5. Mann–Whitney U test was used for two  group comparisons and
Kruskal–Wallis test for >2 groups comparisons of continuous vari-
ables. Multiple linear regression was  employed to adjust for virus
co-detection and bacterial infection. A two-tailed p-value <0.05 was
considered statistically significant. Sensitivity, specificity, positive
and negative predictive values and likelihood ratios were manually
calculated.
4. Results
Between February 2010 and May  2012, paired NPA and BAL
samples were obtained from 75 children (median age = 33 months,
IQR 16, 69; male n = 50, 66.7%). One-third of children (n = 25,
33.3%) were exposed to household cigarette smoke. Chronic cough
(≥4 weeks) was reported in 45 participants (60%) at time of
bronchoscopy. The major diagnoses within the cohort included:
protracted bacterial bronchitis (n = 31, 41%) and bronchiectasis
(n = 17, 23%); the remaining participants had either no specific diag-
nosis (n = 22, 29%) or a congenital airway abnormality (n = 5, 7%).
The most common viruses detected on NPA were HRV (n =  44) and
HAdV (n = 15). In regard to seasonality, HAdV positivity on BAL was
more likely to occur in spring or summer than winter or autumn
(p = 0.004) using chi-square analysis. HRV detections followed a
bimodal distribution with peak detections occurring in spring and
autumn.
4.1. Comparison of yield on paired NPA and BAL samples
Of the 75 paired NPA and BAL samples, 52 (69.3%) children had
one or more virus detected from NPA and 38 (50.7%) had one or
more virus from BAL. When considering detection of any virus, 32
(42.7%) NPA-BAL pairs were concordant PCR-positive, 17 (22.7%)
pairs were concordant PCR-negative and 26 (34.7%) pairs had dis-
cordant PCR results. Of the discordant pairs, most (n =  20, 76.9%)
were PCR positive on NPA but negative on BAL. Detection rates var-
ied among the different viruses (Table 1). Most marked was  the
difference between NPA and BAL for HRV. Using positive PCR on
BAL as an arbitrary gold standard, we  calculated sensitivity, speci-
ficity, positive and negative predictive values and likelihood ratios
(Table 1). HRV and HAdV were the most common viruses detected
from NPA and BAL. Levels of agreement between NPA and BAL var-
ied among the different viruses. The agreement between NPA and
BAL for HRV was  poor, kappa = 0.398 (95%CI 0.218, 0.578, p < 0.001)
but good for HAdV at 0.561 (95%CI 0.321, 0.801, p < 0.001).
4.2. Relationship between virus positivity and BAL neutrophilia
The median lower airway %neutrophils were significantly higher
in children who  were NPA-positive for any virus compared to
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Table 1
Absolute number of virus detections by PCR from paired NPA/BAL samples (n = 75) with diagnostic test parameters (BAL as the arbitrary gold-standard).
NPA/BAL HRV HAdV Othera HBoV HCoV WUPyV/KIPyV Totalb
NPA+ 44 15 5 7 4c 4 52
BAL+  24 13 4 4 3c 1 38
NPA+/BAL−  22 6 1d 5 3 4 20
NPA−/BAL+ 2 4 0 2 2 1 6
NPA+/BAL+ 22 9 4 2 1 0 32
NPA−/BAL−  29 56 70 66 69 70 17
Sensitivity 92% 69% – 50% 33% – 84%
Specificity 57% 90% 99% 93% 96% – 46%
PPV  0.5 0.6 0.80 0.29 0.25 – 0.62
NPV  0.94 0.93 – 0.97 0.97 – 0.74
LR+  2.12 7.15 – 7.10 7.99 – 1.56
LR−  0.19 0.34 – 0.54 0.70 – 0.35
Kappa 0.40 0.56 0.88 0.32 0.25 0.02 0.30
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−,  negative likelihood ratio.
a RSV, IFA/B, HPIV1-3, hMPV.
b Total no. of children with one or more viruses detected.
c HCoV-OC43.
d HPIV-1.
Table 2
Lower airway cellular differential versus virus status on NPA and BAL.
Lower airway cellular profile NPA HRV+ (n = 44) NPA HRV− (n = 31) p-Value NPA AdV+ (n = 15) NPA AdV− (n = 60) p-Value
TCCs (×106/L) 215 (106, 285) 240 (94, 360) 0.894 260 (168, 473) 200 (90, 290) 0.132
Neutr% 16 (6, 55) 13 (4, 32) 0.514 51 (15, 68) 12 (5, 36) 0.017
Macr% 60 (37, 82) 71 (29, 87) 0.605 46 (23, 74) 71 (41, 84) 0.075
Lymph% 6 (4, 13) 6 (3, 15) 0.812 5 (2, 11) 6 (4, 15) 0.183
Eosin% 0 (0, 0) 0 (0, 0) 0.262 0 (0,2) 0 (0,0) 0.314
Lower  airway cellular profile BAL HRV+ (n = 24) BAL HRV− (n = 51) p-Value BAL AdV+ (n = 13) BAL AdV− (n = 62) p-Value
TCCs (×106/L) 210 (108, 413) 230 (95, 350) 0.645 240 (112, 485) 215 (94, 285) 0.534
Neutr% 16 (9, 63) 15 (5, 40) 0.457 44 (14, 70) 12 (5, 37) 0.077
Macr% 65 (27, 82) 68 (39, 84) 0.544 54 (25, 83) 70 (38, 84) 0.497
Lymph% 8 (5, 20) 5 (3, 14) 0.318 3 (2, 7) 7 (5, 15) 0.017
Eosin% 0 (0, 2) 0 (0, 0) 0.162 0 (0, 1) 0 (0, 0) 0.825
Abbreviations: Neutr%, percentage neutrophils; Macro%, percentage macrophages; Lymph%, percentage lymphocytes; Eosin%, percentage eosinophils. Cell counts expressed
as  median (interquartile range) and rounded to nearest whole number.
NPA-negative children (19 [IQR 7, 65] vs. 11 [IQR 3, 21.5];
p = 0.045). Total cell counts (TCCs), %macrophages, %lymphocytes
and %eosinophils were similar across groups (data not shown).
When evaluating the two most frequent viruses, HRV and HAdV
(Table 2), presence of HAdV in the NPA was significantly associated
with increased BAL neutrophilia (p = 0.017) whereas HRV status on
NPA showed no association with %neutrophils (p = 0.514).
Similar to the NPA findings, the presence of any virus in the
BAL was associated with higher median %neutrophils compared to
the virus-negative state (23 [IQR 10, 67] vs. 11 [5,28], respectively;
p = 0.04). Median lower airway TCC was higher in BAL virus-positive
(235 × 106/L [IQR 115, 448]) versus virus-negative (160 × 106/L [58,
255]) groups (p = 0.068). No differences in lymphocyte counts was
observed when considering total viruses, but for individual viruses,
%lymphocytes were significantly lower in HAdV BAL positive com-
pared to HAdV BAL negative participants (p = 0.017). Children who
were HAdV positive on BAL had higher %neutrophils than those
who were HAdV negative on BAL (p = 0.077). In comparison, %neu-
trophils were similar across HRV positive and negative groups on
BAL (p = 0.457).
4.3. Regression analysis adjusting for virus co-detection and
bacterial infection
On multi-variable analysis, HRV in either NPA or BAL showed no
association with lower airway %neutrophils. In contrast, HAdV in
NPA and/or BAL was significantly associated with increased %neu-
trophils on BAL (Table 3). Bacterial infection was detected in over
half (32; 61.5%) of NPA virus positive participants with much lower
rates (6; 26.1%) in virus negative participants (p = 0.005). Rates
of bacterial infection in BAL virus positive (22; 57.9%) children
were also greater than BAL virus negative children (16; 43.2%);
however, this difference was  not significant (p = 0.204). The pre-
dominant bacterial organisms were: H. influenzae,  M. catarrhalis
and S. pneumoniae. Presence of bacterial infection as seen on
BAL had the strongest independent influence on lower airway
neutrophil counts (beta = 0.256 and 0.311 for NPA and BAL, respec-
tively) as shown in Table 3.
5. Discussion
In this study, we  systematically compared upper airway (NPA)
to lower airways (BAL) sampling with regards to diagnostic yield for
respiratory viruses in children with non-acute respiratory illness.
We found that concordance of NPA with BAL is largely dependent
on the virus being investigated. NPA has good concordance with
BAL for detection of HAdV, but poor concordance for HRV. In com-
parison to BAL, sensitivity, specificity, PPV and NPV of the most
frequently detected viruses on NPA differed according to the virus
being investigated. Specificity was  high for all viruses, except for
HRV. The reverse was observed with regards to sensitivity. Lastly,
presence of HAdV on NPA and/or BAL was associated with signifi-
cantly heightened %neutrophils in the lower airway.
To our knowledge, three major studies have compared upper
and lower airway specimens for respiratory virus detection.
All were limited by unpaired specimens or focused on specific
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Table  3
Multiple linear regression of mean difference in lower airway %neutrophils according to infective status on NPA and BAL.
Unadjusteda mean
difference in neutr% (IQR)
p-Value Adjustedb mean difference
in neutr% (IQR)
p-Valuec Betad
NPA
HAdV 20 (3, 37) 0.020 18 (1, 35) 0.042 0.245
HRV  5 (−9, 19) 0.486 −2 (−16, 12) 0.782 −0.033
Bacteria ≥ 105 cfu/ml (on BAL) 16 (3, 30) 0.016 15 (1, 28) 0.035 0.256
BAL
HAdV  15 (−3, 32) 0.097 18 (0.3, 35) 0.046 0.235
HRV  4 (−10, 19) 0.550 0 (−14, 15) 0.950 0.007
Bacteria ≥ 105 cfu/ml (on BAL) 16 (3, 30) 0.016 18 (4, 31) 0.01 0.311
a Unadjusted mean difference in %neutrophils between HAdV, HRV and bacteria positive and negative groups calculated using independent samples t-test.
b Adjusted mean difference in %neutrophils using multiple linear regression (adjusted for viral co-detection and bacterial infection).
c p-Values remain significant after logarithmic transformation of %neutrophils therefore mean differences reported.
d Standardized coefficient indicates independent influence of variable on %neutrophils.
diseases or viruses. The first compared NPA to BAL in lung trans-
plant recipients using unpaired, non-contemporaneous NPA and
BAL specimens obtained from 72 and 56 participants for NPA and
BAL, respectively. A higher yield of hMPV was seen in NPA com-
pared to BAL, with comparable rates of IFAV, HPIV, RSV, HCoV and
HRV [6]. Diagnostic accuracy of NPA for BAL was not assessed in
this study [6]. The second study used paired specimens, obtained
from 21 participants on 92 occasions, and compared induced spu-
tum to NPA for detection of respiratory viruses in children with
cystic fibrosis. HRV was the most common virus identified and
was present in the same frequency (21.7%) in NPA and sputum.
Concordance rates were higher than in the present study (87%
for HRV and 92% for other viruses), with higher sensitivity and
specificity (70% and 91.7%, respectively) [15]. The third study com-
pared paired nasal wash/tracheal suction specimens to BAL in terms
of RSV detection in 6 participants, and found BAL was  superior
for detection of RSV using antigen detection and culture methods
(insensitive methods when compared to PCR) [5].
Studies directly comparing NPA to BAL have focused on atyp-
ical pneumonia. The first study evaluated Pneumocystis jiroveci
pneumonia and the second compared detection methods for
mycoplasma pneumonia. Both studies found high concordance
between NPA and BAL. However, in contrast to our findings, in both
studies, BAL had a higher yield of positive detections than NPA.
Interestingly, in the study on mycoplasma pneumonia, BAL pos-
itivity was associated with increased lower airway %neutrophils,
however, NPA positivity was not. These differing findings may
reflect the different modes of transmission and mechanisms of
disease progression between viral and bacterial infections of the
respiratory tract.
Our study showed that NPA/BAL discordance was most marked
for HRV, where 22 (29.3%) children were NPA-positive but BAL-
negative. In contrast, HAdV was more likely to also be found in
the lower airway, with only 2 NPA-positive/BAL-negative children.
Previous studies have found HRV to have greater propensity to
infect the nasopharynx and proximal lower airways than the dis-
tal airways or alveoli [16]. This may  be related to HRV’s ability
to replicate optimally at cooler temperatures of the upper airway
[17], although this finding is inconsistent across HRV types [18].
In vivo studies demonstrate that HRV induces minimal epithe-
lial cytotoxicity with only a small subset of nasal and bronchial
mucosal cells becoming infected [16,19,20]. These factors may
explain why HRV is an uncommon cause of pneumonia, except in
the immune-compromised host [21]. Whilst HRV and HAdV can
both cause uncomplicated upper respiratory tract infection [22],
disease manifestation differs at the severe end of the spectrum.
HRV has been shown to play an important role in asthma exac-
erbations [23]; HAdV has been implicated in the pathogenesis of
obliterative bronchiolitis and bronchiectasis [24]. Thus, differences
between HAdV and HRV in their mechanisms of propagation and
respiratory disease pathogenesis are likely to explain our observa-
tions.
Our cross-sectional findings of elevated rates of HRV (59%) in
children who were essentially free of acute RVI symptoms is higher
than prior studies showing asymptomatic HRV nasopharyngeal
detection ranging from 12% to 33% [25–27]. HRV is frequently iden-
tified in patients with viral:bacterial co-infection [28], a  fact that
may  have relevance to our cohort of children with high rates of
bacterial infection and chronic cough.
To further understand the implications of our findings in rela-
tion to lower airway neutrophilic inflammation and virus detection,
the distinction between positive virus detection and active viral dis-
ease merits discussion. A PCR-positive NPA in a child without overt
symptoms of acute RVI is often believed to represent viral genome
shedding from a resolving infection [29] or preceding a new symp-
tomatic episode. However, certain HAdV types can cause prolonged
host shedding [30] with intermittent viral excretion over months to
years [31,32]. In contrast, HRVs usually do not persist. Garnett et al.
postulate that “smoldering HAdV at the site of lung inflammation”
may  contribute to the pathogenesis of lung diseases such as chronic
obstructive pulmonary disease (COPD) in adults [33]. Our finding
of low BAL %lymphocytes, together with neutrophilia, in children
who were HAdV DNA positive on BAL, supports the notion that
active lower airway HAdV replication was likely to be occurring (as
opposed to latent HAdV infection of lymphocytes). Whether such
persistence of HAdV viral DNA within the respiratory tract of chil-
dren is benign or contributes to the development of chronic lung
disease/s is unknown.
The major strengths of this study are its prospective design, the
use of highly sensitive PCR techniques to detect a wide range of
respiratory viruses, contemporaneous detection of lower airway
bacteria and inclusion of BAL cellularity findings. However, there
are a number of limitations. Firstly, this study involved children
with chronic respiratory symptoms, predominantly cough. Hence,
these findings may  not be readily extrapolated to healthy children
or to those with acute lower respiratory tract illness. This is par-
ticularly pertinent to influenza and RSV, as there were very few
children in whom these viruses were detected. Secondly, we  used
neutrophilic lower airway inflammation as a surrogate marker for
active pulmonary disease, as used by other authors [34,35]. We  did
not, however, test for additional indirect markers of viral infec-
tion such as Toll-like receptor 3 (TLR3), interferon gamma induced
protein 10 (IP-10) or virus-specific antibodies. Thirdly, we only
obtained BAL samples at a single time-point, precluding the abil-
ity to make inferences regarding causality. Lastly, although we were
fastidious in our BAL technique, contamination of the bronchoscope
in its route through the upper airway is possible. The significant
number of BAL positive/NPA negative cases, however, negates the
D.F. Wurzel et al. / Journal of Clinical Virology 58 (2013) 683– 688 687
argument that contamination could account for all lower airway
detections.
In conclusion, we have shown that while upper airway sampling
is the most practical and frequently used method of assessing virus
presence, it does not necessarily reflect virus in the lower airways
in children with non-acute respiratory illness. However, certain
viruses (e.g., HAdV), when detected on NPA, may  provide clues to
the existence of lower airway neutrophilic inflammation and fur-
ther research is needed. Studies addressing acute viral respiratory
tract illnesses in children are required to ascertain the applicability
of our findings to the acute setting.
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CHAPTER 4 
4.1 INTRODUCTION TO CHAPTER 4 
Adenoviruses are known to be associated with bronchiectasis and bronchiolitis obliterans. 
In Chapters 2 and 3 we have identified the potential role of viruses in chronic respiratory 
diseases in children. We have also demonstrated a link between neutrophilic lower 
airways inflammation and presence of adenovirus (as detected by PCR in BAL or NPA).  
In Chapter 4 we explored the possible role of adenoviruses in chronic endobronchial 
suppuration. Specifically, we examined the adenovirus genotypes detected in the lower 
airways of a large cohort of children with PBB and bronchiectasis. We also explored the 
potential link between adenovirus and presence of bacterial infection. In doing so, we 
aimed to further expand our understanding of the role of viral-bacterial co-infection in the 
pathogenesis of chronic suppurative lung disorders in children.  
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Background. The role of human adenoviruses (HAdVs) in chronic respiratory disease pathogenesis is recog-
nized. However, no studies have performed molecular sequencing of HAdVs from the lower airways of children
with chronic endobronchial suppuration. We thus examined the major HAdV genotypes/species, and relationships
to bacterial coinfection, in children with protracted bacterial bronchitis (PBB) and mild bronchiectasis (BE).
Methods. Bronchoalveolar lavage (BAL) samples of 245 children with PBB or mild (cylindrical) BE were includ-
ed in this prospective cohort study. HAdVs were genotyped (when possible) in those whose BAL had HAdV detected
(HAdV+). Presence of bacterial infection (defined as ≥104 colony-forming units/mL) was compared between BAL
HAdV+ and HAdV negative (HAdV−) groups. Immune function tests were performed including blood lymphocyte
subsets in a random subgroup.
Results. Species C HAdVs were identified in 23 of 24 (96%) HAdV+ children; 13 (57%) were HAdV-1 and 10
(43%) were HAdV-2. An HAdV+ BAL was significantly associated with bacterial coinfection with Haemophilus in-
fluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae (odds ratio [OR], 3.27; 95% confidence interval, 1.38–
7.75; P = .007) and negatively associated with Staphylococcus aureus infection (P = .03). Young age was related to
increased rates of HAdV+. Blood CD16 and CD56 natural killer cells were significantly more likely to be elevated
in those with HAdV (80%) compared with those without (56.1%) (P = .027).
Conclusions. HAdV-C is the major HAdV species detected in the lower airways of children with PBB and BE.
Younger age appears to be an important risk factor for HAdV+ of the lower airways and influences the likelihood of
bacterial coinfection.
Keywords. bronchiectasis; protracted bacterial bronchitis; respiratory bacteria; respiratory viruses; children.
The burden (prevalence, cost, and importance) of pro-
tracted bacterial bronchitis (PBB) and bronchiectasis
(BE) are increasingly appreciated [1–4]. PBB is the
most common cause of chronic cough in children pre-
senting to pediatric pulmonologists in some series [1,
5]. Over the last 2 decades, the diagnosis of BE in
children and adults has increased [6, 7]. Both conditions
are characterized by chronic wet cough, lower airway
endobronchial suppuration with bacterial infection,
intense airway neutrophilia, and upregulation of inflam-
matory and immunemarkers [5, 8–10]. It is hypothesized,
but remains unproven, that PBB and BE represent a
clinical continuum based upon degree of severity, shar-
ing common triggers and/or pathophysiology [11].
To date, research into the microbiology of chronic
suppurative lung diseases (PBB and BE) in children
has largely focused on bacterial pathogens, with a paucity
of research intoviral contributors.Viral–bacterial coinfec-
tion is associated with heightened neutrophilic inflam-
mation of the lower airways of children [12]. Human
adenovirus (HAdV) detection is associated with lower
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airway neutrophilic inflammation in children with chronic respi-
ratory symptoms, [13]and is significantlymore likely to be present
in the lower airways of childrenwith PBB, comparedwith controls
[14]. HAdVs (particularly types 1–5, 7, 14, and 21; members of
HAdV species B, C, and E) are known to be associated with future
small airways dysfunction and bronchiectasis [15, 16]. However,
no studies, to our knowledge, have examined the HAdV geno-
types in the lower airways of children with chronic endobronchial
suppuration to investigate a possible role in pathogenesis.
Thus, we studied the bronchoalveolar lavage (BAL) of 245
children with PBB and mild BE. We aimed to identify (1) the
prevalence of HAdV; (2) the diversity of genotypes/species
using sequence analysis, and (3) whether presence of HAdV in-
creased the odds of bacterial coinfection. We hypothesized that,
in the lower airways of children with PBB and mild BE, certain
HAdV genotypes/species would predominate, and that pres-
ence of HAdV increases the risk of bacterial coinfection.
METHODS
Children included in this study were a subset of a larger pro-
spective, longitudinal cohort study on chronic cough in children
[12]. Ethical approval was obtained from The Queensland
Children’s Health Services Human Research Ethics Committee
(HREC/03/QRCH/17). Written informed consent was obtained
from the parents/guardians.
Children were recruited between March 2008 and September
2013, covering 6 winter seasons. Of 398 children undergoing
flexible bronchoscopy and BAL for clinical indication, 245
were diagnosed with PBB or BE, and were therefore eligible
for inclusion. Children were divided into 2 groups: BAL positive
for HAdV (HAdV+) or BAL negative for HAdV (HAdV−).
Key demographics and cough characteristics were obtained
via completion of a standardized clinical questionnaire. Pro-
spective follow-up of participants was undertaken with daily
cough diaries and monthly contact via email or telephone.
Basic immune function tests were performed on peripheral
blood, including full blood examination, immunoglobulins (IgG,
IgA, IgM, IgE), IgG subclasses, specific antibody (IgG) responses
to Haemophilus influenzae type b and Clostridium tetani, and
lymphocyte subsets (including CD16+ and CD56+ natural killer
[NK] cells). Bronchoscopy and BAL were performed as described
previously [13], in accordance with European Respiratory Society
guidelines [17]. Quantitative bacteriology and cellularity on BAL
specimens were undertaken as outlined in a prior study [8].
Microbiology
Standardized semiquantitative culture of BAL fluid was under-
taken using routine laboratory techniques, as described previ-
ously [8]. Infection with major respiratory pathogens (H.
influenzae, Moraxella catarrhalis, Streptococcus pneumoniae,
and Staphylococcus aureus) was defined by bacterial load of
≥104 colony-forming units (CFU)/mL BAL, using standard cul-
ture techniques described elsewhere [8].
Real-time polymerase chain reaction (PCR) [18–21]was used
to detect a conventional panel of respiratory viruses in all, and
an extended panel in a random subset of, children. Viruses in-
cluded HAdVs, respiratory syncytial virus, human influenza A
virus, human influenza B virus, human parainfluenza viruses
1–3 (HPIV1-3), human metapneumovirus (standard panel),
human rhinoviruses, human bocavirus, human coronaviruses
(NL63, OC43, 229E, HKU1), WU polyomavirus, and KI poly-
omavirus (extended panel).
HAdV PCR testing was undertaken on all BAL samples at a
clinical laboratory (Pathology Queensland, Royal Brisbane and
Women’s Hospital, Brisbane, Australia), using a previously de-
scribed method [22], to identify HAdV+ participants. A ran-
dom subset of HAdV isolates, based upon sample availability,
from 26 HAdV+ on BAL children, underwent nucleotide se-
quencing at a research laboratory (Queensland Paediatric Infec-
tious Diseases Laboratory, Brisbane, Australia).
HAdV genotyping, based on the hexon gene hypervariable re-
gions 1–6, was conducted as previously described [23]. In brief,
2 µL of nucleic acid extract was amplified in a nested PCR reaction.
Round 1 contained primers (0.38 µM; AdHexF1-TICTTTGACA-
TICGIGGIGTICTIGA and AdHexR12-CTGTCIACIGCCTG
RTTCCACA), magnesium chloride (4.75 µM), buffer, and
MyTaq HS DNA polymerase (Bioline kit, Australia) and was in-
cubated for 1 minute at 94°C followed by 35 cycles of 94°C for 1
minute, 45°C for 1 minute, 72°C for 2 minutes, and a final incu-
bation at 72°C for 1 minute. Round 2 used 2 µL of the Round 1
PCR product as template, the same conditions but different prim-
ers (AdHexF2- GGYCCYAGYTTYAARCCCTAYTC and Ad-
HexR2- GGTTCTGTCICCCAGAGARTCIAGCA). Round 2
PCR products were checked by agarose gel electrophoresis, puri-
fied, and subjected to nucleotide sequencing (Australian Equine
Genetics Research Centre, UQ) results were analyzed to deter-
mine the HAdV genotype (Geneious Pro version 6.1).
Relationships between HAdV genotypes, sequenced from 24
HAdV+ study children, were illustrated in a phylogenetic tree
(Figure 1) constructed using the neighbor-joining method
(with evolutionary history inferred) in MEGA5 [24] after se-
quence alignment in Geneious version 6.1 [25]. Additional se-
quences were included from GenBank (labeled with genotype
and accession number) to define the species according to a pre-
viously described approach [23].
Clinical Definitions
BE was diagnosed based on radiological criteria [26] in children
with clinical symptoms consistent with BE [27].All had evidence
of mild (cylindrical) BE on high-resolution computed tomogra-
phy (CT) scan (reconstructed from a multidetector CT scan). A
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diagnosis of PBB wasmade in children who fulfilled the following
criteria: (1) history of chronic (≥4 weeks) wet cough, (2) prospec-
tive evidence (supported by cough diaries) of response to 2 weeks
of amoxicillin-clavulanate antibiotics, and (3) absence of clinical
pointers suggesting an alternative cause for cough [5].
Statistical Analysis
Descriptive statistics were used to summarize baseline patient
characteristics. Median and interquartile range (IQR) were
reported as data were nonnormally distributed. Univariate anal-
yses were performed using Pearson χ2 (or Fisher exact test) for
categorical variables. Mann-Whitney U test was used for 2-
group comparisons and Kruskal-Wallis test for >2-group com-
parisons of continuous variables. Binary logistic regression was
used to calculate odds ratios and P values. A 2-tailed P value of
<.05 was considered statistically significant. Statistical analyses
were performed using IBM SPSS version 20.0 (IBM SPSS, Ar-
monk, New York).
Figure 1. A neighbor-joining method of phylogenetic analysis of human adenovirus (HAdV) genotypes and their assigned species. The 24 nucleotide
sequences (approximately 800 nt long) from the hexon gene of HAdV-positive samples from study patients are prefixed with Royal Children’s Hospital
(RCH). The evolutionary distances were computed using the maximum composite likelihood method [23] and are in the units of the number of base sub-
stitutions per site. Additional sequences for speciation are included from GenBank (labeled with genotype and accession number in bold). The percentage of
replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the major branches.
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RESULTS
Study Population
Of the 245 children with PBB or BE, 40 were HAdV+ and 205
HAdV−. The median age of the children in the study was 30
months (IQR, 17–63 months), 23 months (IQR, 14–47 months)
in those with PBB, and 57 months (IQR, 30–87 months) in
those with BE. The median age was similar between HAdV+
and HAdV− groups in children with BE (P = .312), Table 1.
In children with PBB, those in the HAdV+ group were signifi-
cantly younger than the HAdV− group (P = .001). There were
no differences in the sex of the children according to HAdV sta-
tus within the PBB or BE groups (P = .248 and P = .703). No
seasonal differences in HAdV detection rates were observed
(P = .506).
CD 16+ and CD56+ NK cells were elevated above the normal
range in 20–25 (80%) of HAdV+ and 64 of 114 (56.1%) of
HAdV− children (P = .027). When HAdV was excluded, similar
rates of NK cell elevation were seen in children with or without
standard panel respiratory viruses detected in BAL (P = .601).
Basic immune function tests were otherwise normal.
HAdV Genotypes
HAdV genotyping was performed on a random subset (based
upon sample availability) of 26 HAdV+ on BAL children. Of
24 typeable HAdV isolates, 23 (96%) were identified as
HAdV species C; 13 (57%) as HAdV-1, and 10 (43%) as
HAdV-2. A single HAdV+ isolate was identified as genotype
4, species E, in a child with low-grade fever and mild upper re-
spiratory tract symptoms at time of bronchoscopy (Figure 1).
Bacterial Codetection With HAdV
The major bacterial pathogens detected in both HAdV+ and
HAdV− groups were H. influenzae,M. catarrhalis, and S. pneu-
moniae. HAdV+ status showed positive association with each
major bacterial pathogen (Table 2). Staphylococcus aureus was
the fourth most common bacterium causing lower airway infec-
tion; however, a significant negative association with HAdV+
status was observed (P = .03).
Lower airway infection with 1 or more of the 3 major bacteria
showed significant positive association with HAdV detection
(odds ratio [OR], 3.273 [95% confidence interval {CI}, 1.382–
7.748]; P = .007). After adjustment for age, using multiple logis-
tic regression, this association was no longer significant (OR,
2.383 [95% CI, .980–5.794]; P = .055), whereas the relationship
between bacterial infection and age remained significant (OR,
0.987 [95% CI, .980–.994]; P < .001].
Although there were slightly more detections of HAdV-1
compared to HAdV-2, no further associations between individ-
ual genotypes and bacterial coinfection were observed (data not
shown).
The HAdV+ group was more likely to have lower airway in-
fection with multiple (2 or more) major bacterial species (ex-
cluding S. aureus), compared with the HAdV− group (OR,
2.471 [95% CI, 1.228–4.969]; P = .011). However, on age adjust-
ment, using multiple logistic regression, this association was no
longer significant (OR, 1.674; [95% CI, .807–3.475], P = .166).
Other Pathogens
Mycoplasma pneumoniae detection rates (using PCR) were sim-
ilar between HAdV− and HAdV+ groups (4 in HAdV− and a 1
in HAdV+ groups; P = .580). Similarly, standard panel respira-
tory viruses were detected at similar rates in HAdV− and
HAdV+ children. There were 3 (1.5%) and 0 detections of influ-
enza virus (P = 1.00) and 10 (4.9%) and 2 (5%) detections of
HPIV (P = 1.00) in the HAdV− and HAdV+ groups, respective-
ly. Respiratory syncytial virus was detected in 11 (5.4%) and 0
(P = .22), and human metapneumovirus was detected in 5
(2.4%) and 0 (P = .594) children in the HAdV− and HAdV+
groups, respectively.
Table 1. Characteristics of the Study Population
Group No. (%)
Age, mo Sex
Median (IQR) M F
HAdV+ 40 19 (13–25) 29 11
PBB 33 (83) 17 (12–22) 24 9
BE 7 (18) 30 (22–65) 5 2
HAdV− 205 37 (18–69) 126 79
PBB 126 (61) 26 (15–56) 78 48
BE 79 (39) 57 (31–90) 48 31
Abbreviations:+/–, positive/negative detection; BE,bronchiectasis; HAdV,
human adenovirus; IQR, interquartile range; PBB,protracted bacterial
bronchitis.
Table 2. Univariate Logistic Regression Showing Relationships
Between Human Adenovirus Status and Bacterial Infection on
Bronchoalveolar Lavage
Bacterial
Infection
HAdV+
(n = 40)
HAdV−
(n = 205) OR (95% CI)
P
Value
Haemophilus
influenzae
27 (68%) 96 (47%) 2.36 (1.15–4.83) .019
Moraxella
catarrhalis
14 (35%) 38 (19%) 2.37 (1.13–4.96) .022
Streptococcus
pneumoniae
14 (35%) 46 (22%) 1.86 (.90–3.85) .094
Staphylococcus
aureus
0 (0%) 21 (10.2%) . . . .030a
Abbreviations: +/–, positive/negative detection; CI, confidence interval; HAdV,
human adenovirus; OR, odds ratio.
a Calculated using Fisher exact test.
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Of 52 (41 HAdV− and 11 HADV+) participants who had ex-
tended viral panel testing of BAL, approximately a quarter of
HAdV− children were human rhinovirus positive on BAL
(n = 10 [24.4%]) compared with more than half of HAdV+ chil-
dren (n = 6 [54.5%]; P = .054). Likewise, human bocavirus was
detected less commonly in HAdV−, compared to HAdV+ chil-
dren (1 of 41 [2.4%] vs 3 of 11 [27.3%]; P = .026). Human co-
ronavirus (OC43) was detected in 1 HAdV− participant and no
HAdV+ participants (P = 1.00).
DISCUSSION
This is the first study to examine the HAdV genotypes detect-
able in the lower airways of children with chronic endobron-
chial suppuration (PBB and bronchiectasis). We found HAdV
species C (genotypes 1 and 2) to be the major HAdV species in
the BAL of these children, irrespective of season. We have also
shown that lower airway bacterial infection, with H. influenzae,
M. catarrhalis, and S. pneumoniae, but not S. aureus, are in-
creased in HAdV+ children. Younger age is an independent pre-
dictor of infection with HAdV and common respiratory
bacteria, and age increases the odds of viral–bacterial coinfec-
tion. Our finding of elevated CD16 and CD56 NK cells in the
blood of 80% of HAdV+ children provides indirect evidence of a
systemic immune response to HAdV in the airways of these
children.
The HAdV-C species, comprising genotypes 1, 2, 5, 6, and
57, is one of the most frequent HAdV species known to infect
the respiratory tract of children [28]. Infection can result in a
range of clinical manifestations, from uncomplicated upper
respiratory infection to severe pneumonia. Most primary
HAdV-C infections occur within the first 2 years of life [29].
The highest levels of HAdV DNA are detected in adenotonsillar
tissue of 2-year-old children undergoing routine adenoidec-
tomy or tonsillectomy, and the amount of HAdV DNA decreas-
es with increasing age [30]. HAdVs demonstrate the ability to
establish latent infection within lymphocytes [30], tonsillar
tissue [31], and the lung [32] and are capable of evading host
innate immune responses via multiple mechanisms [33].
Several studies have demonstrated HAdV’s propensity to es-
tablish latent and/or persistent infection within the upper and
lower respiratory tract [34, 35]. In a recent longitudinal study of
children with chronic upper respiratory infections, 13 had re-
peated HAdV detection; 8 carried an identical HAdV genotype
on successive occasions, suggesting chronic rather than repeated
infection [34]. Using repeated lower airway sampling, Macek
and colleagues demonstrated persistence of HAdV in the
lower airways of 9 of 11 children with persistent asthma [35].
In adults, Matsuse and colleagues showed increased presence
of latent HAdV DNA in the lung tissue of patients with chronic
obstructive pulmonary disease (COPD), compared with those
without COPD [32]. No studies to date, however, have geno-
typed HAdV in lower airways of children with chronic endo-
bronchial suppuration.
A higher prevalence of HAdV in the airways of patients with
chronic respiratory diseases has led to speculation that “smol-
dering HAdV at the site of lung inflammation” [30] contributes
to the pathogenesis of chronic lung diseases, including asthma
in children [35] and COPD in adults [32, 36]. Marin et al
showed that HAdV was detected in 78.4% of nasopharyngeal
samples of asthmatic children during symptom-free periods,
vs 5% of healthy controls [37]. Furthermore, we have recently
shown that HAdV is significantly more likely to be detected
in BAL fluid of children with PBB (23%) compared with con-
trols (4%) [14]. It is possible that chronic inflammatory diseases
of the respiratory tract predispose to HAdV persistence in the
respiratory tract, or that HAdVs induce an inflammatory re-
sponse that may be a key factor in chronic respiratory disease
pathogenesis. If the latter is correct, the association of HAdV
with bacterial infection of the lower airways is likely to be a rel-
evant and significant finding.
Childhood lower respiratory infections are known to cause
bronchiectasis. Nontypeable H. influenzae (NTHi) is the most
common bacterium in the lower airways of children with PBB
and other chronic lung diseases [5, 38, 39].Recently, De Schutter
and colleagues showed that NTHi is also the commonest cause
of (nonresponsive or recurrent) community-acquired pneumo-
nia in children [40]. Similarly, compared with controls, elevated
rates of H. influenzae, M. catarrhalis, and S. pneumoniae infec-
tion are detected in the lower airways of children with PBB [14].
The propensity for codetection of HAdV with bacterial path-
ogens (eg, NTHi), has been documented in studies on human
respiratory diseases [41, 42]. However, the most convincing ev-
idence for microbial synergy arises from an animal study on oti-
tis media. In a chinchilla model of experimental otitis media
due to HAdV-1 (species C) and NTHi, Suzuki et al demonstrat-
ed a synergistic effect of the 2 pathogens. They found that in-
flammation was greatest in the presence of both HAdV and
NTHi, compared with HAdV or NTHi alone. Furthermore,
timing of inoculation was important. HAdV inoculation prior
to NTHi inoculation resulted in the greatest tympanic mem-
brane inflammation and mucosal dysfunction [43]. We have
previously shown that neutrophilic lower airway inflammation
is maximal in the presence of viral–bacterial coinfection of the
airways of children [12]. It is indeed plausible that HAdV-C and
H. influenzae may also play a synergistic role in the initiation
and/or exacerbations of chronic suppurative lung diseases in
children, and further research is needed.
The negative association of HAdV with S. aureus in the lower
airways observed in the present study may be due to the in-
creased presence of other bacterial pathogens (eg, H. influenzae)
in HAdV+ compared with HAdV− children. Negative associations
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between S. pneumoniae and S. aureus [44–48] and between H.
influenzae and S. aureus [44, 45] are well described in studies of
the upper respiratory tract. These interactions are believed to
reflect natural competition between colonization with these
organisms [48].
Hence, our findings in relation to HAdV in the lower airways
of children with PBB and BE are likely to have clinical relevance
and may represent an important clue to the underlying patho-
genesis of these disease processes. Our hypothesis is based upon
several key findings. These include (1) a predominance of
HAdV-C in the airways of these children, with a plausible
mechanism for disease; (2) the presence of elevated NK cell lev-
els in HAdV+ children (however, not in those with other stan-
dard panel respiratory viruses), indicating a systemic immune
response to HAdV in the lung; (3) previous research linking
HAdV (in the nasopharynx and/or lung) to heightened neutro-
philic inflammation and lymphopenia of the lower airways
(suggestive of active viral replication) [13]; and (4) the demon-
strated association between HAdV+ status and lower airway
bacterial infection (the latter being a key feature of PBB and
BE). It is therefore unlikely that HAdV is an innocent bystander,
as early epidemiologic studies suggested.
Although we have described 2 novel and important findings,
several limitations to our study merit discussion. First, although
our cross-sectional data highlights important associations, we
cannot attribute causality. Repeated lower airway sampling
would be needed to establish the temporal sequence of lower
airway infection and determine a cause-and-effect relationship.
However, subjecting children to repeated general anesthesia for
lower airway sampling, solely for research, would be unethical.
Second, we did not include HAdV serology in our blood test
panel. This ideally requires repeat venipuncture, which was
not feasible in our context as many children in the study reside
outside the Brisbane area. With regards to methods of HAdV
detection, although culture detects infectious virus, PCR is
more sensitive and is the current clinical standard [16]. Al-
though a positive PCR for HAdV does not readily distinguish
infectious from noninfectious virus, the identification of
HAdV DNA indicates that infection has occurred at some
stage. Further, HAdV’s association with a systemic immune re-
sponse (ie, elevated NK cells) supports the notion that HAdV
may play a clinically relevant role. Third, we detected few con-
ventional respiratory panel viruses (other than HAdV) and only
performed extended viral panel analyses on a subset, limiting
our ability to explore other possible viral–bacterial and viral–
viral interactions. Last, the strong relationship between age
and HAdV status, and the increased odds of bacterial coinfec-
tion with HAdV in younger children, is likely to be significant.
This finding raises the question of whether younger children are
predisposed to polymicrobial infection, via immature immune
system processes, rather than a true viral–bacterial interaction.
Timing of HAdV acquisition, with respect to age, may therefore
be important in further evaluating the link between HAdV and
future development of PBB and/or BE.
We conclude that HAdV-C genotypes 1 and 2 are the dom-
inant HAdV species infecting the lower airways of young chil-
dren with chronic endobronchial suppuration. The significant
association between HAdV and lower airway bacterial infection
suggests a possible role of HAdV-C in the pathogenesis of
chronic suppurative lung diseases in young children. Our find-
ings may have implications for targets in the prevention of
chronic suppurative lung diseases; however, further research
to definitely establish causality would be required.
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CHAPTER 5 
5.1 INTRODUCTION TO CHAPTER 5 
Thus far, we have demonstrated a relationship between adenovirus (of which most are 
adenovirus species C) and bacterial infection of the lower airways of children with PBB 
and bronchiectasis. We have provided further evidence of the role of viral-bacterial co-
infection. In Chapter 5, we refocused on PBB as a clinical entity and explored the 
characteristics of the typical child presenting with this condition.  
In this chapter we compared a cohort of children with PBB to a control group. We 
systematically examined their demographic, clinical, laboratory and bronchoscopic 
findings. Our specific objectives were to compare rates of viral infection between groups 
and to further assess the frequency with which wheeze was observed in PBB. The overall 
aim of this study was to assist clinicians in the more accurate diagnosis of PBB, 
highlighting the similarities and differences between PBB and other common paediatric 
respiratory conditions such as asthma.  
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5.2 Prospective Characterization of Protracted Bacterial 
Bronchitis in Children
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 Chronic cough in children is associated with signif-icant morbidity 1 and a high emotional burden on 
parents. 2 Protracted bacterial bronchitis (PBB) is rec-
ognized as a major cause of chronic cough in children. 3-5 
In a multicenter study of 346 children newly referred 
for chronic cough, PBB was the most common etio-
logic diagnosis. 6 Prior to 2006, when the entity of 
PBB was fi rst characterized by our group, 7 bacterial 
bronchitis was underappreciated as a cause of chronic 
cough in otherwise healthy children. 8 Several inter-
national groups have subsequently studied PBB, with 
concordant fi ndings. 9-11 PBB has now been incorpo-
rated into cough guidelines and education resources 
in many countries. 3,4,12-14 
 The original diagnostic criteria for PBB included 
(1) wet cough for  ! 4 weeks, (2) identifi able lower-
airway bacterial infection on BAL culture, and 
(3) response to antibiotics (amoxicillin/clavulanate) with 
resolution of cough within 2 weeks. 7 For clinical fea-
sibility, criterion 2 was later substituted with “absence 
of specifi c pointers to indicate an alternative specifi c 
cause of cough,” 15 resulting in criteria that were appli-
cable to both primary and tertiary care settings. 
 While defi ning PBB has been transformative in our 
understanding and management of chronic wet cough 
in children, many questions remain. To date, studies 
on PBB have been small 7 and/or retrospective 9-11 ; and 
some argue that PBB is poorly defi ned, 16 with others 
calling for more in-depth studies. 13 Furthermore, chil-
dren with coexistent viruses detected in BAL speci-
mens were excluded from our original PBB cohort. 7 
A large prospective study with further clinical and 
 Background:  Prior studies on protracted bacterial bronchitis (PBB) in children have been retro-
spective or based on small cohorts. As PBB shares common features with other pediatric condi-
tions, further characterization is needed to improve diagnostic accuracy among clinicians. In this 
study, we aim to further delineate the clinical and laboratory features of PBB in a larger cohort, 
with a specifi c focus on concurrent viral detection. 
 Methods:  Children with and without PBB (control subjects) undergoing fl exible bronchoscopy 
were prospectively recruited. Basic immune function testing and lymphocyte subset analyses 
were performed. BAL specimens were processed for cellularity and microbiology. Viruses were 
identifi ed using polymerase chain reaction (PCR) and bacteria were identifi ed via culture. 
 Results:  The median age of the 104 children (69% male) with PBB was 19 months (interquartile 
range [IQR], 12-30 mo). Compared with control subjects, children with PBB were more likely to 
have attended childcare (OR, 8.43; 95% CI, 2.34-30.46). High rates of wheeze were present in 
both groups, and tracheobronchomalacia was common. Children with PBB had signifi cantly ele-
vated percentages of neutrophils in the lower airways compared with control subjects, and ade-
novirus was more likely to be detected in BAL specimens in those with PBB (OR, 6.69; 95% CI, 
1.50-29.80). Median CD56 and CD16 natural killer (NK) cell levels in blood were elevated for age 
in children with PBB (0.7  3 10 9 /L; IQR, 0.5-0.9 cells/L). 
 Conclusions:  Children with PBB are, typically, very young boys with prolonged wet cough and 
parent-reported wheeze who have attended childcare. Coupled with elevated NK-cell levels, the 
association between adenovirus and PBB suggests a likely role of viruses in PBB pathogenesis.
   CHEST 2014; 145(6):1271–1278 
 Abbreviations: CFU  5 colony-forming units; HAdV  5 human adenovirus; HCoV  5 human coronavirus; IQR  5 inter-
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omavirus; RAST  5 radioallergosorbent test 
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pants had prospective follow-up with cough diaries to confi rm 
PBB diagnosis (via antibiotic response). 
 Basic immune function tests were performed on peripheral 
blood samples, including CBC count, immunoglobulin levels (IgG, 
IgA, IgM, and IgE), IgG subclasses, and specifi c antibody (IgG) 
responses to  Haemophilus infl uenzae type b and  Clostridium 
tetani . Lymphocyte subsets (including natural killer [NK] cells) 
and antigen-specifi c IgE (radioallergosorbent test [RAST]) for 
common environmental allergens (eg, cat, dog, molds and yeasts, 
house dust mite, common grass mix) were undertaken in a subset. 
Assays were performed at Queensland Health Pathology. 
 Bronchoscopy and BAL were performed as previously described 
(e-Appendix 1). 7 Multiplex polymerase chain reaction (PCR) tech-
niques were used to detect human adenoviruses (HAdVs), respi-
ratory syncytial virus, metapneumovirus, infl uenza viruses A and B, 
and parainfl uenza viruses in BAL specimens. 18 A random subset 
had extended viral panel testing for rhinoviruses, human bocavi-
rus, human coronaviruses (HCoVs) (HCoV-NL63, OC43, 229E, 
HKU1), and polyomaviruses (PyVs) (KIPyV and WUPyV) using 
PCR techniques as described elsewhere. 18-22 
 Tracheomalacia was defi ned as tracheal deformity at end expi-
ration that was maintained during spontaneous respiration, but 
which could be altered by the passage of the bronchoscope or 
positive airway pressure. Bronchomalacia was defi ned as an appear-
ance of deformity in the right or left main-stem bronchi and/or 
their respective divisions at the lobar or segmental level. 23 
 Statistical Analyses 
 Statistical analyses were carried out using IBM SPSS ver-
sion 20.0 (IBM). Medians and interquartile ranges (IQRs) were 
reported as data that were non-normally distributed. Compari-
sons of categorical variables were performed using the Pearson 
 x 2 test or Fisher exact test (if expected value was  , 5). For contin-
uous variables, the Mann-Whitney  U test was used for two-group 
comparisons and Kruskal-Wallis test for comparisons of more than 
two groups. Univariate logistic regression was used to calcu late ORs. 
A two-tailed  P value  , .05 was considered statistically signifi cant. 
 Results 
 At the time of recruitment, median cough duration 
in the 104 children with PBB was 28 weeks (IQR, 
6-57 weeks) and median cough score was 3 (IQR, 1-3), 
indicative of frequent coughing. 17 The primary indi-
cations for bronchoscopy in the control subjects were 
stridor, cough, and other respiratory symptoms ( Fig 1 ). 
Of the nine control subjects who reported cough on 
the day of bronchoscopy, the median duration was 
6 weeks (IQR, 3-19 weeks). All children with PBB 
had a normal physical examination without evidence 
of chronic lung disease. Children with PBB were 
more likely to have attended childcare ( Table 1 ). 
 Immune Function 
 Basic immune function test results in children with 
PBB were normal, except for median NK-cell levels 
( Table 2 ). All control data were within normal reported 
limits (not shown). Median peripheral blood eosino-
phil counts were low in both groups (PBB group: 
0.3  3 10 9 /L [IQR, 0.1-0.6] vs control group: 0.3  3 10 9 /L 
[IQR, 0.2-0.4]; normal range, 0.10-1.00). Median 
laboratory descriptors will assist clinicians to differ-
entiate PBB from other causes of cough in children. 
We hypothesized that PBB would be associated with 
a well-defi ned set of clinical characteristics and that 
virus rates in BAL specimens would be increased 
compared with those of control subjects. In our study 
of 104 children with PBB, we, thus, provide more 
extensive clinical, laboratory, and BAL characteriza-
tion of PBB. 
 Materials and Methods 
 The Queensland Children’s Health Services human research 
ethics committee (HREC/03/QRCH/17) approved the study, and 
written informed consent was obtained from each parent/guardian. 
Children undergoing fl exible bronchoscopy and BAL for a clinical 
indication between March 2008 and November 2012, excluding 
those with cystic fi brosis, were eligible for inclusion. Of 343 poten-
tially eligible children, 104 fulfi lled clinical and BAL criteria for 
PBB, and 49 with chronic respiratory symptoms (without PBB) 
were allocated as control subjects. Any child with symptoms or 
signs of acute lower respiratory tract infection (eg, high fever, 
shortness of breath or tachypnea, recent-onset wheeze, rattle or 
crepitations on chest auscultation), was deemed (by an anesthetist) 
to be unfi t for anesthesia and thereby excluded. 
 All caregivers completed a standardized clinical questionnaire 
including the following: cough descriptors (eg, cough score 17 and 
duration), current antibiotic treatment, and demographic factors 
(eg, age, sex, number of siblings, prior radiograph-confi rmed pneu-
monia, indigenous status, childcare attendance, tobacco smoke 
exposure). Baseline examination fi ndings were collected. Partici-
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group: n  5 22; median, 0.53 cells [IQR, 0.39-0.89 cells]; 
 P  5 .123). Blood NK-cell levels were more likely to 
be elevated above the normal for age in HAdV posi-
tive, compared with HAdV negative, participants (12 of 
13 children vs 30 of 52, respectively;  P  5 .023). 
 Bronchoscopic and BAL Findings 
 Of the 104 children with PBB, tracheo- and/or bron-
chomalacia were present in approximately two-thirds 
with similar rates in the control group (PBB group, 
n  5 71 [68%] vs control group, n  5 26 [53%];  P  5 .068). 
Laryngomalacia was more common in the control 
total IgE levels, in 24 control subjects and 47 children 
with PBB, were normal (PBB group: 32 kU/L [IQR, 
13-149 kU/L]; control group: 58 kU/L [IQR, 13-256]; 
normal range,  , 100 kU/L). Of the 39 children with 
PBB who underwent RAST for common aeroaller-
gens, 26% were positive for one or more allergens 
compared with 25% of 20 control subjects ( P  5 .957). 
 Peripheral-blood lymphocyte subsets were tested 
in 46 children with PBB, of whom 33 (72%) had 
NK-cell levels above the upper limit of normal for 
age. 24 Median NK-cell levels ( 3 10 9 /L) were higher 
in children with PBB than control subjects (PBB group: 
n  5 46; median, 0.72 cells [IQR, 0.50-0.93 cells]; control 
 Figure 1. Bar graph showing primary indication for bronchoscopy in control subjects. *Includes 
wheeze, exercise-induced symptoms, imaging abnormality, and hemoptysis. 
 Table 1— Background Characteristics of Children in the Cohort 
Characteristic PBB Group (n  5 104) Control Group (n  5 49)  P Value a 
Sex, male to female ratio, % male 72:32 (69) 33:16 (67) .815
Age, mo (IQR), y 19 (12-30) 20 (8-63) .967
Household tobacco smoke exposure 39 (38) 15 (33) .565
Siblings, median (IQR) 1 (1-2) 1 (1-2) .788
Childcare attendance 48 (91) (n  5 53) 15 (58) (n  5 26) .001
Indigenous status b 10 (10) 1 (2) .106
Previous pneumonia 15 (14) 8 (16) .659
Wheeze (ever) 63 (81) (n  5 78) 12 (67) (n  5 18) .192
Data given as No. (%) unless otherwise indicated. IQR  5 interquartile range.
 a P   , .05 considered statistically signifi cant.
 b Defi ned as those who identifi ed as aboriginal or Torres Strait Islander.
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tional viruses identifi ed in children with PBB included 
human rhinovirus (n  5 11, 41%), human bocavirus 
(n  5 1, 4%), and HCoV (n  5 1, 4%). Additional viruses 
identifi ed in control subjects included human rhino-
virus (n  5 2, 15%), WUPyV (n  5 1, 8%), and HCoV-C43 
(n  5 1, 8%).  Table 3 presents results of univariate 
logistic regression for common lower-airway bacteria 
and viruses. 
 Median total cell counts were 270  3 10 6 /L (IQR, 
150  3 10 6 /L to 520  3 10 6 /L) in PBB vs 102  3 10 6 /L 
(IQR, 47  3 10 6 /L to 203  3 10 6 /L) in control subjects 
( P  , .001). The median percentage of neutrophils was 
markedly elevated at 42% (IQR, 19%-66%) in children 
with PBB compared with 4% (IQR, 2%-8%) in con-
trol subjects ( P  , .001) and higher in HAdV-positive 
participants (43%; IQR, 14%-55%) vs HAdV-negative 
participants (16%; IQR, 5%-55%) ( P  5 .044). The 
median percentage of macrophages was correspond-
ingly depressed at 45% (IQR, 24%-68%) in children 
with PBB compared with 90% (IQR, 80%-94%) in con-
trol subjects ( P  , .001). The percentages of lympho-
cytes were 9% (IQR, 5%-15%) and 6% (IQR, 3%-10%) 
in PBB and control groups, respectively ( P  5 .033). 
The median percentage of eosinophils was 0% (IQR, 
0%-0%) in both groups. 
 Discussion 
 In this large prospective study on PBB in children, 
we advanced our understanding of PBB by further 
examining clinical, laboratory, and BAL descriptors 
in a large cohort of children. In addition to chronic 
group (PBB group, n  5 10 [9.6%] vs control group, 
n  5 15 [30.6%];  P  5 .001), likely explained by the fact 
that stridor was the major indication for bronchoscopy 
in control subjects ( Fig 1 ). 
 Bacterial infection ( ! 10 4 colony-forming units 
[CFU]/mL) with common respiratory pathogens was 
present in BAL specimens of all patients with PBB 
(n  5 104, 100%) and 19 control subjects (39%,  P  , .001). 
Nine children with PBB (9%), and four in the con-
trol group (8%) ( P  5 .933) received antibiotics in the 
24 h prior to bronchoscopy.  H infl uenzae was the most 
common bacterial pathogen in both groups. A minority 
of strains were  b -lactamase positive (PBB group: 
n  5 17 [16%]; control group: n  5 4 [8%];  P  5 .213]. One-
half of the participants with PBB (n  5 52, 50%) had 
two or more bacterial species at levels  ! 10 4 CFU/mL 
compared with four children in the control group (8%) 
( P  , .001). Of those with PBB, most (n  5 30; 56%) were 
found to be infected with  H infl uenzae and  Moraxella 
catarrhalis on culture.  Staphylococcus aureus infec-
tion was more common in BAL specimens of control 
subjects than those with PBB (18% vs 11%, respec-
tively;  P  5 .19).  Mycoplasma pneumonia was detected 
(on PCR) in a single child with PBB ( , 1%) and a 
single control participant (2%). Children with PBB 
were signifi cantly more likely than control subjects 
to have coinfection with HAdV and  H infl uenzae 
(PBB group: n  5 22 [23%]; control group: n  5 1 [2%]; 
 P  5 .001). A random subset of children (n  5 27 with 
PBB, n  5 13 control subjects) had extended viral-panel 
analyses performed. In those with PBB, 18 of 27 sam-
ples (67%) were positive for any virus compared with 
fi ve of 13 (38%) of control subjects ( P  5 .066). Addi-
 Table 2— Basic Immune Function Tests 
Immunologic Parameter Median (IQR) (n  5 104) a Normal Range
Immunoglobulins (g/L)
 IgG 7.1 (5.6-8.5) 3.0-13.0
 IgA 0.5 (0.3-0.8) 0.4-1.4
 IgM 0.9 (0.7-1.1) 0.5-1.6
IgG subclasses (g/L)
 IgG 1 5.2 (4.1-6.7) 2.9-8.5
 IgG 2 0.8 (0.6-1.1) 0.45-2.6
 IgG 3 0.3 (0.2-0.4) 0.15-1.13
 IgG 4 0.05 (0.02-0.2) 0.03-0.79
Lymphocyte subsets ( 3 10 9 /L) (n  5 46)
 CD3 (T cells) 3.4 (2.7-4.4) 2.3-3.5
 CD4 1 /CD3 1 (helper T cells) 1.9 (1.4-2.6) 1.9-2.5
 CD8 1 /CD3 1 (cytotoxic T cells) 1.2 (0.9-1.6) 0.35-2.5
 CD 19 (total B cells) 1.4 (0.9-1.7) 0.43-3.3
 CD56 and CD16 (NK cells) 0.7 (0.5-0.9) b 0.05-0.52
 Complement levels (hemolytic complement assay, CH50), U/mL n  5 70, 794 (725-874)  . 520
Vaccine responses
 IgG  Clostridium tetani , IU/mL n  5 86, 0.5 (0.2-1.1) Protective level:  . 0.16 IU/mL
 IgG  Haemophilus infl uenza  type B,  m g/mL n  5 75, 1.1 (0.3-4) Short-term protection:  . 0.15  m g/mL
IU  5 International Units; NK  5 natural killer. See  Table 1 legend for expansion of other abbreviation.
 a Where n  , 104, patients were either recruited later in the study or insuffi cient specimen volume was available to perform the test.
 b Parameters outside the normal range are denoted in bold.
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with doctor assessment. 29,30 This fact is likely to con-
tribute to asthma overdiagnosis, particularly in primary 
care settings. 
 Coexistent asthma is unlikely to explain the high 
rates of parent-reported wheeze in children with PBB 
in the present study. This is supported by the fact that 
all children with PBB in this cohort had resolution of 
their cough with 2 weeks of antibiotic therapy (a crite-
rion for PBB diagnosis). Our fi ndings of low median 
IgE levels coupled with absence of eosinophilia (both 
in the lower airway and peripheral blood) provide 
further laboratory evidence against asthma. 
 Our previous descriptions of the immune status of 
children with PBB were limited to basic immuno-
globulin levels. 7 In the present study, we further eval-
uated immune function. We have demonstrated that 
antibody-mediated responses (to a protein-based 
[tetanus] and conjugate [ H infl uenzae type b] vaccine) 
and lymphocyte subsets are normal in PBB, with the 
exception of elevated levels of NK cells CD16 1 and 
CD56 1 . This is a novel fi nding, and likely to be asso-
ciated with recent viral infection. Although the cross-
sectional nature of this study precludes making causal 
associations, it is probable that the high NK-cell levels 
seen in children with PBB were related to elevated 
virus detection rates in BAL specimens (38% of BAL 
specimens on a standard respiratory panel and 67% 
of BAL specimens on an extended viral panel). More-
over, the association between HAdV in BAL specimens 
and NK-cell elevation is consistent with published 
literature suggesting that NK cells play a role in innate 
immune defense against HAdV. 31 Although we are 
unable to draw conclusions regarding the signifi -
cance of HAdV in the airways of children with PBB, 
it deserves further research. A possible mechanism 
includes reactivation of HAdV in response to certain 
stresses, as HAdV can remain in a quiescent state in 
tonsillar and adenoidal tissue. 32 
 In accordance with previous fi ndings, 33 increased 
total cell counts, neutrophilia, and reduced percentage 
wet cough in PBB, we observed high rates of parent-
reported wheeze, and an association between PBB 
and childcare attendance. Children with PBB dem-
onstrated, within-population normal immunoglobulin 
levels, antibody responses (to tetanus and  H infl uenzae 
type b vaccines) and propensity to atopy (IgE and 
RAST); however, many children had elevated NK-cell 
levels in blood specimens. Tracheobronchomalacia 
was common, but rates were similar in the control 
group. The BAL specimens from children with PBB 
showed a high prevalence of viruses, particularly 
HAdV, in addition to bacterial infection and airway 
neutrophilia. 
 Our study concurs with existing published studies 
on PBB regarding the demographics of these chil-
dren. These factors include the young median age of 
children with PBB, 7 the predominance of boys, 10 and 
the coexistence of central airway anomalies (tracheo- 
and/or bronchomalacia). 10 Our new fi nding of high 
rates of childcare attendance is likely to have rele-
vance to the rates of virus detection in our PBB cohort, 
notwithstanding the ongoing immune maturation also 
occurring at this age. Thus, boys with several months’ 
history of wet cough, who attended childcare, and 
who were between their fi rst and second birthdays 
typifi ed our PBB cohort. Wheezing episodes were also 
commonly reported in children with PBB. 
 A high proportion of caregivers reported “wheeze 
ever” in their child (74%). This supports the fi ndings of 
Saglani et al 25 of high rates of bacterial infection (43%) 
and neutrophilic infl ammation (54%) in the BAL speci-
mens of young children with severe recurrent wheeze, 
and those of Bisgaard et al 26 in their birth cohort study 
linking bacteria (in the naso- or hypopharynx) with 
wheeze. The similar rates of wheeze in children with 
PBB and the control subjects may relate to the high 
airway malacia rates also observed. However, it is 
important to acknowledge the inherent inaccuracy 
of parent-reported wheeze, which poorly refl ects true 
wheeze and asthma 27,28 and has low-level agreement 
 Table 3— Univariate Logistic Regression for Lower Airway Bacteria and Viruses 
Infective Findings (BAL) PBB Group, No. (%) (n  5 104) Control Group, No. (%) (n  5 49) OR (95% CI)  P Value
Bacteria
 Haemophilus infl uenzae 75 (72) 10 (20) 10.09 (4.46-22.82)  , .001
 Moraxella catarrhalis 45 (43) 5 (10) 6.71 (2.46-18.30)  , .001
 Streptococcus pneumonia e 41 (39) 8 (16) 3.34 (1.42-7.83) .006
Viruses
 HAdV 22 (23) 2 (4) 6.78 (1.52-30.22) .012
 RSV 5 (5) 0 (0) … NS
 HMPV 2 (2) 0 (0) … NS
 IFV 2 (2) 2 (4) 0.24 (0.02-2.71) .248
 HPIV 7 (7) 0 (0) … NS
 Any virus n  5 92, 35 (38) n  5 45, 4 (9) 6.30 (2.08-19.09) .001
HAdV  5 human adenovirus; HMPV  5 human metapneumovirus; HPIV  5 human parainfl uenza virus; IFV  5 infl uenza virus; NS  5 not signifi cant; 
RSV  5 respiratory syncytial virus.
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the importance of clear-cut diagnostic criteria for PBB. 
The most convincing evidence for PBB in the children 
studied was a clear response to 2 weeks of amoxicillin-
clavulanate antibiotics—a key clinical factor in the 
diagnosis of PBB. While bronchoscopy has been under-
taken in this study and included in our original descrip-
tion of PBB, 35 we do not advocate that all children 
with a chronic wet cough should undergo fl exible bron-
choscopy. In the Australian guidelines for chronic cough 
in children, 15 the clinical defi nition of PBB does not 
include BAL criteria. The validity of this approach 
was documented in a recent, multicenter, randomized 
controlled trial on the management of chronic cough 
in children. 36 
 The importance of accurate PBB diagnosis and 
timely management extends beyond the signifi cant 
fi nancial and social repercussions of protracted cough 
in children. 2 Many authors postulate that recurrent 
episodes of PBB and/or untreated lower airway bac-
terial infection predispose to later development of 
bron chiectasis. 37-39 Douros et al 40 described the asso-
ciation between duration of wet cough and abnor-
malities seen on CT scans. However, the question of 
whether recurrent PBB is antecedent to later devel-
opment of bronchiectasis remains unanswered to 
date, and warrants elucidation in a longitudinal cohort 
study. 
 Our study’s fi ndings provide further depth to the 
clinical profi le and our overall understanding of PBB. 
Children with PBB are, typically, very young boys with 
protracted wet cough and parent-reported wheeze, 
and without elevated IgE or eosinophilia, who have 
attended childcare. Elevated rates of viruses in BAL 
specimens (in particular, HAdV), and heightened levels 
of NK cells in blood provide both direct and indirect 
evidence for a role of viruses in PBB pathogenesis. 
In view of our fi ndings, we postulate that interactions 
between the innate immune system, environmen-
tal exposures, and viruses and bacteria underlie the 
development of PBB in children, and further research 
is needed. 
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of macrophages were observed in the BAL specimens 
of children with PBB. Notably, airway eosinophilia 
was absent. Previous research has linked viral-bacterial 
coinfection to signifi cantly heightened neutrophil levels 
in the lower airways of children—higher than that 
of bacterial or viral infection alone. 34 This fi nding is 
likely to have relevance to our cohort with PBB, as 
high rates of viral-bacterial coinfection and greatly 
elevated percentages of neutrophils in BAL speci-
mens (median, 42%) were apparent. Furthermore, 
HAdV was signifi cantly more likely to be detected in 
the lower airways of children with PBB compared 
with control subjects and was associated with height-
ened levels of NK cells in blood specimens and with 
neutrophilia in the airways (indicating a systemic and 
airway immune response to the virus). 
 A link to chronic cough and bacterial bronchitis 
has been reported previously in airway malacias. 10 
A causal relationship (in either direction) may exist 
between large airway malacias and PBB to explain the 
high rates of tracheobronchomalacia (68%) in children 
with PBB. The similar tracheobronchomalacia rates 
in children with PBB and the control group (53%), and 
the high rates of bacterial infection (39%) observed 
in the control group are likely interrelated. These 
fi ndings refl ect the fact that children in the control 
group had chronic respiratory symptoms leading to 
bronchoscopy. Another possible explanation for the 
high rates of bacterial infection in the control group 
is contamination of the bronchoscope during the pro-
cedure. However, our fastidious BAL technique and 
use of a  ! 10 4 CFU/mL cutoff to indicate infection 
should minimize this likelihood. 
 A number of limitations of our study merit consid-
eration. First, its cross-sectional nature precluded 
making causal links relating to the role of viruses in 
PBB pathogenesis. Second, due to the inherent eth-
ical issues regarding use of control subjects for studies 
involving bronchoscopy, our comparator group com-
prised children with chronic respiratory symptoms 
(other than PBB). This likely reduced the strength 
of our observations. Third, we had missing data on 
childcare attendance and wheeze, as these questions 
were introduced later in the course of the study. Last, 
extended viral panel analyses were only performed 
on a small subset of participants, limiting our ability 
to make inferences regarding the signifi cance of other 
viruses (eg, rhinovirus). 
 The major strengths of this study are its prospec-
tive design, the large cohort, and the inclusion of a 
control group. Our lower-airway fi ndings confi rm our 
previous observations in relation to PBB, with the 
addition of new information regarding environmental 
exposure (ie, childcare attendance, and virus and 
wheeze prevalence). Our fi ndings illustrate the symp-
tom overlap between PBB and asthma, 7,9 highlighting 
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CHAPTER 6 
6.1 INTRODUCTION TO CHAPTER 6 
In Chapter 5, we further expanded our understanding of PBB by describing the typical child who 
presents with this condition. These findings will assist the clinician in the more accurate diagnosis 
of PBB and assist in its differentiation from other common causes of chronic cough. Further 
research to evaluate the longer-term significance of PBB, with respect to risk of bronchiectasis, 
was needed. Availability of such data is relevant when counselling parents of children who 
experience recurrent episodes of PBB.  
Chapter 6 explored the significance of PBB with respect to a later diagnosis of bronchiectasis. It 
evaluated the accuracy of the hypothesis that PBB and bronchiectasis rest upon a common clinical 
spectrum of disease severity. 
In this study, we followed a cohort of children with PBB over a two-year period to determine the 
proportion later diagnosed with bronchiectasis. We also examined risk factors for bronchiectasis. 
Findings from this study would aid the clinician in identifying those children with PBB at greatest 
risk of bronchiectasis. The relevance of these findings is that they would enable closer monitoring 
of children at risk of bronchiectasis hence leading to earlier diagnosis. 
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6.2 Protracted Bacterial Bronchitis in Children: Natural 
History and Risk Factors for Bronchiectasis at 2 years  
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ABSTRACT 
Importance: Protracted bacterial bronchitis (PBB) and bronchiectasis are distinct diagnostic 
entities sharing common clinical and laboratory features. It is postulated, but remains unproven, 
that PBB precedes bronchiectasis in a subset of children. 
 
Objective: In a cohort of children with PBB, our objectives were to: (a) determine the medium-
term risk of bronchiectasis and (b) identify risk factors for bronchiectasis and recurrent episodes 
of PBB. 
 
Design: Between March 2008 and October 2012, children undergoing flexible bronchoscopy and 
BAL for a clinical indication were recruited to this longitudinal cohort study. All had basic 
immune function testing. Caregivers completed clinical questionnaires at baseline and cough 
diaries during periods of illness. CT chest was undertaken if they developed clinical features 
suggestive of bronchiectasis.  
 
Setting: The study was undertaken in a large, tertiary paediatric hospital in Brisbane, Australia.  
 
Participants: Of 343 children undergoing bronchoscopy, 161 met criteria for PBB including: i) 
history of chronic (≥ 4 weeks) wet cough, (ii) response to 2 weeks of treatment with amoxicillin-
clavulanic acid and (iii) absence of clinical pointers suggesting an alternative cause for cough. In 
total, 106 children reached the 2-year follow-up time-point (13 withdrew, 42 had incomplete 
cough diaries). 
 
Main outcome and measures: The primary study outcome was the proportion of children with 
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PBB, at study entry, diagnosed with bronchiectasis during the follow-up period. 
 
Results: Of 161 children with PBB (66% male), 13 (8.1%) were diagnosed with bronchiectasis. 
Almost half (43.5%) with PBB had recurrent episodes (>3/year). Major risk factors for 
bronchiectasis included: H. influenzae lower airway infection (in BAL) (p=0.013) and recurrent 
episodes of PBB (p=0.003). H. influenzae infection conferred >7 times higher risk of 
bronchiectasis [HR 7.55 (95%CI 1.66 - 34.28), p=0.009] compared to absence of H. influenzae. 
The majority of isolates (82%) were non-typeable H. influenzae. No risk factors for recurrent 
PBB were identified.  
 
Conclusion: PBB is antecedent to a diagnosis of bronchiectasis in a subgroup of children. H. 
influenzae lower airway infection and recurrent PBB are significant risk factors. Clinicians 
should be cognisant of the need to monitor children with PBB over time for evidence of 
bronchiectasis, particularly those with risk factors.   
 
At a glance: 
• Protracted bacterial bronchitis (PBB), a major cause of chronic cough in children, may be 
associated with later development of bronchiectasis.  
• In this study, we have shown that approximately 1 in 12 children with PBB are diagnosed 
with bronchiectasis at 2-year follow-up. 
• Risk factors for bronchiectasis include: lower airway infection with H. influenzae and 
recurrent episodes of protracted bacterial bronchitis.  
• Children with PBB should be monitored over time for bronchiectasis and specialist 
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referral should be considered in those with risk factors. 
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INTRODUCTION 
Protracted bacterial bronchitis (PBB), first described by our group in 2006, is a major cause of 
chronic cough in children who present to respiratory specialists.1,2 PBB is now well recognised in 
Australia,3 Europe 4 and the US.5,6 It is characterised by persistent wet cough, response to a 2-
week course of appropriate antibiotics and absence of indicators to suggest an alternative cause 
for cough.1,7 PBB is more common in young boys and children who have attended childcare.8 
When compared to controls, children with PBB are more likely to have lower airway infection 
with bacteria, such as H. influenzae, M. catarrhalis and S. pneumoniae, as well as viruses e.g. 
adenovirus.8  
 
Currently, there are limited published data,9 and no prospective follow-up studies, evaluating the 
outcomes of children with PBB. This clinical gap limits the clinician’s ability to prognosticate on 
the likely natural history of PBB in an individual child. Anecdotally, many otherwise healthy 
children experience recurrent episodes of PBB without long-term consequences. However, in a 
subgroup of children, recurrent PBB may be an important risk factor for, or herald the onset of, 
non-cystic fibrosis bronchiectasis, though this remains unproven. Certain characteristics of the 
lower airway microbiota may also predispose to the development of chronic lung disease. 
  
PBB and bronchiectasis share many common features, spanning from respiratory symptoms (i.e. 
chronic wet cough) to intense neutrophilic lower airway inflammation and innate immune system 
activation.10-12 The lower airway microbiota,13 including presence of adenovirus type C 14 and 
predominance of nontypeable Haemophilus influenzae (NTHi),1,8 are also alike. Such similarities 
underpin the notion that PBB and bronchiectasis occupy distinct poles of a common clinical 
continuum.15 To date, the accuracy of this proposed continuum is uncertain, and warrants 
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evaluation in a prospective cohort study. If it is indeed correct, then risk factors for bronchiectasis, 
in children with PBB, warrant elucidation in order to further inform clinical practice and 
potentially determine intervention points. 
 
Hence, in 161 children with PBB and 25 controls, we aimed to determine: (a) the 2-year 
outcomes with respect to development of bronchiectasis and; (b) the risk factors for diagnosis of 
bronchiectasis and those for recurrent episodes of PBB.  
 
METHODS 
Study participants 
Participants were enrolled as part of a larger prospective cohort study aimed at evaluating the 
long-term outcome of children with chronic cough. Written informed consent was obtained from 
all parents/guardians and ethics approval granted by The Queensland Children’s Health Services 
(RCH) Human Research Ethics Committee (HREC/03/QRCH/17).  
 
Between March 2008 and October 2012, 343 children were enrolled. Of these, 161 fulfilled 
criteria for PBB and 25 were recruited as control participants (15 undergoing evaluation for 
respiratory symptoms other than chronic cough, and 10 healthy controls). Data from the 15 
control children undergoing respiratory evaluation have previously been described 8 (see e-
supplement). The 10 healthy controls were recruited from colleagues and friends.  
 
All children (excluding the 10 healthy controls) underwent flexible bronchoscopy and 
bronchoalveolar lavage (BAL) as per clinical indication, and were recruited prior to their 
bronchoscopy. BALs were processed for cellularity and microbiology. Bacterial infection was 
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defined as bacterial load of ≥104 colony-forming units (cfu)/ml BAL.8,11 Laboratory tests for 
suppurative lung diseases were performed, as described previously.14 H. influenzae 
characterisation was undertaken at a research laboratory (Menzies School of Child Health 
Research, Darwin) when BAL was available (see e-supplement).  
 
Follow up 
Follow-up included monthly contacts (phone-calls or emails) to capture respiratory exacerbations 
(undertaken by research nurses). Parents completed cough diaries during periods of illness. The 
majority of children were seen by their pediatric pulmonologist, as part of routine clinical follow-
up, 3-4 monthly. At 2-year follow-up, a subset of children (n=106) also underwent clinical 
assessment (by DW and/or AC) for bronchiectasis. 
  
Given the ethical considerations pertaining to research-related CT chest in children,16,17 
participants underwent CT scans only when clinical features of bronchiectasis were present.18 
Clinicians had similar practices whereby CT chest was undertaken for: (a) chronic wet cough 
non-responsive to 4 weeks of antibiotic therapy;19 (b) persistent chest radiographic changes 
despite appropriate antibiotic therapy or (c) recurrent hospitalisations for acute respiratory events.  
 
Definitions 
PBB was defined as: (i) history of chronic (≥ 4 weeks) wet cough, (ii) prospective evidence 
(supported by cough diaries) of response to 2 weeks of treatment with amoxicillin-clavulanate 
and (iii) absence of clinical pointers suggesting an alternative cause for cough.1 Bronchiectasis 
diagnosis was based on pediatric radiological (CT) criteria,20 in the context of a child having 
clinical symptoms of bronchiectasis. Recurrent PBB was defined as >3 episodes of PBB in the 
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first year after enrolment. 
 
Statistical analyses 
Descriptive statistics were utilized to summarize demographic and clinical characteristics. 
Median and inter-quartile ranges were reported as data were non-normally distributed. Pearson’s 
chi-square (or Fisher’s exact test) was used for categorical and Mann-Whitney U for continuous 
variables. Logistic regression was employed to calculate odds ratios (OR) and 95% confidence 
intervals (95%CI). A survival analysis (using Cox’s proportional hazards regression) examined 
the relationship between time to diagnosis of, and risk factors for, bronchiectasis. A 2-tailed p-
value of <0.05 was considered statistically significant. Statistical analyses were performed using 
SPSS (version 21.0, Armonk, NY: IBM Corp.,USA) and STATA (version 12.1, StataCorp, 
Texas,USA). 
 
RESULTS 
Clinical and demographic characteristics of participants  
Of the 161 children with PBB, 106 completed the 2-year follow-up period and had clinician 
assessment for bronchiectasis (Figure 1). The median duration of follow-up was 25 months (IQR 
24, 28) in children with PBB and 27 months (IQR 26, 29) in controls undergoing bronchoscopy. 
  
There was no difference between children who completed the 2-year follow-up and those who 
did not (Table 1), with regards to: length of cough at recruitment (p=0.807), H. influenzae status 
(p=0.518) or proportion with 2+ siblings (p=0.260). However, those completing the 2-year 
follow-up (n=106) were significantly more likely to have had recurrent PBB (p=0.003). Thus, to 
reduce the potential for bias, 161 was used as the denominator in subsequent analyses. The 55 
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additional children who did not complete 2-year follow-up were assumed to be bronchiectasis-
free at the 2-year time-point. Comparison of groups at baseline showed that children with PBB 
had a higher burden of doctor visits in the preceding 12 months, as compared to controls (Table 
1). At 2-year follow-up, children with PBB were more likely to be coughing compared to 
controls (p=0.005) and to have had parent-reported wheeze in the preceding 12 months (p=0.001) 
(Table 2). Of the 161 children with PBB, 154 had completed cough diaries up until at least the 1-
year time-point. Of these, 67 (43.5%) had recurrent PBB (>3 episodes/year). 
 
 
Bronchiectasis diagnoses on chest CT scan 
Multi-detector CT with HRCT reconstruction was performed in 25 of 161 children with PBB. 
Radiological evidence of bronchiectasis was present in 13 (8.1%). In those with bronchiectasis, 
CT was performed at median duration of 9 months (IQR 4, 19) post recruitment. The median age 
of these children was 38 months (IQR 27, 58). Compared to those that did not undergo CT, 
children with PBB who underwent CT chest, had similar rates of lower airway infection with H. 
influenzae (p=0.142) and S. pneumoniae (p=0.135), however, those undergoing CT scan were 
less likely to have M. catarrhalis infection, than those that did not undergo CT (34.2% vs 17%, 
p=0.029) (this is likely to have been a chance occurrence.) Similar rates of ‘recurrent PBB’ status 
were recorded in those children that underwent CT and those that did not (p=0.118).  
 
No children in the control group developed clinical features of bronchiectasis. Of the control 
children, 3 had CT scan performed for other indications. None had radiological evidence of 
bronchiectasis. 
 
Risk factors for bronchiectasis and recurrent PBB 
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Univariate analysis showed that bronchiectasis was significantly more likely to be diagnosed 
during follow up when the child had recurrent PBB, when H. influenzae infection was present (i.e. 
cultured at a clinically significant level of ≥104 cfu/ml in the BAL) or in children with two or 
more siblings (table 3). There was no significant difference between groups for other factors.  
 
Multivariate logistic regression showed that recurrent PBB status and H. influenzae infection 
were significantly associated with bronchiectasis diagnosis [OR 11.48 (95%CI 2.33-56.50) 
p=0.003 and OR 7.60 (95%CI 1.53-37.79), p=0.013, respectively], whereas having ≥2 siblings 
was no longer significant [OR 3.53 (0.98, 12.70), p=0.054]. Survival analysis, using Cox 
regression, concurred with logistic regression findings. Participants with H. influenzae lower 
airway infection were > 7 times more likely to be diagnosed with bronchiectasis per month of 
follow-up, compared to those without H. influenzae, and recurrent PBB status conferred >9 times 
greater risk of bronchiectasis diagnosis per month (Table 4).  
 
The percentage of lower airway neutrophils was similar in children with and without a 
subsequent diagnosis of bronchiectasis (Table 5). Although the percentage of eosinophils in BAL 
was slightly higher in those who developed bronchiectasis, the median eosinophil count was 
within the normal range (i.e. <2.5%),21 and hence considered clinically insignificant. Further, the 
difference was no longer observed when the major outlier was removed.  
 
In the examination of predictors for recurrent PBB, univariate and multivariate analysis showed 
no significant difference between children with and without recurrent PBB for the factors 
examined (sex, age, prior pneumonia, tobacco smoke exposure, maternal tobacco smoking in 
pregnancy, Indigenous status, number of children in household, childcare attendance and BAL 
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cellularity and microbiology) (eTable 1). Notably, H. influenzae infection in the BAL was not 
predictive of recurrent PBB.  
 
H. influenzae typing 
Thirty-four of 55 (62%) H. influenzae positive samples were available for further characterisation 
in the research laboratory (laboratory methods in e-supplement). Of these, H. influenzae from the 
majority of samples (n=28; 82%) were identified as NTHi; encapsulated H. influenzae were not 
identified. H. influenzae from the remaining 6 samples were reassigned as H. haemolyticus 
following species-specific PCR. 
!DISCUSSION 
This is the first prospective longitudinal cohort study of children with PBB. In our cohort, based 
in a major teaching hospital, almost half (43.5%) had recurrent episodes (>3 in the first year after 
recruitment) and approximately 1 in 12 were diagnosed with bronchiectasis at 2-year follow-up. 
We have identified 2 significant risk factors for bronchiectasis: recurrent (>3 /year) episodes of 
PBB and presence of H. influenzae infection of the lower airways. Further, H. influenzae in the 
BAL conferred >7 times higher risk of bronchiectasis diagnosis, compared to H. influenzae 
negative state.  
 
Findings from this study, the first to investigate the 2-year outcomes of children with PBB, 
support the hypothesis that PBB and bronchiectasis likely represent a clinical spectrum. Children 
with PBB have endobronchial bacterial infection and neutrophilic airway inflammation, factors 
known to be injurious to the airways.22 Our findings suggest that, in a subset of children receiving 
close follow-up by pediatric pulmonologists, recurrent episodes (>3 per year) of PBB precede a 
diagnosis of bronchiectasis. Further, although a cause-effect relationship cannot be concluded, a 
relationship between H. influenzae infection and later diagnosis of bronchiectasis has been shown. 
This finding is in accordance with increasing recognition, amongst researchers and clinicians, of 
the role of H. influenzae in chronic respiratory disease pathogenesis.23 
 
H. influenzae is the most common bacterial species infecting the lower airways of children with 
chronic endobronchial suppuration, including PBB,8 recurrent or non-responsive community-
acquired pneumonia 24 and bronchiectasis.8,10,25 It is also the major bacterial pathogen associated 
with chronic respiratory disorders in adults e.g. bronchiectasis and COPD.23,26,27 The exact role of 
NTHi in bronchiectasis pathogenesis, however, remains unclear. It may represent the primary 
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insult, or alternatively, a secondary phenomenon whereby damaged and/or dilated airways act as 
a nidus for H. influenzae. Our finding that H. influenzae infection (predominantly NTHi on 
typing in this study) may be a risk factor for chronic respiratory diseases such as bronchiectasis is 
consistent with current literature.25,28-31 Nevertheless, there are likely to be other contributory 
factors.  
 
Our earlier studies identified that children with PBB were significantly more likely, than controls, 
to have attended childcare, and to have viral infection of the lower airways, particularly with 
adenovirus type C.8,14 It is plausible, although beyond the scope of this study, that co-infection 
with specific microbial pathogens e.g. adenovirus C and H. influenzae,32 initiates the vicious 
cycle of lower airway infection and inflammation inherent to these conditions.33 Factors such as 
young age (and concomitant immune system and respiratory tract immaturity) at initial infection, 
are likely to play a key role in the aetio-pathogenesis of these disorders.14 
 
In this study, bronchiectasis was diagnosed at an early age (median 38 months), similar to our 
other cohorts of children with bronchiectasis.10,19,34 Together with findings from our previous 
studies on PBB,8,14 this observation raises the question of whether timing of airway infection 
(with bacteria and/or viruses), with respect to age, influences the likelihood of later diagnosis of 
bronchiectasis.  
 
In support of previous studies on PBB, our present study showed that PBB is characterised by 
active neutrophilic inflammation of the lower airways. Although the median percentage of 
neutrophils in BAL was greater in those with PBB who were subsequently diagnosed with 
bronchiectasis, compared to those who were not (median 35 vs 25, respectively), this difference 
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was not statistically significant. This suggested that the degree of airway neutrophilia was not a 
predictor of subsequent bronchiectasis. Regarding the inter-group disparity in airway eosinophil 
levels observed between those with and without bronchiectasis, this is unlikely to be of clinical 
relevance for two reasons. First, eosinophil levels in both groups were within normal reported 
ranges, and second, when the major outlier (16% eosinophils in a child with features consistent 
with persistent asthma in addition to PBB) was removed from the ‘bronchiectasis present’ group, 
this difference was no longer significant.  
 
Several limitations to this study merit discussion. Firstly, we did not universally perform CT 
scans on all children at study entry and exit. In view of the potential increased lifetime risk of 
developing cancer and the relatively common nature of PBB in otherwise well children,35 we 
could not justify exposing all children to the radiation dose associated with 2 CT scans.17 The 
impact of this is two-fold. First, bronchiectasis may have been missed in some children at 
recruitment and/or follow-up. Hence, we cannot conclude that PBB progresses to bronchiectasis 
per se. Rather, our findings indicate that, in children with PBB (who are followed closely by 
pulmonologists over a 2-year period) a proportion (approximately 8%) will be diagnosed with 
bronchiectasis on CT chest. Second, we acknowledge the fact that performing CT scan only in a 
select subgroup introduces the possibility of selection bias in that individual clinicians may have 
different indications for performing CT chest. To address this, we compared children with PBB 
undergoing CT chest to those who did not and found no significant differences between groups 
with respect to bronchiectasis risk factors.  
 
The major strengths of this study are the longitudinal nature of data collection and the inclusion 
of lower airway inflammatory and microbiological findings. However, as we only performed 
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bronchoscopy and BAL at a single time-point, the temporal relationship between infection with H. 
influenzae and development of bronchiectasis remains unclear. This does not, however, diminish 
the utility nor the relevance of our findings. Irrespective of whether H. influenzae is a cause (or 
consequence) of bronchiectasis in young children, its presence in a child with recurrent PBB 
should alert the pulmonologist to the increased possibility of bronchiectasis, suggesting the need 
for closer monitoring and/or further investigation. This is a novel finding with direct clinical 
relevance to those managing children with chronic cough. 
 
Findings from this longitudinal cohort study provide further evidence for the link between PBB 
and bronchiectasis in young children. We have shown that at least 8% (1 in 12.4 children, median 
age 23 months at recruitment) with PBB are diagnosed with bronchiectasis at 2-year follow-up. 
Of those with PBB, at least 43.5% had recurrent episodes in their first year after recruitment. We 
have identified key risk factors for bronchiectasis i.e. H. influenzae lower airway infection and 
recurrent episodes of PBB.  
 
In view of this study’s findings, clinicians should be cognisant of the need to monitor children 
with PBB over time and consider CT chest in those with risk factors for bronchiectasis. Ongoing 
research into the potential role of H. influenzae in the pathogenesis of bronchiectasis in children 
is needed in order to inform future preventative and therapeutic strategies.
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Table 1: Baseline demographic and clinical characteristics of study participants 
 PBB 
followed-up 
(N=106)  
         PBB total 
         (N=161) 
Controls 
(N=25)  
P-value1 
Sex, M:F 74:32  106:55  12:13    0.085 
 
Age - Mo 23 (14, 53)   22 (13, 50) 44 (7, 97)   0.061 
 
Prior pneumonia – X-ray 
confirmed2 
 
24 (23%)   35 (22%)   2 (8%)   0.109 
Household tobacco smoke 
exposure 
 
36 (34%)   55 (34%) 6 (24%)   0.662 
Aboriginal or Torres Strait 
Islander 
 
  3 (3%)   10 (6%) 0    0.363 
Current cough 89 (84%) 134 (83%) 2 (8%) <0.001 
Length of current cough – 
wks, median (IQR) 
 
26 (7, 52)   26 (6, 52) 0 <0.001 
 
Current antibiotics 16 (15%)   19 (12%) 1/15 (7%)   0.695 
 
>5 doctor visits past yr for 
cough 
95 (90%) 140 (87%) 3/15 (20%) <0.001 
Abbreviations: PBB followed-up = Subset of patients with PBB who completed 2-year follow-up; 
PBB total = all patients with PBB irrespective of whether 2-year follow-up was completed. 
1 Comparison of ‘PBB total’ to controls; 2 Parent-reported  
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Table 2: Clinical characteristics of study participants at 2-year follow-up 
Characteristic PBB 
followed-up 
(N=106) 
Controls 
(N=25)  
P-value 
Current cough 47 (44%) 3 (12%)   0.005 
Current antibiotics 20/98 (20%) 0    0.012 
 
Recurrent OM (>5 episodes) 58/97 (60%) 7/20 (35%)   0.042 
 
>5 doctor visits past yr for cough  43/97 (44%) 1/20 (5%)   0.001 
 
Asthma diagnosed ever 
 
57/95 (60%) 
 
4/20 (20%) 
 
  0.001 
 
Eczema diagnosed ever 29/92 (32%) 3/19 (16%)   0.265 
 
Wheeze ever1  
 
76/95 (80%) 7/19 (37%) <0.001 
Wheeze past 12 months 54/93 (58%) 3/19 (16%)   0.001 
 
Family history of atopy2  
 
Recurrent PBB3 
 
CT chest (any indication) 
 
12/88 (14%) 
 
67 (63%) 
 
20 
 
1/20 (5%) 
 
0   
 
3 
 
  0.455 
 
<0.001 
 
  0.564 
 
Abbreviations: PBB followed-up = Subset of patients with PBB who completed 2-year follow-up; 
PBB total = all patients with PBB irrespective of whether 2-year follow-up was completed. 
1 Parent-reported (‘has your child ever had a high-pitched whistling or wheezing sound’) 
2 Asthma, eczema and/or hay fever in first-degree relative/s  
3  In 12-month period after enrolment 
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Table 3: Uni- and multi-variate analysis of risk factors for bronchiectasis (BE) in children 
with PBB 
Risk factor  Group 1 
BE present 
(N=13) 
Group 2 
BE absent 
(N=148) 
Odds ratio 
(95% CI)  
 
P-value 
Univariate analysis 
 
    
Sex, M:F  8:5  98:50 0.816 (0.25, 2.63) 0.733 
 
Recruitment age – 
mths, median (IQR) 
 
29 (10, 45)  22 (13, 50) 0.99 (0.97, 1.01) 0.521 
Prior pneumonia  
 
  3 (23%)  32 (22%) 1.09 (0.28, 4.19) 0.903 
 
Recurrent PBB  
(>3 ep/year)1 
 
11 (85%)  56 (38%) 9.04 (1.93, 42.27) 0.005 
Household tobacco 
smoke exposure 
 
  3 (23%)  52 (35%) 0.55 (0.14, 2.08) 0.377 
Maternal smoking in 
pregnancy 
 
  3 (23%) 18/85 (21%) 1.40 (0.34, 5.81) 0.647 
Aboriginal or Torres 
Strait Islander 
 
  1 (8%)    9 (6%) 1.29 (0.15, 11.03) 0.818 
No. children in 
household, median 
(IQR) 
 
≥2 siblings 
≥1 sibling 
  3 (2, 4) 
 
 
 
  8 (62%) 
13 (100%) 
   2 (2, 3) 
 
 
 
  47 (32%) 
123 (83%) 
1.28 (0.91, 1.80) 
 
 
 
3.44 (1.07, 11.08) 
- 
0.156 
 
 
 
0.039 
 
 
Childcare attendance, 
ever  
 
8/9 (89%) 71/82  (87%) 1.24 (0.14, 10.90) 0.847 
BAL organism     
Adenovirus positive 
(on PCR)2 
  
3/12 (25%) 26/138 (19%) 1.44 (0.36, 5.68) 0.606 
 
H. influenzae  11 (85%)   72 (49%) 5.81 (1.24, 27.10) 0.025 
M. catarrhalis    4 (31%)   43 (29%) 1.09 (0.32, 3.71) 0.896 
S. pneumoniae   3 (23%)  41 (28%) 0.78 (0.21, 2.99) 0.720 
! 25!
S. aureus    1 (8%)  12 (8%)  0.94 (0.11, 7.90) 0.958 
Multivariate analysis     
 
H. influenzae   7.60 (1.53, 37.79) 0.013 
 
≥2 siblings 
 
Recurrent PBB (>3 
ep/year) 
  3.53 (0.98, 12.70) 
 
11.48 (2.33, 56.50) 
0.054 
 
0.003 
 
1 As determined at 1-year time-point in study. 7 children had not reached the 1-year time-point, 
for the purposes of the multi-variate analysis these children were assumed to have non-recurrent 
PBB.   
2 As compared to previously published rate of 4% (adenovirus positivity) in BAL samples of 
control children.8 
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Table 4: Survival analysis – PBB to bronchiectasis (Months) (n=161) 
 HR (95% CI) P-value 
Univariable 
H. influenzae1 
 
5.81 (1.28 – 26.37) 
 
0.022 
≥2 siblings       3.18 (1.04 – 9.73) 0.042 
Recurrent PBB (>3 episodes/yr) 7.65 (1.67 – 34.92) 0.009 
   
Multivariable   
H. influenzae1 7.55 (1.66 – 34.28) 0.009 
Recurrent PBB (>3 episodes/yr) 9.77 (2.13 – 44.80) 0.003 
1 Lower airway infection with H. influenzae defined as ≥104 cfu/ml growth on BAL fluid culture 
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Table 5: Cellularity from BAL of children with and without bronchiectasis (BE) 
Cellularity,  
median (IQR) 
BE present 
(N=12)1 
BE absent 
(N=138)1 
P-value 
BAL TCC x 106/L 
 
240 (210, 560) 240 (120, 420) 0.29 
BAL neutr%,  
 
 35 (12, 75)  25 (10, 55) 0.35 
BAL macro%,  
 
 56 (25, 72)  61 (35, 80) 0.47 
BAL lymph%,  
 
  6 (4, 9)   9 (4, 14) 0.51 
BAL eosin%,  
 
  1 (0, 2)   0 (0, 0) 0.0012 
1 Cellularity was unavailable, due to insufficient sample, from 11 participants (10 ‘BE absent’ 
children and 1 ‘BE present’ child). 
2 When outlier (16% eosinophils) is removed from ‘BE present’ group, the difference between 
groups, for eosinophil percentage, was no longer significant. 
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FIGURE LEGENDS 
Figure 1: CONSORT diagram 
!
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CHAPTER 7 
7.1 INTRODUCTION TO CHAPTER 7 
Previous chapters have focused on original research relating to chronic wet cough and 
PBB in children. Chapter 7 is comprised of 2 manuscripts that reviewed the current 
literature relating to cough treatments. Chapter 7.1 was a Cochrane meta-analysis 
examining the efficacy of short-course antibiotics (treatment duration of 4 weeks or less), 
in the treatment of bronchiectasis in children and adults. Chapter 7.2 was a review of 
available literature pertaining to cough remedies in children. Both manuscripts are highly 
applicable to clinical practice, with the latter having direct relevance to clinicians working in 
general practice. 
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7.2 Cochrane systematic review: short courses of 
antibiotics for children and adults with bronchiectasis  
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A B S T R A C T
Background
Bronchiectasis is an important cause of respiratory morbidity in both developing and developed countries. Antibiotics are considered
standard therapy in the treatment of this condition but it is unknown whether short courses (four weeks or less) are efficacious.
Objectives
To determine whether short courses of antibiotics (i.e. less than or equal to four weeks) for treatment of acute and stable state
bronchiectasis, in adults and children, are efficacious when compared to placebo or usual care.
Search methods
The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE, EMBASE, OLDMEDLINE,
CINAHL, AMED and PsycINFO and handsearching of respiratory journals and meeting abstracts were performed by the Cochrane
Airways Group up to February 2011.
Selection criteria
Only randomised controlled trials were considered. Adults and children with bronchiectasis (defined clinically or radiologically) were
included. Patients with cystic fibrosis were excluded.
Data collection and analysis
Two review authors independently reviewed the titles, abstracts and citations to assess eligibility for inclusion. Only one study fulfilled
the inclusion criteria and thus meta-analysis could not be performed.
Main results
The single eligible study showed a small benefit, when compared to placebo, of four weeks of inhaled antibiotic therapy in adults with
bronchiectasis and pseudomonas in their sputum. There were no studies in children and no studies on oral or intravenous antibiotics.
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Authors’ conclusions
There is insufficient evidence in the current literature to make reasonable conclusions about the efficacy of short course antibiotics in the
management of adults and children with bronchiectasis. Until further evidence is available, adherence to current treatment guidelines
is recommended.
P L A I N L A N G U A G E S U M M A R Y
Short courses of antibiotics for children and adults with bronchiectasis
There is a paucity of evidence to conclude whether short courses of antibiotics (i.e. less than or equal to four weeks) are equivalent or
superior to placebo in the treatment of stable or exacerbation state bronchiectasis. One single study showed some benefit of short-course
inhaled antibiotics over placebo, in terms of microbiological response and subjective improvement in medical condition, although this
was balanced against an increase in adverse effects and antimicrobial resistance in the treatment group. Given the potential benefits of
shorter duration antibiotic therapy in bronchiectasis, further RCTs are clearly needed to answer this important question.
B A C K G R O U N D
Non cystic-fibrosis bronchiectasis, previously termed an ’orphan
disease’ is increasingly recognised as a major cause of respira-
tory morbidity both in developing countries as well as affluent
countries, and particularly within Indigenous populations (Chang
2008; Edwards 2003; Singleton 2000).
There are many known aetiological associations with bronchiec-
tasis. Severe lower respiratory tract infection has previously been
identified as the most common preceding medical condition in
children diagnosed with bronchiectasis (Chang 2008b; Eastham
2004; Karakoc 2009; Singleton 2000), and continues to be amajor
cause of bronchiectasis worldwide (Callahan 2002; Edwards 2003;
Karakoc 2009). However, diseases that affect the pulmonary sys-
tem (such as immunodeficiency) have become increasingly identi-
fied as important causes of bronchiectasis within developed coun-
tries (Li 2005; Shoemark 2007).
In adults, the major aetiological associations include post-infec-
tion pneumonia or TB, primary ciliary dyskinesia, allergic bron-
chopulmonary aspergillosis and immunodeficiencies (Shoemark
2007). Primary lung diseases such as chronic obstructive pul-
monary disease (COPD) (O’Brien 2000; Patel 2004), sarcoido-
sis (Lewis 2002), and bronchiolitis obliterans (Chang 1998) have
been associated with bronchiectasis as a secondary manifestation.
In children, immunodeficiency, aspiration, primary ciliary dysk-
inesia and congenital airway anomalies are important consider-
ations (Li 2005). Despite intensive investigations, an underly-
ing cause is often not found in many children and adults with
bronchiectasis (Shoemark 2007).
Description of the condition
Bronchiectasis is a disease that primarily affects the airways in
the initial disease phase. The postulated pathophysiology includes
a ’vicious circle’ of infection, inflammation and impairment of
mucociliary clearance mechanisms eventually leading to airway
destruction and bronchial dilatation (Cole 1986).
Adult patients usually present with cough, daily sputum produc-
tion, dyspnoea, rhinosinusitis, haemoptysis and recurrent pleurisy
(King 2004). Children usually present with chronic wet cough or
recurrent pneumonia (Singleton 2000). They may have clinical
signs such as crackles and wheeze on chest auscultation and some-
times peripheral clubbing (King 2004). With appropriate treat-
ment (usually antibiotics and airway clearance), the chronic cough
can totally resolve (Kapur 2009), as can radiological evidence of
bronchiectasis (Gaillard 2003). High-resolution Computed To-
mography (HRCT) of the chest is considered the gold-standard in
diagnosis of bronchiectasis. However, controversy exists as to the
normal cut-off of broncho-arterial ratio (particularly in children)
(Chang 2008b). Hence, bronchiectasis is sometimes defined clin-
ically in children (Chang 2008b; Singleton 2000). Recent studies
suggest that volumetric scans acquired using multi-detector CT
are substantially more sensitive and accurate than conventional
HRCT for assessing bronchiectasis (Hill 2009).
A combination of airway clearance techniques and antibiotic
therapy, with or without other therapies such as anti-inflamma-
tory agents and bronchodilators, are current recommended treat-
ment for non-cystic fibrosis bronchiectasis (Chang 2008b). Spe-
cific treatments targeted to the underlying aetiology (such as in-
travenous immunoglobulin for common variable immunodefi-
ciency) is also important in the management of bronchiectasis.
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Early recognition and treatment of bronchiectasis may improve
long term outcomes (Kapur 2010).
Description of the intervention
Antibiotics are the mainstay of therapy in the management of
bronchiectasis (Prasad 2007). There are various methods to de-
liver antibiotics to the pulmonary system (oral, intravenous or in-
haled). The type of antibiotics given may be targeted to the pa-
tient’s known airway organism(s) or used empirically.
How the intervention might work
Infection and inflammation are key components in the aetiopatho-
genesis of bronchiectasis (Cole 1986). Bronchiectatic airways facil-
itate chronic bacterial colonisation and predispose them to recur-
rent infections (Loebinger 2007). Chronic bacterial infection elic-
its a systemic inflammatory response with local release of inflam-
matory cytokines (including TNF-α and IL-8) causing migration
of inflammatory cells such as neutrophils and lymphocytes (Gaga
1998; Shum 2000). Neutrophils release proteolytic enzymes e.g.
neutrophil elastase (Amitani 1995) and reactive oxygen species
(Anderson 1996), into the airway lumen which cause epithelial
damage and stimulate mucous production (Adler 1990). Antibi-
otics can potentially halt the bacterial infection and subsequently
limit ongoing neutrophilic inflammation.
An existing Cochrane Review found that prolonged courses of
antibiotics for bronchiectasis, i.e. greater than fourweeks in length,
are effective in reducing sputum volume and purulence but have
a limited impact on the natural history of the condition (Evans
2007). We have reviewed the literature to determine the impact of
shorter courses of antibiotics during stable state and exacerbation
state in bronchiectasis.
Why it is important to do this review
Most adults and children with bronchiectasis are given frequent
courses of antibiotics, the optimal duration of which is unknown.
The published Cochrane Review on antibiotics for bronchiectasis
is limited to prolonged courses greater than four weeks in duration
(Evans 2007).
In clinical practice, short courses of antibiotics during stable and
exacerbation states of bronchiectasis often result in improvement
in symptoms. Objective measures of airway inflammation also im-
prove, as some studies have shown, for example use of short-course
inhaled gentamicin resulted in improvement in airway hypersecre-
tion and inflammation (Lin 1997).
There is currently a paucity of evidence on the optimal duration
of antibiotics in stable and exacerbation states. However, there is
a trend towards use of shorter courses (i.e. less than two weeks)
amongst clinicians. The risks of antibiotic side effects and resis-
tance are a significant concern when using longer courses of an-
tibiotics. A review of the literature to determine the evidence for
use of shorter courses of antibiotics in adults and children in stable
and exacerbation states of bronchiectasis is important to assist in
guiding clinical practice.
O B J E C T I V E S
To evaluate the efficacy of short courses (i.e. four weeks or less) of
antibiotics in children and adults with bronchiectasis;
(a) during stable state bronchiectasis; and
(b) for reducing the severity and frequency of acute respiratory
exacerbations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any randomised controlled trial comparing outcomes with use of
antibiotics (intravenous, oral or inhaled) versus placebo or usual
care as the control, for periods of less than, or equal to, four weeks,
in non-cystic fibrosis bronchiectasis. Participants are allowed to
have adjunctive therapies (such as airway clearance) as long as they
have equal chance of having these adjunctive therapies.
Types of participants
Adults and children with bronchiectasis (defined clinically or ra-
diologically) not related to cystic fibrosis.
Types of interventions
Any short (four weeks or less) course of antibiotics given by intra-
venous, oral or nebulised routes.
Types of outcome measures
Primary outcomes
The primary outcome measures were change in:
1. Symptom score (e.g. bronchiectasis severity control, cough-
specific/respiratory-specific quality of life (QoL) or generic
health-specific QoL)
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2. Lung function indices (airway resistance or airway calibre
measurements)
3. Adverse events
Secondary outcomes
1. Sputum or airway markers (weight, purulence, colour
(Bronkotest), inflammatory profiles)
2. Microbiological data (density, resistance patterns)
3. Exacerbation data (length, time to next exacerbation)
Search methods for identification of studies
Electronic searches
Randomised controlled trials were identified using the Cochrane
Airways Group Specialised Register of trials, which is derived
from systematic searches of bibliographic databases including the
Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE,OLDMEDLINE, CINAHL, AMEDand
PsycINFO, and handsearching of respiratory journals and meet-
ing abstracts (please see the Airways Group search methods for
further details). We searched all records in the Specialised Register
coded as ’bronchiectasis’ using the following terms:
antibiotic* OR *cillin OR *tetracycline OR *mycin OR
macrolide* OR quinolone* OR *oxacin OR trimethoprim OR
*sulpha OR *ceph or anti-bacteri* or “anti bacteri* OR anti-mi-
crobial* OR anti*
The search was conducted in February 2011.
Searching other resources
We handsearched all the papers and reviews identified for further
references and contacted authors to request their identification of
any unpublished ormissed trials.We contacted researchers directly
as required to establish whether other unpublished or ongoing
studies were available for assessment.We handsearched clinical tri-
als web sites (www.clinicalstudyresults.org; www.clinicaltrials.gov;
www.fda.gov).
Data collection and analysis
Selection of studies
Following electronic literature searches, AC and DW indepen-
dently reviewed the searches to identify potentially relevant trials
for full review. We searched bibliographies and texts to identify
additional studies. From the full text using specific criteria, AC
and DW independently selected trials for inclusion. There was
complete agreement between review authors.
Data extraction and management
We extracted information from each study for the following char-
acteristics:
1. Design (description of randomisation, blinding, allocation,
number of study centres and location, withdrawals)
2. Participants (N, mean age, age range of the study, baseline
lung function, duration of antibiotics < 4 weeks versus no
antibiotics)
3. Intervention (type and duration of antibiotic,
appropriateness of antibiotic choice, dosing schedules of groups)
4. Outcomes (type of outcomes and results of outcomes)
We requested further information from the trial authors where
required. This occurred with Barker 2000 as explained in the in-
cluded studies section of the Results.
Studies were translated to English where possible.
Assessment of risk of bias in included studies
We assessed trial bias protection in the following domains and
study quality according to whether studies met the following pre-
specified quality criteria (as met, unmet or unclear) using the risk
of bias (RoB) table in Review Manager 5.
1. Sequence generation
2. Allocation concealment
3. Blinding of participants and investigators
4. Loss to follow-up
Measures of treatment effect
We extracted data for each of the outcomes (where data were
available) from the trial publication that fulfilled the inclusion
criteria.
We performed an initial qualitative comparison of all the indi-
vidually analysed studies taking into account differences in study
populations, inclusion/exclusion criteria, interventions, outcome
assessment and estimated effect size, to examine whether pooling
of results (meta-analysis) was reasonable.
Unit of analysis issues
We sought to obtain data that were reported with patients (rather
than events) as the unit of analysis for the primary outcomes.
Dealing with missing data
The proportion of randomised patients who provided data for the
main outcomes was reported and we had planned to compare this
with the number of patients with events in each outcome category.
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Assessment of heterogeneity
Wehad planned to describe and explore heterogeneity between the
study results, and to use the 95% confidence interval, estimated
using a random-effectsmodel, whenever therewere concerns about
statistical heterogeneity.
Assessment of reporting biases
If combining data was possible, we had planned to assess publica-
tion bias using a funnel plot. We planned to identify and report
on any selective reporting in the included trials.
Data synthesis
We combined data using Review Manager 5, with a view to us-
ing a fixed-effect mean difference (calculated as a weighted mean
difference) for continuous data variables. If different scales were
combined, we had intended to use the standardised mean differ-
ence.
For the dichotomous outcome variables of each individual study,
we had planned to calculate odds ratios using a modified inten-
tion-to-treat analysis (i.e. failure assumed if participant drops out
of study). This analysis assumes that children or adults not avail-
able for outcome assessment have not improved (and probably
represents a conservative estimate of effect).
For the primary outcomes we intended to calculate a number
needed to treat (benefit or harm) when possible for the different
levels of risk as represented by control group event rates over a
specified time period using the pooled Odds Ratio and its confi-
dence interval using an online calculator, Visual Rx (Cates 2003).
A summary of findings (SoF) table would be constructed for the
primary outcomes.
Subgroup analysis and investigation of heterogeneity
We had intended to perform an a priori subgroup analysis for:
1. Children versus adults (adult studies will be considered as
those which recruited participants from 18 years upwards)
2. Type of antibiotics (oral, intravenous, inhaled)
3. Type of control arm (placebo/no treatment or control
antibiotic i.e. prolonged duration antibiotics)
4. State during enrolment (stable state or exacerbation)
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the
potentially important factors on the overall outcomes:
1. variation in the inclusion criteria;
2. differences in the medications used in the intervention and
comparison groups;
3. analysis using random-effects model;
4. analysis by ”treatment received“; and
5. analysis by ”intention-to-treat“.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
From the searches, the Cochrane Airways Group specialised reg-
ister/search identified 187 potentially relevant titles. After assess-
ing the titles/abstracts, we obtained19 papers for consideration for
inclusion in the review. We reviewed 11 full text articles and 8
further abstracts. We excluded 18 studies (see Excluded studies).
We found two potentially eligible studies, however they appeared
to have used the same patient population, leaving only one eligible
study in adults. We identified no studies in children.
Included studies
The included studies were Barker 2000 and Couch 2001a, which
described the same study populations. Couch 2001a was an ”early
review of data“ for a chest supplement on aerosolised therapeutics
as discussed by Fiel 2001 in his editorial. For this reason, we used
the final data in Barker’s paper in this Cochrane Review.
The sole study was a multicentre parallel RCT that examined the
effect of nebulised tobramycin (Tobramycin Solution for Inhala-
tion) versus placebo, in adults with CT confirmed bronchiectasis
and Pseudomonas aeruginosa infection. There were 16 study sites,
74 adults enrolled with completion rate of 81% (60/74). Further
details are described in the Characteristics of included studies.
Excluded studies
Eighteen studies were excluded as they did not fulfil criteria for
the review. Fifteen of the eighteen studies excluded had no suitable
comparator/placebo group, one study did not specify bronchiec-
tasis as an inclusion criterion, one study had treatment periods
greater than four weeks, two studies shared a common study pop-
ulation, resulting in the exclusion of one.
Bilton 2006 and Shrewsbury 2004 examined short courses of an-
tibiotics in bronchiectasis and compared oral ciprofloxacin (in
treatment doses) plus placebo to oral ciprofloxacin plus inhaled
tobramycin. Although these studies almost fulfilled criteria for in-
clusion, there was no ”antibiotic-free“ placebo for comparison, re-
sulting in their exclusion from this review.
Couch 2001a was excluded as it was an early review of the same
data used in the included study Barker 2000. Attempts to con-
tact the corresponding author were unsuccessful, but this was con-
firmed in the editorial Fiel 2001 which accompanied the paper.
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Risk of bias in included studies
Allocation concealment was unclear in this study (Barker 2000).
Block randomisationwas utilised to balance group sizes. The study
was double-blinded,with both investigators andparticipants being
blinded to study group allocation to reduce selection bias. Six
patients were withdrawn from the placebo group due to need for
an antibiotic other than the study drug.
Allocation
Block randomisation of patients was used. Eligible patients were
randomly assigned in blocks of two to parallel groups at each study
centre to receive either inhaled tobramycin or placebo.
Blinding
The study was double-blinded i.e. both participants and investiga-
tors were blinded to the study drug assignment until completion
of the follow-up visit and data were collected from all study sites.
The placebo used (quinine sulphate) was chosen because of its
similar taste to tobramycin. It was unclear whether investigators
were blinded to the study hypothesis.
Incomplete outcome data
The number of participants withdrawn (due to adverse events
or use of antibiotic other than the study drug) and those lost to
follow-up were reported for both inhaled tobramycin and placebo
groups.
Selective reporting
There was no suggestion that selective reporting had occurred.
Effects of interventions
The included trial involved 74 patients with 60 completing the
study. In the absence of additional suitable studies, there were
insufficient data to perform a meta-analysis. The outcomes from
the single study (also presented in the forest plot) were:
Primary Outcomes
1. Symptom score (e.g. bronchiectasis severity control,
cough-specific/respiratory-specific quality of life (QoL) or
generic health-specific QoL)
The study did not specificallymeasure any symptoms to determine
a symptom score. Instead, the investigator’s subjective assessment
of a change in the patient’s general medical condition (”improved“
or ”not improved“) was recorded at week six: 23 of 37 (62%)
patients in the tobramycin-treated group significantly improved
compared to 14 of 35 (40%) in the placebo group that improved
(Analysis 1.1; OR 0.37; 95% CI 0.14 to 0.95).
2. Lung function indices (airway resistance or airway calibre
measurements)
Percent change in forced expiratory volume in one second (FEV1)
percent predicted and in Forced Vital Capacity (FVC) percent
predicted from baseline to week four were not statistically signif-
icant between the tobramycin and placebo groups (-2.2% versus
1.5% respectively, P = 0.41) for FEV1 % predicted and FVC %
predicted (-2.8% versus 2.2%, P = 0.19). Airway reactivity (per-
cent change in FEV1 from pre- to post-study drug administration)
was not significantly different from zero percent for either the to-
bramycin group (mean = -1%, Week 0, -3% Week 4) or placebo
group (mean = -3% Week 0, -1% Week 4).
3. Adverse events
Thirty-one of 37 (84%) patients in each treatment group re-
ported at least one adverse event. Respiratory system adverse events
were reported by 26 (70%) tobramycin patients and by 19 (51%)
placebo patients. There was no statistical significance, but results
favoured the placebo group (OR 2.24; 95% CI 0.86 to 5.82;
Analysis 2.1). Five patients in the tobramycin group and one pa-
tient in the placebo group were hospitalised and treated for an
exacerbation of their pulmonary disease (OR 5.63; 95% CI 0.62
to 50.73; Analysis 2.2).
Secondary outcomes
1. Microbiological response (i.e. change in P. aeruginosa
density from baseline to week 4 and week 6 and antibiotic
resistance)
At the endof the trial, significantlymore subjects in the tobramycin
group (13 of 37) had P. aeruginosa eradicated from their sputum
compared to the placebo group (0 of 37); (OR 0.03; 95% CI 0.01
to 0.14; Analysis 3.1.) Furthermore, a further 12 patients in the
tobramycin group had reduced P. aeruginosa carriage (PA cfu/g
decreased by at least 2 log10 at week 4), compared to two patients
with reduced carriage in the placebo group.
However, at follow-up two weeks post cessation of antibiotics,
the mean reduction in the tobramycin group was smaller than
in previous weeks, suggesting some regrowth of organisms after
ceasing the antibiotic.
Four of 36 patients in the tobramycin group and one of 32 in the
placebo group, who began the study with susceptible P. aeruginosa,
had resistant P. aeruginosa at their last visit (P = 0.36). Three of the
four patients in the tobramycin group who developed resistant P.
aeruginosa showed no microbiological response. All four patients
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were considered to have not improved when their general medical
condition was assessed.
D I S C U S S I O N
This review is limited to a sole study in adults. The data suggest
that short term inhaled antibiotics show some benefit in the treat-
ment of patients with bronchiectasis and P. aeruginosa. The study
followed the patients for only two weeks post-treatment to as-
sess longevity of response. Despite its weaknesses, this single study
supports previous Cochrane Reviews on the use of longer term
antibiotics in bronchiectasis (Evans 2007), in showing subjective
improvement in general medical condition as assessed by an in-
vestigator.
This review has highlighted the fact that, although antibiotics are
themainstay of treatment in adults and children with bronchiecta-
sis, there remains a paucity of data, particularly high quality data,
to support this practice. In today’s evidence based medical era and
with bronchiectasis becoming increasingly recognised as a major
cause of respiratory morbidity, there will be an increasing need to
provide evidence-based answers to these common questions.
A small number of patients in the study antibiotic arm developed
”resistant“ pseudomonas. This highlights an important compli-
cation of antibiotic therapy, particularly when antibiotic use in
any one patient is prolonged or recurrent. Previous research by
Hillier 2007 has shown that antibiotic resistance increases with
increased duration of antibiotic therapy. These findings are related
to urinary tract infections but are likely to be applicable to infec-
tions elsewhere in the body including the lung. This issue, com-
bined with the likely improved quality of life for patients receiv-
ing shorter courses of antibiotics, highlights the need for further
studies to determine the optimal duration of antibiotic therapy in
bronchiectasis.
The included study followed patients for only two weeks post-
therapy. Given that antibiotics are known to indirectly limit neu-
trophilic inflammation in the airways and ideally eradicate the bac-
terial infection, it is not surprising that patients showed improve-
ment over this follow-up period. It is unknown if two weeks is an
optimal timeframe to assess bacterial eradication adding further
to the limitations of this study. To assess longevity of symptom
response and microbiological eradication, a longer timeframe of
follow-up would have been required.
Evans 2007’s Cochrane Review on prolonged antibiotics found
a significant benefit of prolonged antibiotics (i.e. four or more
weeks) in terms of response rates. They found no significant differ-
ence between placebo and prolonged antibiotics in terms of exac-
erbation rates and lung function. This would concur with Barker
2000, which found a subjective improvement in patients’ general
medical condition with inhaled tobramycin therapy as compared
to placebo, with no significant differences in lung function be-
tween treatment groups.
The single included study (Barker 2000) showed some benefit of
four weeks of inhaled antibiotic therapy compared with placebo
in patients with bronchiectasis and P. aeruginosa infection in terms
of microbiological response (at the expense of increased resistance)
and improvement in general medical condition. The lack of other
suitable studies for this Cochrane Review precluded a meta-analy-
sis, and as a result we could not draw any firm conclusions on the
topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When considering implications for practice, one must acknowl-
edge the fact that this review was based on one study of adult pa-
tients and the intervention was ”inhaled“ antibiotics. This study
showed a small benefit in microbiological response and overall
subjective improvement in general medical condition, with no ef-
fect on lung function and an increase in adverse events in the in-
tervention group. The study failed to address primary outcome
measures with symptom scores or objective outcomes. Therefore,
although this one study is suggestive of benefit of short courses
of antibiotics for bronchiectasis, one would conclude, for current
practice implications, that there is insufficient evidence available
in the current literature tomake any reasonable conclusions. How-
ever until further evidence is available, clinicians should adhere
to guidelines (Chang 2010; Pasteur 2010) that include data from
non RCTs.
Implications for research
Well-designed, double-blinded, parallel, randomised controlled
trials are required to assess the role of short courses of antibiotics
in the treatment of bronchiectasis. These studies should include
validated outcome measures such as improvements in symptom
score, QOL and lung function, balanced against adverse effects
as primary outcome measures. Trials including oral, inhaled and
intravenous antibiotic administration methods are needed. Future
RCTs should be undertaken in paediatric as well as adult patients.
Well-designed studies should include sufficient longitudinal fol-
low-up of patients to assess longevity of intervention response and
therefore applicability of evidence to practice. Such well-designed
research would have the potential to improve the quality of life for
individuals with bronchiectasis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barker 2000
Methods The study was a randomised placebo-controlled, double-blinded trial with antibiotics
administered for 4 weeks. Eligible patients were randomly assigned in blocks of two
to parallel groups at each of 16 study sites across the United States to receive either
Tobramycin solution for inhalation or placebo. This was administered twice daily for 4
weeks in bronchiectasis patients whose sputum contained Pseudomonas aeruginosa. Pa-
tients were then observed for 2 weeks after administration of their last dose. Of patients
enrolled, they were divided equally between the two treatment groups. Patients were
withdrawn if they required any additional antibiotics at any stage during study partici-
pation
Patients were screened 2 weeks prior to their initial dose of the study drug, were dosed
for 4 weeks, and then observed for 2 weeks after their last dose. Thus the total duration
of the study was 8 weeks. At each visit a sputum sample was obtained and the density
of the P. aeruginosa in sputum was measured. Pulmonary function testing (FEV1 and
FVC) was performed at baseline and at the final treatment visit (week 4). Tobramycin
levels were measured. Adherence was measured at week 4 by counting the number of
vials of study drug used. A subjective clinical assessment of the patient’s general medical
condition was made, by a study investigator, at the follow-up visit on week 6
There were 6 patients who withdrew from the tobramycin group (3 for adverse events,
2 for use of antibiotics other than study drug, and 1 was lost to follow-up.) 8 withdrew
from the placebo group (2 for adverse events, and 6 for use of antibiotics other than the
study drug.)
Participants 125 patients were screened and 74 patients (45 female), mean age 66.6 (tobramycin
group) and 63.2 (placebo group) were enrolled. Patients were block randomised to receive
either 300 mg of inhaled tobramycin or placebo twice daily for 4 weeks. 37 received
inhaled tobramycin and 37 received placebo
Inclusion: Bronchiectasis diagnosed by conventional or high-resolution CT and sputum
containing at least 104 cfu/mL P. aeruginosa.
Exclusion: cystic fibrosis, allergic bronchopulmonary aspergillosis, acute pulmonary pro-
cess requiring medical intervention as indicated by a new infiltrate on a chest radiograph,
significant recent haemoptysis, or had received antibiotics within 2 weeks of the screen-
ing visit
Interventions Nebulised tobramycin solution for inhalation (300mg tobramycin) twice daily or placebo
for 4 weeks
Outcomes Primary end point was (1) Change in P. aeruginosa density from baseline to week 4.
Additional endpoints included: (1) change in P. aeruginosa density from baseline values
to week 2 and to week 6; (2) an investigator’s subjective assessment of a change in
the patient’s general medical condition (”improved“ or ”not improved“) was made and
recorded at week 6, (3) the percent change in FEV1percent predicted and in FVCpercent
predicted from week 0 to week 4 and (4) Safety endpoints included the incidence of
adverse events, change in serum chemistry and haematology measurements, and airway
reactivity
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Barker 2000 (Continued)
Each patient’s microbiological response was categorised according to whether P. aerugi-
nosawas eradicated, reduced by treatment, or did not respond to treatment. P. aeruginosa
was considered eradicated if it was not detected at week 6 or if it was not detected at
week 4 and the patient was unable to produce sputum at week 6. A patient’s response was
defined as reduced by treatment if P. aeruginosa was recovered from the week 6 sputum
and reduced by at least 2 log 10 cfu/g at week 4 compared with baseline. A patient had
no microbiological response if P. aeruginosa did not decrease 2 log 10 cfu/g at week 4 or
if the patient withdrew from the study
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and investigators. Low risk Patients and investigators were blinded to
the study drug assignment
Incomplete outcome data assessed? Low risk Number of dropouts and loss to follow-up
included.
Free of selective reporting? Low risk No suggestion that selective reporting may
have occurred.
Free of other bias? Low risk No other bias identified
Sequence generation. Low risk Sequence generation was referred to, how-
ever details were not provided
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bilton 2006 No suitable placebo/comparator group. (Comparator was not adequate to satisfy inclusion criteria, i.e. no
”antibiotic-free/placebo“ or long-term antibiotic group for comparison.)
Chrysanthopoulos 1989 No suitable placebo/comparator group.
Couch 2001a Overlap of study participants with included study.
Douglas 1957 No suitable placebo/comparator group.
Howie 1976 Study participants had unknown bronchiectasis status.
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(Continued)
Lam 1989 No suitable placebo/comparator group.
Lin 1996 No suitable placebo/comparator group.
Matsumoto 1986 No suitable placebo/comparator group. Not an RCT.
May 1972 No suitable placebo/comparator group.
Mehta 1991 No suitable placebo/comparator group.
Messens 1973 Translated from French. No suitable placebo/comparator group
Mijuskovic 1972 No suitable placebo/comparator group.
Nagy 1968 No suitable placebo/comparator group. (Compared antibiotic treatment to surgery.)
Oki 1993 No suitable placebo/comparator group. (Examined long term antibiotic treatment, no short course treat-
ment arm.)
Santiveri 1995 No suitable placebo/comparator group.
Shrewsbury 2004 No suitable placebo/comparator group. (Comparator was not adequate to satisfy inclusion criteria, i.e. no
”antibiotic-free/placebo“ or long-term antibiotic group for comparison.)
Tagaya 2002 No suitable placebo/comparator group.
Twiss 2008 Longer-course antibiotics (i.e. 2 to 3 months) compared to placebo. No short course group
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D A T A A N D A N A L Y S E S
Comparison 1. Change in general medical condition
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in general medical
condition
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Respiratory system adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Respiratory system adverse
events
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Hospitalised for respiratory
events
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Microbiological response
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological response 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 4. Development of pseudomonas resistance (when initially sensitive)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pseudomonas resistance 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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Analysis 1.1. Comparison 1 Change in general medical condition, Outcome 1 Improvement in general
medical condition.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 1 Change in general medical condition
Outcome: 1 Improvement in general medical condition
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 14/37 23/37 0.37 [ 0.14, 0.95 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 14 (TSI), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours TSI Favours placebo
Analysis 2.1. Comparison 2 Respiratory system adverse events, Outcome 1 Respiratory system adverse
events.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 2 Respiratory system adverse events
Outcome: 1 Respiratory system adverse events
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 26/37 19/37 2.24 [ 0.86, 5.82 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 26 (TSI), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours TSI Favours placebo
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Analysis 2.2. Comparison 2 Respiratory system adverse events, Outcome 2 Hospitalised for respiratory
events.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 2 Respiratory system adverse events
Outcome: 2 Hospitalised for respiratory events
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 5/37 1/37 5.63 [ 0.62, 50.73 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (Tobramycin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 3.1. Comparison 3 Microbiological response, Outcome 1 Microbiological response.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 3 Microbiological response
Outcome: 1 Microbiological response
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 12/37 33/35 0.03 [ 0.01, 0.14 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (TSI), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours TSI Favours placebo
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Analysis 4.1. Comparison 4 Development of pseudomonas resistance (when initially sensitive), Outcome 1
Pseudomonas resistance.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 4 Development of pseudomonas resistance (when initially sensitive)
Outcome: 1 Pseudomonas resistance
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 4/36 1/32 3.88 [ 0.41, 36.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (TSI), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
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Drug treatments of childhood coughs 
SUMMARY
Appropriate management of cough in children depends upon accurate assessment. The diagnosis 
is often unclear at the initial presentation.
Acute cough is frequently caused by a viral infection, and often no specific therapy is indicated. 
Urgent treatment may be needed if history suggests a more serious disorder such as a foreign 
body or pneumonia. 
When treating children with chronic cough, paediatric-specific algorithms should be used. 
Empirical use of medicines without looking for a specific cause should be avoided.
In the absence of an alternative specific cause of cough, chronic wet cough (lasting at least four 
weeks) is most frequently due to protracted bacterial bronchitis. Antibiotics are indicated.
a Melbourne-based community study involving 600 
families showed fewer episodes and an age-dependent 
trend (see Table).1 The mean duration of episodes was 
6.3 days (range 1–70 days) and younger children were 
more likely to have a longer duration of cough (6.8 days 
in youngest age group and 5.5 days in oldest group).
Management
Supportive therapy is the mainstay of treatment 
for viral acute respiratory infections. Paracetamol 
and ibuprofen are useful for related symptoms. 
Over-the-counter cough and cold medicines are 
not recommended due to a lack of proven efficacy 
and the possibility that they may present a safety 
risk.3 The Therapeutic Goods Administration now 
recommends that they should not be used in children 
under 6 years and only in children aged 6–11 years on 
advice from a doctor.4 
Honey,5,6 and menthol-based rubs7 may reduce 
the impact of nocturnal cough. It is reasonable to 
recommend one teaspoon of honey before bedtime for 
children aged over one year. Honey should be avoided 
in children under one year due to the risk of botulism. 
Introduction
Cough is the most common symptom presented to 
GPs and pharmacists in Australia. An Australian study 
found that ‘one in three (28.7%) respiratory episodes 
were associated with a doctor’s visit, and one in four 
(23%) necessitated time off school or work’.1 When 
a child first presents with cough, determining the 
precise diagnosis is not always possible. 
Acute cough 
Acute cough in a child may represent a variety of 
pathologies, from self-resolving viral-induced acute 
respiratory infection to acute severe respiratory disease 
or an acute presentation of an underlying chronic 
disorder. Appropriate management depends on 
accurate assessment. Patient history should include:2 
 đ cough duration (acute <2 weeks, sub-acute 
2–4 weeks, chronic >4 weeks) 
 đ characteristics of cough (whooping cough, wet vs 
dry cough) 
 đ questions about choking episodes and previous 
respiratory illness
 đ associated wheeze
 đ other symptoms such as weight loss, appetite 
or rash
 đ immunisation history.
In the differential diagnosis, it is important to consider 
inhaled foreign body, pneumonia and other treatable 
infections like pertussis and underlying lung disease 
such as bronchiectasis.
Uncomplicated acute upper respiratory 
infections
It is commonly said that young children have up to 
6–12 acute respiratory infections per year. However, 
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Table    Australian rates of uncomplicated 
acute upper respiratory infections 
in children and young adults 1
Age (years) Mean number of episodes a year
0–1 3.8
2–3 3.3
4–5 2.8
6–10 2.2
11–20 2
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upper abdominal pain. Signs of severity include grunt 
and intercostal recession. Wheeze is usually absent in 
bacterial pneumonia. 
A chest X-ray does not need to be performed 
routinely in all children with suspected pneumonia. 
However, it should be considered in any child with 
an atypical presentation (recurrent pneumonia, 
prolonged fever, signs of pleural effusion) or severe 
pneumonia requiring hospital admission.11
Recommendations for antimicrobial therapy vary 
according to the age of the child, context, presence 
of underlying disease (risk factors), presence of 
hypoxaemia, non-respiratory symptoms (such as 
vomiting), length and severity of symptoms and the 
presence of complications. Guidelines for antimicrobial 
therapy should be consulted.11-13 For a child with 
subacute onset and prominent cough (with or without 
headache or sore throat), or who is not improving, 
mycoplasma pneumonia should be suspected.13 
Indications for hospitalisation for community-acquired 
pneumonia include:
 đ very young children (less than 6 months) with 
suspected bacterial pneumonia12
 đ clinical evidence of moderate to severe 
pneumonia, including hypoxaemia and signs of 
respiratory distress12
 đ significant comorbidities or factors which 
predispose to more severe disease e.g. 
immunodeficiency, congenital heart disease, 
bronchiectasis11
 đ pneumonia suspected or confirmed to be 
secondary to a pathogen with increased virulence 
e.g. community-acquired methicillin-resistant 
Staphylococcus aureus (MRSA)12
 đ dehydration or inability to tolerate oral therapies11
 đ significant parental concern or anxiety11
 đ family unable to provide appropriate care or 
adhere to management plan12
 đ toxic-looking child e.g. pale or cyanotic, lethargic 
or inconsolably irritable
 đ complicated pneumonia e.g. empyema
 đ poor response after 48 hours of oral antibiotics.
All children with suspected pneumonia should be 
followed up regularly to ensure complete resolution of 
their symptoms. A repeat chest X-ray is not routinely 
performed following simple pneumonia unless there 
are persisting symptoms.11
Bronchiolitis
Children under two years presenting acutely with 
cough, tachypnoea (with or without poor feeding) 
and often with a history of a viral prodrome may 
Antibiotics should be avoided for the treatment of 
acute cough associated with mild upper respiratory 
tract infection, as the cough is most likely viral in 
origin. A recent Cochrane review reported that in cases 
of confirmed or suspected exposure to influenza in 
healthy children, oseltamivir shortens the time to first 
alleviation of symptoms by 29 hours (95% confidence 
interval 12–47 hours, p=0.001).8 No effect however was 
seen in children with asthma. Oseltamivir may reduce 
the risk of otitis media in children aged 1–5 years, 
especially if commenced within the first 12 hours, 
but is associated with a significantly increased risk of 
vomiting.9 Laboratory-based polymerase chain reaction 
(PCR) techniques enable rapid influenza diagnosis.10 
Management of acute cough should include 
counselling and advice on: 
 đ the expected duration of cough (typically 
5–7 days, but up to 3 weeks)
 đ when to come back and see the GP and when to 
seek urgent medical review (for example suspected 
foreign body, tachypnoea, dyspnoea, vomiting, 
inability to feed, persistent fever, lethargy)
 đ avoidance of passive smoke exposure.
Specific causes of acute cough 
A number of specific diseases need to be considered 
in a child presenting with acute cough. Many of these 
have specific symptoms and signs. 
Croup 
The acute or sub-acute onset of a barking ‘brassy’ 
cough, hoarse voice, stridor with or without evidence 
of upper airway obstruction, is characteristic of croup. 
It often begins with a viral upper respiratory tract 
infection (for example rhinorrhoea, sore throat with 
or without fever) and typically affects children aged 
1–6 years. Children outside this age range or with 
severe or recurrent stridor or other symptoms require 
careful evaluation for an underlying airway lesion. 
Children with bacterial causes of stridor such as 
tracheitis or epiglottitis usually appear more toxic. 
Prednisolone 1–2 mg/kg orally for two consecutive days 
is effective for croup. Dexamethasone 0.15 mg/kg orally 
is an appropriate alternative therapy. In severe croup, 
when a child has ongoing stridor at rest, increasing 
fatigue and marked tachycardia with or without signs 
of impending hypoxaemia (for example, lethargy and 
increased irritability), urgent transfer to an emergency 
facility is recommended. Potentially distressing 
interventions, such as throat examination, should be 
avoided, as these may worsen respiratory obstruction.
Pneumonia
Children with pneumonia often have cough, fever and 
tachypnoea, but occasionally present with fever and 
Childhood coughs
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or erythromycin (10 mg/kg up to 250 mg orally, 
6-hourly for 7 days) is recommended.13 Treat early 
to improve symptoms (within 1−2 weeks of start 
of symptoms) and reduce the infectious period. 
Patients are seldom infectious after having a cough 
for longer than three weeks and antibiotics are not 
recommended at this point. 
Chronic cough
The common causes of chronic cough in children 
differ from those in adults14 so adult-type 
management approaches directed at asthma, rhinitis 
and gastro-oesophageal reflux disease do not apply. 
In a multicentre study involving 346 new referrals to 
respiratory paediatricians for chronic cough, the most 
common diagnoses included protracted bacterial 
bronchitis (41%), asthma (15.9%) and bronchiectasis 
(9%). In 13.9% of children, cough resolved without a 
specific diagnosis.15 
A detailed respiratory history and examination as well 
as use of a chronic cough algorithm (see Fig.)16 assist 
in the assessment and diagnosis of chronic cough. 
have viral bronchiolitis. Clinical examination reveals 
hyperinflation with widespread wheeze and crackles 
on chest auscultation. Respiratory syncytial virus is the 
most common infection associated with bronchiolitis. 
Any infant with apnoeas, hypoxia (oxygen saturations 
)92%), dehydration or poor feeding requires hospital 
admission for supplemental oxygen with or without 
hydration therapy. Children frequently worsen in the 
first 72 hours before showing improvement. The cough 
can persist for 2–3 weeks after other symptoms resolve. 
There is no evidence for the routine use of antibiotics, 
steroids or asthma drugs in viral bronchiolitis. 
Pertussis
Pertussis (whooping cough) typically presents 
with cough lasting two or more weeks with cough 
paroxysms, inspiratory whoop or post-tussive 
vomiting. Confirmation with a PCR-positive 
nasopharyngeal aspirate or swab is recommended. 
If there is a high clinical suspicion, start antibiotics 
before receiving the test results. Clarithromycin 
(7.5 mg/kg up to 500 mg orally, 12-hourly for 7 days) 
Fig.    Simplified paediatric chronic cough algorithm
Adapted from reference 16
ASSESSMENT
History: cough characteristics, specific features suggestive of an underlying diagnosis (e.g. pertussis), wheeze or recurrent lower respiratory tract 
infections, feeding difficulties, medications, neurodevelopmental problems, malnutrition, failure of previous treatment
Examination: chest wall deformity, clubbing, abnormal auscultation
Consider: chest X-ray with or without spirometry
No specific diagnostic features
Features of specific diseases such as  
asthma or bronchiectasis
Wet cough Dry cough
Features of protracted  
bacterial bronchitis
No specific features
If cough continues If cough continues
Antibiotics  
+ repeat course  
if necessary
Refer to specialist
Consider 
trial of therapy (e.g. 
bronchodilator), consider 
specialist referral 
Watchful waiting  
and review
Investigate and treat according to  
likely diagnosis, consider specialist referral 
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 đ chest radiographic changes lasting more than six 
weeks despite appropriate antibiotic therapy.17 
Antibiotic therapy is usually started at the onset of 
wet cough in children known to have bronchiectasis. 
Antibiotic selection is based upon lower airway 
culture, local antibiotic susceptibility patterns and 
clinical severity. If symptoms do not respond promptly 
or adequately to oral antibiotic therapy patients should 
be hospitalised for intravenous antibiotics. Regular 
physiotherapy, physical exercise, avoidance of triggers 
(for example tobacco smoke) and routine vaccinations 
are recommended.17 Aboriginal and Torres Strait 
Islander children are at increased risk of bronchiectasis 
and doctors should be aware that cough may be 
under-reported by those from remote communities.18 
Asthma and chronic cough
While asthma can cause chronic cough, isolated 
chronic cough without any other symptoms in 
children is rarely due to asthma.19,20 Other symptoms 
usually present in asthma are wheeze, dyspnoea, 
chest tightness or exercise limitation. Risk factors such 
as eczema, hay fever, allergies or a family history of 
asthma in a first-degree relative are often present. 
Spirometry and measurements of airway 
responsiveness (for example exercise challenge) in 
children aged over five years can help to diagnose 
asthma. The presence of atopy does not distinguish 
asthma from other causes of chronic cough. Previous 
response to asthma therapies may be helpful, 
however response on a single occasion does not 
necessarily mean that the child has asthma.  
Guidelines for the management of asthma are 
available from the National Asthma Council of 
Australia (www.nationalasthma.org.au/handbook).
Conclusion
Accurate diagnosis of cough in children depends upon 
a thorough clinical history and examination to guide 
appropriate prescribing. The nature of the cough and 
its chronicity provide important diagnostic clues as 
to a specific cause of cough. Cough guidelines and 
algorithms further enhance diagnostic accuracy and 
may help to ensure more effective prescribing of 
cough therapies in children. 
D Wurzel is funded by a National Health and Medical 
Research Council (NHMRC) postgraduate scholarship and 
the Queensland Children’s Medical Research Institute, and 
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Australia and New Zealand (Allen and Hanbury’s Award). 
A Chang is supported by an NHMRC fellowship and various 
NHMRC grants including a Centre of Research Excellence 
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Children grant.
The cough algorithm also significantly improves 
quality of life and reduces duration of cough.16 This 
approach is based on determining the cause of the 
cough (through systematic history taking and a 
thorough examination), in addition to spirometry (in a 
child >5 years of age) and chest X-ray. Indications for 
referral to a specialist are listed in the Box. 
Protracted bacterial bronchitis
Protracted bacterial bronchitis is the most common 
cause of chronic wet cough in Australian children.14,16  
It is defined as:
 đ cough lasting more than four weeks
 đ response to two weeks of antibiotic therapy 
 đ absence of specific pointers indicating an 
alternative cause. 
A history of a preceding viral infection is common. 
Protracted bacterial bronchitis is more common in 
boys than girls and in those aged 1–3 years. 
Lower airway bacterial infection is frequently found 
on bronchoalveolar lavage sampling and is usually 
accompanied by elevated neutrophils suggestive 
of active airway inflammation. The major bacterial 
organisms found are Haemophilus influenzae, Moraxella 
catarrhalis and Streptococcus pneumoniae. After 
exclusion of other causes of chronic cough, a two-week 
course of amoxycillin-clavulanate is recommended. 
Children should receive follow-up after 2–3 weeks 
to ensure complete resolution of cough. A chest 
X-ray should be performed in any child with clinical 
suspicion of an alternative cause of chronic cough or  
if their cough persists despite antibiotic therapy.
Bronchiectasis 
Bronchiectasis is another important cause of wet 
cough to consider, and should be suspected in any 
child with the following:
 đ chronic wet cough lasting longer than eight weeks
 đ two or more episodes of chronic wet cough (lasting 
*4 weeks) per year responding to antibiotics
Box    Common indications for specialist referral in chronic 
childhood cough
Chronic cough (>4 weeks) of unclear aetiology (with or without failure to thrive)
Suspected airway malformation e.g. tracheo-oesophageal fistula, vascular ring
Cough and feeding difficulties (suspected aspiration disease)
Clinical features of chronic lung disease e.g. clubbing 
Persisting auscultatory findings e.g. crepitations
Recurrent pneumonias 
Abnormalities on chest X-ray or spirometry
Failure to respond to treatment e.g. in asthma
SELF-TEST 
QUESTIONS
True or false? 
1. Aboriginal and Torres 
Strait Islander children 
have an increased risk 
of bronchiectasis.
2. There is evidence for 
use of steroids in viral 
bronchiolitis.
Answers on page 143
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CHAPTER 8 
8.1 DISCUSSION 
Over the past two decades, the significance of chronic wet cough has been increasingly 
appreciated. Using a systematic approach to evaluate the most common cause of chronic 
cough in children, the relationship between wet cough, bacterial infection and neutrophilic 
airway inflammation was identified and the clinical entity of protracted bacterial bronchitis 
(PBB) was first described in 2006 [2]. Early research into PBB was subsequently 
supported by studies by other research groups, both locally and internationally [75-77]. 
Defining the clinical entity of PBB has been pivotal in our understanding of chronic wet 
cough in children. It has also facilitated further studies on the most common aetiologies of 
chronic cough in children [16, 27].  
Prior to this PhD thesis, several research gaps existed in the area of PBB and chronic wet 
cough in children. These included:  
1) the significance of wet cough as a symptom  
2) the role of viruses in PBB  
3) the clinical profile of children with PBB and  
4) the validity and accuracy of the postulated link between PBB and bronchiectasis.  
Addressing these questions in this PhD has resulted in a body of research that has direct 
relevance to the clinician, whilst also providing insight into areas that warrant further study. 
Our findings in relation to wet cough progress our understanding of the ‘grass roots’ 
symptom (and sign) of PBB.  
My PhD work has demonstrated that children with wet cough are significantly more likely 
to harbour lower airways infection with bacteria, viruses and viral-bacterial co-infection, 
when compared to children without wet cough [130] (Chapter 2). We have shown that 
viral-bacterial co-infection is associated with maximal neutrophilic lower airway 
inflammation, suggesting that microbial synergy may also play a role in the pathogenesis 
of chronic bronchitis in children [130]. In further exploring the potential role of viruses, 
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chapter 3 showed that adenoviruses and rhinoviruses are the most common viruses 
detected in the lower airways of children with chronic respiratory symptoms (most of whom 
had chronic cough). Further, adenovirus detection (via PCR) on NPA or BAL is associated 
with significantly increased lower airway neutrophilic inflammation, when compared to 
adenovirus negativity [131]. This finding was independent of the presence of bacterial 
infection, suggesting that adenovirus is an independent predictor of neutrophilic lower 
airway inflammation in children. Further supporting the potential relevance of this finding 
was the fact that adenovirus was significantly more likely to be detected in the BAL of 
children with PBB compared to controls (23% vs 4% respectively) [132](Chapter 5) 
suggesting a possible role in disease pathogenesis.  
As adenovirus had not previously been described in PBB, the logical next step was to 
examine the genotypes of adenovirus in the lower airways of children with PBB and 
bronchiectasis (Chapter 4). We showed that adenovirus species C (genotypes 1 and 2) is 
the major adenovirus species detected in the lower airways of children with PBB and 
bronchiectasis [133]. Adenovirus C is known to establish latent infection within 
lymphocytes and is believed to remain dormant within tonsillar and adenoidal tissues of 
young children [102, 134] and to persist in the lung [135]. We also found adenovirus to be 
positively associated with lower airway bacterial infection with H. influenzae and M. 
catarrhalis [133]. These findings provide further evidence for a role of (viral-bacterial) 
microbial synergy in the development of PBB and/or bronchiectasis.  
In further delineating the clinical entity of PBB, chapter 5 describes the typical child who 
presents with PBB. We have shown that young boys, in their second year of life, who have 
attended childcare and have a history of protracted wet cough and parent-reported 
wheeze, typify the average child with PBB [132]. We have also shown that basic immune 
function in these children is intact. However, natural killer (NK) cell levels are often 
elevated [132]. This latter finding is in keeping with the observation that viruses are 
significantly more likely to be detected in the lower airways of children with PBB compared 
to controls, a common factor in NK cell elevation. However, the postulated link between 
PBB and bronchiectasis is perhaps the most significant theme addressed in this PhD 
thesis in chapter 6.  
We prospectively followed a group of young children with PBB over a two-year period and 
showed that a significant proportion (8.1%) were subsequently diagnosed with 
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bronchiectasis on HRCT chest [136] (chapter 6). Predictors of bronchiectasis included: 
recurrent episodes of PBB (defined as >3 episodes in the first year after recruitment) and 
lower airway infection with H. influenzae (most commonly non-typeable H. influenzae) 
[136]. These findings are first to lend support to the proposed clinical spectrum linking PBB 
and bronchiectasis, suggesting that this theory [51] is likely to be accurate and robust.  
I have thus far summarised the major novel findings arising from the original research 
encapsulated within this PhD. In addition, a review of the broader medical literature on 
major cough treatments available for children was summarised in chapter 7. This was 
followed by a Cochrane review examining the efficacy of short-course antibiotic therapy for 
the treatment of bronchiectasis. The relevance of this chapter extends beyond the 
paediatric community and has direct utility for general practice. 
The findings of the original research studies contribute to previous work on this topic and 
allow us to come closer to a hypothesis on the complete pathophysiological process 
underlying chronic wet cough and PBB in children. The following schematic diagram 
depicts this proposed theory and I have further elaborated in the text below. The theory 
expands on Cole’s vicious circle hypothesis [81] and Chang’s proposed clinical spectrum 
of PBB and bronchiectasis [51]. I have intentionally omitted discussion of extrinsic factors, 
such as antibiotic therapy, that are likely to attenuate the infection/inflammation process, 
as it was beyond the scope of our findings. 
8.1 Schematic diagram of proposed pathophysiological process uniting PBB and 
bronchiectasis (figure adapted from Chang’s proposed clinical spectrum of PBB and 
bronchiectasis [51]).  
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A primary insult to the lung occurs in a window of susceptibility. This window of 
susceptibility is defined by an immature immune system as well as structural immaturity of 
the lung. The insult is an extrinsic initiating event, such as adenovirus C infection. This 
event impairs host respiratory defences, including mucociliary clearance and immune 
surveillance mechanisms. This impairment in lung defences increases host susceptibility 
to secondary bacterial infection. Infection with respiratory bacteria e.g. non-typeable H 
influenzae occurs, or, bacterial load increases if infection is already present. Microbial 
synergy between pathogens heightens mucosal inflammation and dysfunction further 
promoting persistence of both virus and bacteria in the airways. Viral-bacterial co-infection 
underlies and drives the vicious cycle of airway inflammation and infection. For a period of 
time (weeks/months), airway epithelial injury occurs at the same rate as repair. As lung 
growth and immune system maturation occur, airway clearance improves and epithelial 
repair exceeds injury and the vicious cycle abates. This ‘reversible airway epithelial injury’ 
occurs in the majority of children with PBB.  
In a subset of susceptible individuals (approximately 8.1%[136]), however, a threshold of 
‘irreversible airway epithelial injury’ whereby injury has exceeded repair, is reached. This 
airway damage acts as a nidus for ongoing infection and inflammation. As the rate of 
airway injury continues to exceed repair, the discrepancy between the two increases, and 
the trajectory from PBB to bronchiectasis begins.   
8.2 LIMITATIONS OF THIS THESIS 
The limitations of this thesis are outlined in the manuscripts contained within each chapter. 
I will summarise some of the major limitations common to the majority of studies in this 
thesis.  
With the exception of the longitudinal follow-up component of Chapter 6, studies were 
cross-sectional in nature. Hence, interpretation of lower airway findings, obtained from 
single time-point sampling, is limited to the observation of association. Cause-effect 
relationships cannot be assumed. Nevertheless, there is substantial value in the analysis 
of lower airway data from such a large cohort of young children. Due to the high numbers 
of included participants, our findings provide invaluable clues to the state of the lower 
airways in children with (and without) chronic cough. The inability to perform longitudinal 
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studies involving BAL in children is based upon ethical constraints that are inherent to 
studies in children.  
A second limitation that merits discussion is the duration of follow-up of children with PBB. 
In Chapter 6, the clinical outcomes of a cohort of children with PBB followed for a 2-year 
period were described. Indeed, this relatively short period of follow-up allowed detection of 
a number of children with bronchiectasis. However, it is likely that this observed value 
would be higher with a longer period of follow-up e.g. 5 years. Furthermore, only a subset 
of children with PBB underwent CT scan of their chest. 
Due to the ethical issues pertaining to the performing of CT chest primarily for research 
purposes, children in this study did not have routine CT scan at study entry. Only those 
with clinical suspicion of bronchiectasis were subjected to CT scan. The consequences of 
this are two-fold. First, as not all children had CT at baseline, we cannot assume that those 
subsequently diagnosed with bronchiectasis entered the study free of bronchiectasis. 
Hence, progression from PBB to bronchiectasis per se cannot be assumed. Second, as 
not all children had CT at follow-up, bronchiectasis may have been unrecognised in a 
subset that did in fact develop it, hence under-estimating the true rate of this disease in the 
cohort.  
8.3 FUTURE PROJECTS AND FURTHER RESEARCH  
The findings from the research arising from this PhD thesis provide the foundation for 
future research in the area of chronic wet cough and PBB. Potential studies are outlined 
below. Concepts are presented in preliminary format.  
BIRTH-COHORT STUDY 
The exact influence of early life respiratory tract infections upon the trajectory of lung 
health is unknown. Findings from our research suggest that viral-bacterial co-infection is 
likely to be relevant to the pathogenesis of chronic suppurative lung diseases in children. 
In addition to organism type/s, it is possible that the timing and sequence of early 
respiratory tract infections is of clinical significance and impacts upon the risk of 
development of bronchiectasis.  
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A birth cohort study would enable documentation of early viral and bacterial respiratory 
tract infections. Frequent, time-intervalled sampling of respiratory tract secretions when a 
child is in the well-state, with additional samples during periods of illness, would enable 
determination of both the timing and sequence of viral and bacterial respiratory tract 
infections and their relationship to clinical symptoms.  
NPA would be used for detection of an extended panel of common respiratory viruses via 
PCR. Further speciation and genotyping of adenoviruses and rhinoviruses would establish 
the duration of infection with individual virus types and identify chronic carriage, if any. 
Cough swab or induced sputum would be used to obtain respiratory specimens for 
bacteriology.  
Documentation of clinical symptoms and PBB episodes, undertaken over time, with regular 
follow-up with a specialist respiratory physician, would identify those children requiring 
further investigation for bronchiectasis. The frequency of PBB episodes in relation to 
presence and timing of viral and bacterial infection would be analysed. Risk factors for 
recurrent PBB and bronchiectasis (as separate outcome measures) would be determined 
using longitudinally collected data. 
CHRONIC COUGH AND OBSTRUCTIVE SLEEP APNOEA  
The observation in clinical practice that chronic cough is often associated with obstructive 
sleep apnoea (OSA) symptoms and that the chronic cough often resolves after effective 
intervention for OSA, has been the focus of recent research [137, 138]. Several theories in 
relation to the cause of cough in children with OSA have been proposed. These range 
from aspiration of upper airway secretions during sleep (resulting in bacterial bronchitis) to 
mechanical irritation of the epiglottis by enlarged tonsillar tissue [139]. Indeed an 
association between asthma and sleep-disordered breathing has also been observed in 
both adults [140] and children [140-143]. 
In this PhD we have also collected data on OSA symptoms in a large number of children 
who have undergone bronchoscopy for investigation of chronic cough. Hence, a cross-
sectional study, further examining the relationship between chronic cough and OSA, with 
exploration of clinical and laboratory factors influencing this association, would be highly 
clinically relevant. Further, it is possible that PBB is the cause of chronic cough in children 
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with large adenoids and tonsils and analysis of already collected data would enable further 
evaluation of this postulated link. 
8.4 CONCLUSION 
The novel findings of this PhD thesis complement current knowledge on chronic wet cough 
and PBB in children in several ways. We have shown that viruses, in addition to bacteria, 
are likely to play a role in wet cough and PBB. We have also provided further depth to our 
understanding of PBB as a diagnostic entity by delineating the major clinical features of 
this condition. We have shown that adenovirus C is the major adenovirus species in the 
airways of children with PBB and bronchiectasis and, in demonstrating an association with 
bacterial co-infection, we have provided evidence for the possible role of microbial 
synergy. Lastly, we have evaluated the accuracy of the proposed clinical spectrum of PBB 
and bronchiectasis and shown that this is likely to be robust. We have identified key risk 
factors for bronchiectasis and highlighted important areas for future research. 
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e-Appendix 1. 
Bronchoscopy and BAL were undertaken as per European Respiratory Society guidelines.[1] The first aliquot was 
utilized for microbiology (bacteria and viruses), the second for total cell counts and cellular differentials.[2, 3] 
Bacterial infection was defined as growth of ≥104 colony-forming units (cfu)/mL of any of the following pathogens: 
Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenza or Staphylococcus aureus using standard culture 
methods previously described.[3]  
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Indications for flexible bronchoscopy in controls 
Indications for bronchoscopy in the 15 control participants undergoing respiratory 
evaluation included: stridor in 6 (40%), apnoeas in 3 (20%), dyspnoea in 3 (20%), 
haemoptysis in 1 (7%), congenital lung lesion in 1 (7%) and imaging abnormality in 1 
(7%). 
 
H. influenzae typing  
H. influenzae characterisation was based upon colony morphology and hemin and 
nicotinamide adenine dinucleotide (X and V factor) dependence.36 Non-typeable H. 
influenzae (NTHi) were identified by failure to react with capsular antisera (Phadebact® 
Haemophilus coagglutination test). A fucP-based real time PCR assay was used for 
differentiation of NTHi from H. haemolyticus 37.  
 
eTable 1: Univariate analysis of predictors of recurrent PBB (>3 episodes/yr)1 
Characteristic  Recurrent 
PBB 
(N=67) 
Non-
recurrent 
PBB 
(N=94) 
Odds ratio (95% CI) P-
value 
Sex, M:F, %male 48:18, 73% 57:36, 61% 1.767 (0.90, 3.49) 0.101 
 
Recruitment age, 
mths, median 
(IQR) 
 
24 (16, 53) 
 
20 (12, 49) 
 
1.003 (0.994, 1.012) 
 
0.508 
     
Prior x-ray 
confirmed 
pneumonia  
16 (24%) 19 (20%) 1.24 (0.583, 2.63) 0.578 
 
Household 
tobacco smoke 
exposure 
 
22 (33%) 
 
33 (36%) 
 
0.89 (0.46, 1.73) 
 
0.728 
 
Maternal 
smoking in 
pregnancy 
 
 
13/60 (22%) 
 
 8/36 (22%) 
 
0.97 (0.36, 2.62)  
 
0.949 
Aboriginal or 
Torres Strait 
Islander 
 
  1 (2%)   9 (10%) 0.143 (0.018, 1.158) 0.068 
No. children in 
household, 
median (IQR) 
 
≥ 3 children 
  2 (2, 3) 
 
 
 
 22 (33%) 
  2 (2, 3) 
 
 
 
33 (35%) 
1.005 (0.784, 1.288) 
 
 
 
0.904 (0.466, 1.753) 
 
 
0.971 
 
 
 
0.765 
 
Childcare 
attendance, ever 
 
37/41 (90%) 42/50 (84%) 1.762 (0.490, 6.331) 0.385 
TCC x 106/L 
 
260 (100, 420) 200 (130, 415) 1.000 (0.999, 1.000) 0.476 
BAL neutr%, 
median (IQR) 
 
  25 (8, 55)  27 (11, 56) 0.997 (0.986, 1.010) 0.680 
BAL macro%, 
median (IQR) 
 
  63 (30, 79)  60 (35, 80) 1.002 (0.990, 1.014) 0.734 
BAL lymph%, 
median (IQR) 
 
   6 (5, 12)    9 (4, 15) 0.997 (0.964, 1.032) 0.869 
BAL eosin%, 
median (IQR) 
 
   0 (0, 0)    0 (0, 0) 1.164 (0.926, 1.463) 0.194 
HAdV on BAL  
 
10/60 (17%)  19/90 (21%) 0.747 (0.320, 1.743)  0.500 
H. influenzae*  
 
 30 (45%)   53 (56%) 0.627 (0.334, 1.179) 0.147 
M. catarrhalis*  
 
 16 (24%)   31 (33%) 0.638 (0.314, 1.293)  0.212 
S. pneumoniae* 
 
 18 (27%)   26 (218%) 0.961 (0.475, 1.943) 0.911 
S. aureus*      6 (9%)     7 (7%) 1.222 (0.392, 3.817) 0.729 
1Multi-variate analysis did not identify any significant predictors of recurrent PBB.  !
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Pulmonary Innate Immunity in Children with
Protracted Bacterial Bronchitis
Anne B. Chang, PhD1,2, Stephanie T. Yerkovich, PhD3,4, Peter G. Gibson, MD5, Sophie Anderson-James, BSN1,
Helen L. Petsky, BSN1, Melanie L. Carroll, BSc3, I. Brent Masters, PhD1, Julie M. Marchant, PhD1, Danielle Wurzel, MBBS1,
and John W. Upham, PhD3
Objective To determine bronchoalveolar lavage (BAL) levels of 3 innate immunity components (human b-defen-
sin-2 [hBD2], mannose-binding lectin [MBL], and surfactant protein-A [SP-A]), the relationship with airway neutro-
philia and infection, and cytokine production of stimulated BAL cells in children with current protracted bacterial
bronchitis (PBB), children with resolved PBB (PBB well), and controls.
Study design BAL of 102 children (mean age 2.8 years) fulfilling predefined criteria of current PBB (n = 61), PBB
well (n = 20), and controls (n = 21) was cultured (quantitative bacteriology) and viruses examined by polymerase
chain reaction. hBD2, MBL, and SP-A were measured, and cytokine production by lipopolysaccharide-
stimulated BAL cells was determined.
Results Median hBD2 and MBL levels were significantly higher in the current PBB group (hBD2 = 164.4, IQR
0-435.5 pg/mL; MBL = 1.7, 0.4-4 ng/mL) than in the PBB well group (hBD2 = 0, IQR 0-85.2; MBL = 0.6, IQR
0.03-2.9) and controls (hBD2 = 3.6, IQR 0-126; MBL = 0.4, IQR 0.02-79). hBD2 was significantly higher in children
with airway infection (n = 54; median 76.9, IQR 0-397.3) compared with those without (n = 48; 0, IQR 0-236.3),
P = .04. SP-A levels and cytokine production of stimulated BAL cells were similar between groups.
Conclusion In children’s airways, hBD2, but not MBL and SP-A, relates to inflammation and infection. In children
with PBB, mechanisms involving airway hBD2 andMBL are augmented. These pulmonary innate immunity compo-
nents and the ability of BAL cells to respond to stimuli are unlikely to be deficient. (J Pediatr 2012;161:621-25).
P
rotracted bacterial bronchitis (PBB) is a relatively new and significant diagnostic clinical entity characterized by chronic
wet cough and resolution of cough within 2 weeks of treatment with appropriate antibiotics.1,2 PBB, increasingly rec-
ognized as an important pediatric condition worldwide,2-6 is a common cause of chronic cough in children.2 Not only is
PBB easily treatable (thus improving health-related quality of life7,8) but, if left untreated, it may progress to chronic suppu-
rative lung disease and radiological bronchiectasis.3,7
The lower airways of children with PBB are characterized by bacterial infection and airway neutrophilia.1,7 The latter suggests
that pulmonary innate immunity likely plays a pivotal role.9,10 However, there are few prospective studies on PBB; only 29,10 have
evaluatedmechanistic links. Innate immune defense involves recognition and clearing responses. In the recognition arm, specific
pattern recognition receptors are key components and include Toll-like receptors (TLRs) and lectin-like molecules such as, sur-
factant protein-A (SP-A) and mannose-binding lectin (MBL).11 Pulmonary collectins (eg, SP-A, MBL) play roles in pulmonary
innate immunity and regulate inflammatory responses.12,13 SP-A also has antimicrobial properties.14 Serum MBL deficiency is
associatedwith bronchiectasis but there is only 1 article onMBL in children’s bronchoalveolar lavage (BAL). Fidler et al15 reported
MBL in the BAL of children with lung infection. The MBL levels were not associated with bacteria or systemic inflammation but
correlated with neutrophil elastase.15 However, quantitative bacteria culture was
not defined, polymerase chain reaction for viruses was undertaken in only 4
children, and no other innate immunity components were examined.15
The clearing mechanism of the innate immune system includes antimicrobials
such as the defensin family. In the lungs, epithelial production of b-defensin sub-
types 1-3 are likely important.14,16 In themiddle ear, human b-defensin-2 (hBD2)
has bactericidal activity against Streptococcus pneumoniae, Moraxella catarrhalis,
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and nontypeableHaemophilus influenzae.17 These bacteria are
the same dominant pathogens in the lower airways of children
with PBB7 and bronchiectasis.18 Yet there is only 1 small study
(n = 20) that has measured airway human b-defensin in chil-
dren.16 In children, human b-defensin is relevant to several
conditions including inflammatory gut disease like Crohn’s
disease.17
In a cohort of 102 children, we determined whether BAL
levels of hBD2, SP-A, andMBL: (1) differed between children
with current PBB, children with resolved PBB (PBB well),
and controls; and (2) were related with airway neutrophilia
and endobronchial infection. We further examined if the
cytokine production of lipopolysaccharide (LPS)-stimulated
BAL cells were different in these groups. We tested the
hypothesis that current PBB would be associated with
deficient levels of hBD2, SP-A, and MBL.
Methods
Children undergoing flexible bronchoscopy for clinical rea-
sons were eligible for enrollment. Informed consent was
obtained and the study was approved by the Ethics Commit-
tees of the Royal Children’s Hospital (No. 2003/017)
and the University of Queensland School of Medicine (No.
2008000064). Enrolled children had a standardized medical
history taken that focused on the respiratory system includ-
ing cough quality (wet/dry)19 and key demographics that
contribute to frequency of respiratory infections (day care
attendance, smoke exposure, number of siblings in house-
hold). Post bronchoscopy, children with a wet cough were
treated with amoxillin-clauvanate (45 mg/kg/d in 2 doses).1
A validated cough diary card20 was used to document
response to antibiotics, defined as absence of cough or
>75% reduction in score (for $3 days) within 2 weeks of
antibiotic use post bronchoscopy.
Flexible bronchoscopy was performed under general anes-
thesia and BAL was obtained using European Respiratory
Society guidelines as previously described1; 3 aliquots of ster-
ile normal saline were instilled. The first aliquot was used for
microbiology examination; the second and third aliquots
were pooled for cytology, fluid phase measurements, and
cell cultures. Microbiological assessment (previously de-
scribed1,21) included quantitative aerobic cultures of bacteria
and positive bacterial culture and was defined as growth of
$105 colony-forming units/mL.9,10 Viral assessment on
BAL to detect respiratory syncytial virus, adenovirus, parain-
fluenza virus types 1-3, influenza, Mycoplasma pneumoniae,
and human meta-pneumovirus21 were performed using
polymerase chain reaction.21
For this study, only children who fulfilled the clinical def-
initions of PBB, PBB well, and controls were included. Chil-
dren were classified before innate immunity studies were
performed. We defined children as PBB if there was a history
of chronic (>4 weeks) wet cough and response to antibiotic
treatment with resolution of the cough within 2 weeks in
the absence of signs and symptoms of other disease.2 PBB
well were children who previously had a wet cough that
had responded to antibiotics and were treated by a pediatric
pulmonologist but were no longer coughing when the
bronchoscopy was undertaken. Controls were children
having bronchoscopy for the assessment of the airways
(eg, stridor) with no history of chronic cough and no acute
respiratory infection in the preceding 2 weeks. In all children,
immune deficiencies and cystic fibrosis were excluded
through serum immunoglobulins (IgG, IgM, IgA), neonatal
screening for controls, and sweat test for PBB and PBB
well. Children with recurrent pneumonia (>2), bronchiecta-
sis (on high-resolution computed tomography scan), and
neurological abnormalities were also excluded.
Measurement of hBD2, MBL, and SP-A
The cellular and supernatant components of the BAL fluid
were separated within 3 hours of collection, with the cellular
portion used immediately to assess cytokine production and
the supernatant stored at !20"C for later batch analysis.
hBD2 (Phoenix Pharmaceuticals, Burlingame, California),
MBL (Bioporto Diagnostics, Gentofte, Denmark), and
SP-A (Biovendor, Modrice, Czech Republic) were measured
using commercial kits according to the manufacturers’ direc-
tions. The limits of detection were 3.9 pg/mL (hBD2), 200 pg/
mL (MBL), and 500 pg/mL (SP-A).
Measurement of Cytokine Production by LPS-
Stimulated BAL Cells
Where available, BAL cells were resuspended in Roswell Park
Memorial Institute with 10% fetal calf serum at 2# 104 cells/
well in round-bottom culture plates. Cells were stimulated
with 1 ng/mL LPS (Alexis Biochemicals, Lausen, Switzerland)
for 24 hours at 37"C.Cytokine (interleukin [IL]-6, IL-8, IL-10,
and tumor necrosis factor-a) production was measured in
culture supernatants using in-house enzyme-linked immuno-
sorbent assays with commercially available paired antibodies
and recombinant cytokines (Becton Dickinson, Franklin
Lakes, New Jersey). The limit of detection was 15 pg/m.
Statistical Analyses
Data were examined for type of distribution using normality
plots. Data that had a normal distribution were described us-
ing mean and SD values; medians and IQRs were used for
nonparametric data. Chi-squared tests were used for com-
parison of categorical data, Mann-Whitney for 2-group com-
parisons, Kruskal-Wallis used for >2-group comparisons,
and ANOVA for age comparison between groups. Spearman
correlation (rs) was used to examine correlations among vari-
ables. The “enter” method was used for multiple regression
analyses. SPSS (SPSS Inc, Chicago, Illinois) was used, and
a 2-tailed P value of <.05 was considered significant.
Results
Of the 164 children enrolled, 62 were excluded because they
did not fulfil the criteria of current PBB, PBB well, or con-
trols. The demographics of the cohort of the 102 children
(Table) showed that the groups significantly differed in age
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and sex. The PBB group had the highest number of boys, and
children in the PBB well group were older. There was no
significant difference in exposure to tobacco smoke or
number of children in the household.
Analysis by Clinical Group
Figure 1 depicts the significantly higher median hBD2 level
in the PBB group compared with the PBB well and the
control groups. There was no significant difference between
the PBB well group and controls. For MBL, the PBB group
also had significantly higher levels than controls but was
not significantly different from the PBB well group
(Figure 2). There was no difference in SP-A between
groups (Figure 3, Kruskil-Wallis P = .505). Similarly, there
was no difference in the LPS-stimulated cytokine response
by BAL cells between the groups (Figure 4; available at
www.jpeds.com). There was no correlation between any
cytokine and the proportion of either macrophages or
neutrophils within the cellular component (data not shown).
Analysis by Presence/Absence of Bacteria, Viruses,
and Other Potential Factors
Considering the whole cohort, hBD2 was significantly higher
in the group with BAL presence of either bacteria or virus (n
= 54, median 76.9 pg/mL, IQR 0-397.3) compared with the
absence of both bacteria and virus antigens (n = 48, median
0, IQR 0-236.3) (P = .04). There was no significant difference
in MBL or SP-A between groups (P = .17 and .61, respec-
tively). However, when the children were grouped by the
presence of positive bacteria culture (n = 43) compared
with the absent (n = 59), there was no significant difference
between groups for hBD2, MBL, or SP-A (P = .393, .051,
and .393, respectively). Likewise, there was no significant dif-
ference in hBD2, MBL, or SP-A when the groups were di-
vided by presence/absence of virus (present in 18, absent in
84) (P = .196, .61, and .664, respectively).
There were modest but significant correlations between
hBD2 with MBL (rs = 0.22, P = .027), BAL% neutrophils
(rs = 0.43, P = .0001), BAL% macrophages (rs = 0.32, P =
.0001), and blood% neutrophils (rs = 0.27, P = .010) but
not with SP-A (P = .25), blood% monocytes (P = .79),
age (P = .78), and sex (P = .21). MBL also significantly cor-
related with BAL% neutrophils (rs = 0.44, P = .0001) and
BAL% macrophages (rs = 0.4, P = .0001). There was no sig-
nificant correlation between MBL and any of the other fac-
tors (blood% neutrophils, SP-A, blood% monocytes, age,
and sex; P = .25-.57). SP-A did not correlate to any factor
(P = .25-.99).
In multivariate regression analysis, hBD2 significantly
related to BAL% neutrophils (b coefficient 5, 95% CI,
1.3-8.9, P = .012) and MBL (b coefficient = 16.5, 95% CI,
7.2-25.9, P = .001) but did not relate to BAL% macrophages
(P = .26), blood neutrophils (P = .13), age (P = .8), or sex
(P = .7). With MBL as the dependent variable, the only sig-
nificant factor in multivariate regression analysis was hBD2
(b coefficient 0.01, 95% CI, 0-0.013, P = .0001). There was
no significant association in any of the other factors (BAL
% neutrophils, BAL% macrophages, age, and sex, P range
.23-.94). Because lower airway bacteria infection causes air-
way neutrophilia and both are present in those with PBB,1
we excluded both these factors in our regression analyses.
Discussion
In a cohort of 102 children, we found that hBD2 and MBL
levels in BAL were significantly higher in children with PBB
Table. Baseline data
Demographics Current PBB group (n = 61) PBB well group (n = 20) Control group (n = 21) P
Age, y (mean, SD) 2.5 (2.3) 4.2 (3.0) 2.2 (2.8) .018
Sex, M:F 47:14 10:10 11:10 .025
Length of current cough, wk* 28 (8-57) 0 0 .0001
Household tobacco smoke exposure, n (%) 20 (32.8%) 6 (30%) 7 (33.3%) .97
No. of children in household (median, range) 2 (1-8) 2 (1-10) 2 (1-6) .13
BAL data (median, IQR)
Total cell count (!106/L) 305 (157-498) 131 (78.5-277.5) 100 (45-139) .0001
% Macrophage 45.5 (26.0-68.5) 87.0 (80.5-93.0) 91.0 (81-95) .0001
% Neutrophil 41.5 (18.7-69.0) 5.0 (2.5-7.8) 2.0 (1.0-8.0) .0001
% Eosinophil 0 (0-8.0) 0 (0-0.0) 0 (0-0.0) .021
% Lymphocyte 9.0 (4.0-12.0) 5.5 (4.0-12.0) 5.0 (3.0-9.0) .171
Bolded values are P <.05.
*From day of bronchoscopy.
Figure 1. hBD2 levels in the BAL of children grouped into
current PBB, PBB well children, and controls. Median hBD2
levels were significantly higher in the PBB group compared
with the PBB well and the control groups. There was no dif-
ference between PBB well and controls.
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compared with children who have recovered from a PBB
episode (PBB well) and controls. We have also found that
hBD2 levels were associated with airway infection and are re-
lated to airway neutrophilia and MBL levels. However, SP-A
levels in the BAL and cytokine production of stimulated BAL
cells were similar between the groups.
Discoveries of the complex innate immune system and its
contributions to health and disease are rapidly expanding.
Augmentation of the innate system may have a therapeutic
role,22 yet there are relatively little BAL data relating to innate
immunity in children, outside of cystic fibrosis. In this study,
we examined key components of the human pulmonary in-
nate immunity defense system with respect to PBB, an in-
creasingly recognized clinical entity.1-7 Innate immunity
may be particularly important in light of the recognition of
the likely association between PBB, especially when recurrent,
and chronic suppurative lung disease and bronchiectasis.3,7
hBD2 is 1 of 6 b-defensins identified in humans.23 Only
hBD2-4 can be induced and produced by airway epithelial
cells. As hBD2 has been shown to have bactericidal activity
against S pneumoniae, M catarrhalis, and nontypeable H
influenzae in otitis media,17 we considered it to be a key in-
nate immunity component relevant to PBB and bronchiecta-
sis because these bacteria are major lower airways pathogens
in these conditions.7,18 We also examined MBL given its rel-
evance to bronchiectasis and lung infection.15 If children
with PBB have a deficiency in these selected innate immunity
mechanisms, reduced levels in BAL fluid would have been
found. Instead, we found increased hBD2 and MBL levels
in the BAL from children with PBB compared with controls.
Although the PBB well group formed an intermediate group,
their values were similar to controls and different from the
current PBB group. This suggests that children with PBB
are unlikely to have a deficiency in the hBD2 and MBL com-
ponents of the complex pulmonary innate immunity system.
We also found that the cytokine production of stimulated
BAL cells was similar in children with current PBB, children
with resolved PBB (PBB well), and controls, supporting our
data that these aspects of the pulmonary innate system are
not deficient in children with PBB.
However, it remains unknown if children with recurrent
PBB differ from those without recurrent PBB as some chil-
dren with PBB develop recurrence while others do not.7 It
is also possible that children with PBB have an initial subop-
timal innate immune response that becomes excessive later
in the course of the illness, in a similar mechanism to
influenza-infected BAL cells. Didierlaurent et al showed
that influenza-infected ex vivo BAL cells have an initial
reduced neutrophil recruitment that later resulted in height-
ened bacterial load during secondary respiratory infection
and increased neutrophilia.24 They also showed that this
was related to TLR signals.24 Children with PBB in our
cohort have sustained bacterial infection for many weeks
and thus it is possible a differential response may be found
in the early phase of the infection. Indeed, in our earlier
study, we found that mRNA expression of preprotachykinin
I, TLR-2, and TLR-4 in BAL cells of children who did not
present to respiratory clinics (hence likely to be less severe)
and had bacterial infection in their airways were lower
than those of controls.10
In our current cohort, hBD2, but not MBL, varied signif-
icantly in relation to airway neutrophilia and airway infec-
tion (defined by presence of bacteria or viruses). This
suggests that the epithelial–neutrophil interaction is actively
engaged in PBB. hBD2 also varied significantly in relation to
MBL. Reasons for this include independent stimulation of
both MBL and hBD2 responses. It is also biologically plausi-
ble that MBL, which functions in part as a pattern recogni-
tion receptor and further stimulates pathogen clearance,
likely involves hBD2, an important antimicrobial peptide
in the lungs. A highly significant association does not prove
causality, so this is merely speculative as we were unable to
find any published reports that have measured both MBL
and hBD2 in BAL.
In adults, increased hBD2 levels in the BAL have been asso-
ciated with inflammatory lung disease and infection.23 How-
ever, pediatric data are important in light of the known
difference in mucosal immunity and other immunity of the
airways of children compared with adults.25 Our findings on
hBD2 are in contrast to the sole published study in
children16 that has measured BAL hBD2. The study by
Figure 2. MBL levels in the BAL of children grouped into
current PBB, PBBwell, and controls. Themedian MBL level in
the PBB group was significantly higher than that of controls
but was not significantly different from the PBB well group.
Figure 3. SP-A levels in the BAL of children grouped into
current PBB, PBB well, and control groups. Median SP-A
levels did not differ between groups.
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Chen et al16 did not find any relationship between hBD2 levels
and airway inflammation or infection, in contrast to our
study’s findings. Themost likely explanation relates to sample
size; n = 102 in our study and n = 20 in the earlier study.16 Our
data on SP-A are consistent with a study that described no
change in BALSP-A levels in childrenwith acute lung injury.26
Although we have investigated a previously unexplored
area in children, we have not examined many other impor-
tant components of the innate system, especially mechanisms
involved in resolution of inflammation, which might explain
the persistence of symptoms and neutrophilic inflammation
in children with PBB. There are also many other possible
contributors to PBB such as impaired airway clearance
related to tracheobronchomalacia4 (from mechanical inter-
ference) and other causes such as mucus hypersecretion,
deficient efferocytosis, and epithelial cell dysfunction, among
others.
We conclude that innate immune pathways involving
hBD2 and MBL are augmented in the lower airways of chil-
dren with PBB. Components of the pulmonary innate system
represented by BAL levels of hBD2, MBL, and SP-A and
cytokine production of BAL cells are unlikely to be deficient
in children with established PBB. We also conclude that
in the airways, hBD2 is strongly associated with MBL,
neutrophilia, and infection. n
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Figure 4. LPS-stimulated A, IL-6,B, IL-8,C, tumor necrosis factor-a, andD, IL-10 cytokine production fromBAL cell showed no
difference between current PBB (n = 27), PBB well (n = 15), and control (n = 13) groups.
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Case Report
A Case for Early Bronchoscopic Airway Assessment
After Disc Battery Ingestion
Danielle F. Wurzel, MBBS, FRACP,1,2* I. Brent Masters, MBBS, FRACP,PhD,1,2 Kelvin L. Choo, MBBS, FRACS,3
and Alan F. Isles, MBBS Msc FRACP, FRCP (C)1,2
Summary. Disc battery ingestion in children is becoming increasingly common with the
proliferation of small battery-powered electronic devices. In the case of esophageal impaction, the
likelihood and severity of complications are proportionate to the time between ingestion and
removal. Tracheo-esophageal fistulae (TOF) are a recognized complication and can be life-
threatening. We describe an interesting case of disc battery ingestion with delayed recognition of
a TOF. We document the tracheal mucosal healing process of a large airway defect and
describe the role of bronchoscopy in guiding the timing of surgical intervention. This case
highlights the important role of early bronchoscopic assessment inmanagement of these patients.
Pediatr Pulmonol. 2014; 49:E72–E74. ! 2013 Wiley Periodicals, Inc.
Key words: disc battery ingestion; button battery ingestion; acquired tracheo-
esophageal fistula; paediatric bronchoscopy.
Funding source: Thoracic Society of Australia, National Health and Medical Research
Council and Queensland Children’s Medical Research Institute.
INTRODUCTION
Disc battery ingestion by young children can have
devastating or even fatal consequences.1 When impaction
in the esophagus occurs, the time between ingestion and
removal is critical. When batteries !20 mm in size are
ingested, they are likely to lodge in the esophagus,
typically at sites of physiological narrowing, for example,
the thoracic inlet. Tissue necrosis occurs predominantly
via hydrolysis.1 We report on a case of delayed
recognition of lithium disc battery ingestion and impac-
tion, which resulted in severe esophageal necrosis with
tracheo-esophageal fistula (TOF) formation. We describe
the role of bronchoscopy and advocate early airway
assessment in the case of deep esophageal ulceration;
initially, for TOF diagnosis, and subsequently for
monitoring tracheal mucosal healing during esophageal
rest.
CASE REPORT
A 13-month-old child presented with his parents to a
regional general practitioner with a history of sudden
onset of cough and irritability. The child had rhinorrhea
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but an otherwise normal physical examination. He was
presumed to have an early viral upper respiratory tract
infection and was discharged home.
The family returned the following morning after the
child had been unusually irritable overnight and was not
tolerating oral intake. He appeared mottled and pale, and
was referred to the local Emergency Department where a
chest X-ray was performed (Fig. 1). Further history taking
revealed the child had experienced a choking episode at
4 pm the day prior.
On examination in the Emergency Department, he was
febrile at 38.08C, tachycardic at 175 bpm, and tachyp-
noeic with respiratory rate of 42. He had intercostal
recession, moist cough, and was drooling. His oxygen
saturations were initially 88% on room air, improving
with suctioning of his oral secretions. Attempts to
examine him in the supine position were unsuccessful
due to increased irritability.
The rounded opacity on his chest film was initially
thought to be a coin lodged in his upper esophagus. After
discussion with pediatric gastroenterologists at a tertiary
pediatric hospital, the patient was transferred urgently for
endoscopic removal. The patient arrived 23 hr after the
choking episode. Three hours later, flexible endoscopy
revealed a button battery impacted in the wall of the
esophagus, 2.5 cm distal to the cricopharyngeus muscle.
Circumferential esophageal sloughing and necrosis was
noted at the impaction site. The battery was removed
intact and identified as a lithium 3 V disc battery. The
depth of the injury initially appeared to be confined to the
esophageal mucosa.
The child remained unwell in hospital, with fevers,
rhinorrhea, and moist cough. A nasopharyngeal aspirate
was positive for respiratory syncytial virus. He continued
to produce large amounts of frothy secretions for several
days, requiring frequent oropharyngeal suctioning and
supplemental oxygen.
On day 7, a contrast study demonstrated flow of
contrast into the trachea andmainstem bronchi, indicative
of a TOF. The child proceeded to flexible bronchoscopy.
A large posterior tracheal wall defect, 3 cm proximal to
the carina, was visualized. Air bubbles could be seen
passing through the defect (Fig. 2A). Ventilation during
anesthesia was challenging due to gas leak from the large
tracheal defect and gastric hyperinflation. Following the
bronchoscopy, the child was admitted to the intensive care
unit, antibiotic cover was broadened for possible
mediastinitis, and surgical consultation obtained.
The surgical opinion was that primary repair of the
fistula would involve a high degree of risk due to the
child’s compromised respiratory state; the large size of the
fistula and the degree of tissue necrosis. Esophageal
diversion to protect the airways was considered the safest
initial option.
The esophagus, approached via a low-neck incision,
was divided and diverted proximally as an esophagos-
tomy. Via a laparotomy, the gastro-esophageal junction
was also divided and a gastrostomy fashioned for enteral
ABBREVIATION:
TOF tracheo-esophageal fistula
Fig. 1. A: Frontal CXR demonstrating rounded, midline opaci-
fication in the inter-clavicular region measuring roughly 2 cm in
diameter with lateral bowing of the trachea to the right. The
“double rim” or “halo” appearance of the opacity in the AP view
confirms the foreign body to be a disc battery.1 B: Lateral CXR
demonstrating anterior orientation of negative node of battery
(narrower side).
Fig. 2. A: Acute phase TOF: posterior tracheal wall defect with
evidence of patency and free flow of secretions and air from
esophagus to trachea. B: Acute phase TOF: fronds of (pulsatile)
granulation tissue protruding from the TOF site into the trachea.
Pulsatility was likely due to proximity to vessels. C: Chronic
phase TOF: by 10 weeks there had been significant interval
healing with tracheal mucosalization. Although not visible in
this image, during esophageal insufflation a small residual
fistula was observed at the lower aspect of the earlier large
defect. D:Chronic phaseTOF: at 6months, healingwas complete
however there was a small residual fistula in the lateral groove of
trachea, allowing passage of 0.9 mm guide wire.
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feeding. The child improved quickly and was discharged
after establishment of gastrostomy feeds on day 22.
A repeat bronchoscopy, 3 weeks post-discharge,
showed interval healing with “pulsatile” fronds of
granulation tissue, suspicious of vascular proximity to
the TOF site (Fig. 2B). A contrast magnetic resonance
angiogram showed no evidence of vasculitis or aneurysm.
Serial bronchoscopies were performed to monitor healing
(Fig. 2C and D) of the TOF. At 6 months post-injury,
despite complete resolution of inflammatory granulation
tissue, a pinhole fistula remained necessitating surgical
closure.
A right thoracotomy was performed, the fistula was
divided, and the trachea reinforced with a pedicled
intercostal muscle flap. The remaining isolated segment
of intra-thoracic esophagus, badly strictured at the fistula
site, was sacrificed. Three months later, esophageal
reconstruction was undertaken using a retrosternally
tunnelled greater curve gastric tube, and the esophagos-
tomy was closed. When full oral nutrition was main-
tained, gastrostomy closure was performed. At most
recent review, the patient was tolerating an oral diet and
achieving normal growth and developmental milestones.
DISCUSSION
Disc battery ingestion poses a special hazard to young
children, as the initial ingestion may be unwitnessed and
the child often presents with non-specific symptoms.1
This case illustrates how delays in diagnosis and
treatment can occur. Although the choking episode was
witnessed, the significance was not initially appreciated.
The full extent of the injury was determined only after
performing a flexible bronchoscopy a week after first
presentation.
In the case of esophageal impaction, tissue necrosis has
been documented to occur within 2–2.5 hr of battery
lodgement.1 The risk of severe injury after disc battery
ingestion is also influenced by the age of the child and the
battery size, residual charge, and orientation within the
esophagus.1 This case involved a large (>20 mm) 3-volt
lithium manganese battery.
When a battery lodges in the esophagus, tissue injury is
caused predominantly by generation of an electrolytic
current that hydrolyses tissue fluids and produces
hydroxide at the battery’s negative terminal, the narrower
side of the battery.2,3 If the negative terminal is positioned
anteriorly in the esophagus, as it was in this case, erosion
through the esophagus into the trachea may occur. If the
negative terminal is positioned posteriorly, erosion into
the mediastinum and aorta may occur.4 Bronchoscopy
plays an important role in assessing the presence,
location, and extent of potential airway injury.
Prior literature emphasizes the role of timely broncho-
scopic airway examination in disc battery impaction with
“meticulous endoscopic examination of the esophagus
and trachea after battery removal” for early diagnosis of
complications.5 Bronchoscopy is generally considered
superior to esophagoscopy for diagnosing TOF, as
eosophagoscopy may not discover a small fistula hidden
behind a mucosal fold.6 Early bronchoscopic airway
assessment may facilitate more timely surgical interven-
tion and improved symptomatic management.
Our case serves to illustrate several important points.
Firstly, it reinforces previously published studies
highlighting the significance of the orientation of the
impacted battery within the esophagus;2,3 when the
negative node is facing anteriorly, the risk of TOF is
increased. Secondly, it demonstrates the extent of tissue
injury that can occur from delayed disc battery removal,
indicating the need for a high level of suspicion for TOF in
children with respiratory symptoms who have ingested a
battery. Lastly, it emphasizes the important role of
bronchoscopic airway assessment, in the diagnosis and
management of TOF after disc battery ingestion.
CONCLUSION
We recommend bronchoscopic airway assessment at
the time of endoscopic battery removal, particularly if
removal is delayed, the negative pole of the battery is
anteriorly orientated within the esophagus and/or respi-
ratory symptoms are present.
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